{"questions": [{"id": "5a6f960fb750ff445500005c", "body": "Centor criteria are used for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7786133", "http://www.ncbi.nlm.nih.gov/pubmed/11255530", "http://www.ncbi.nlm.nih.gov/pubmed/29523424", "http://www.ncbi.nlm.nih.gov/pubmed/11385345", "http://www.ncbi.nlm.nih.gov/pubmed/31727872", "http://www.ncbi.nlm.nih.gov/pubmed/19769278", "http://www.ncbi.nlm.nih.gov/pubmed/15147065", "http://www.ncbi.nlm.nih.gov/pubmed/33839717", "http://www.ncbi.nlm.nih.gov/pubmed/26141740", "http://www.ncbi.nlm.nih.gov/pubmed/28991775"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571", "text": "CONCLUSIONS Our results confirm the ineffectiveness of Centor criteria as a predicting factor for finding GABHS in a throat swab culture in children.", "offsetInBeginSection": 1763, "offsetInEndSection": 1912, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571", "text": "INTRODUCTION Centor criteria (fever >38.5\u00b0C, swollen, tender anterior cervical lymph nodes, tonsillar exudate and absence of cough) are an algorithm to assess the probability of group A \u03b2 haemolytic Streptococcus (GABHS) as the origin of sore throat, developed for adults.", "offsetInBeginSection": 0, "offsetInEndSection": 274, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926", "text": "BACKGROUND Rapid antigen detection testing (RADT) is often performed for diagnosis of group A beta-hemolytic streptococcal (GABHS) pharyngitis among children.", "offsetInBeginSection": 0, "offsetInEndSection": 158, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22432746", "text": "0-2 Centor criteria to relieve symptoms.", "offsetInBeginSection": 1068, "offsetInEndSection": 1108, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22432746", "text": "In diagnosis, Centor clinical scoring system or rapid antigen test can be helpful in targeting antibiotic use.", "offsetInBeginSection": 200, "offsetInEndSection": 310, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22432746", "text": "In patients with high likelihood of streptococcal infections (e.g.", "offsetInBeginSection": 436, "offsetInEndSection": 502, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27493985", "text": "We hypothesize that addition of palatal petechiae to Centor Criteria will increase the possibility of clinical diagnosis of group A streptococcal pharyngitis in children.", "offsetInBeginSection": 274, "offsetInEndSection": 444, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926", "text": "However, even among pediatric patients with > or =3 Centor criteria for GABHS pharyngitis, the sensitivity of RADT is still too low to support the use of RADT without culture confirmation of negative results.", "offsetInBeginSection": 2052, "offsetInEndSection": 2260, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27493985", "text": "Our study concludes that addition of petechiae over the palate to Centor Criteria will increase the possibility of diagnosing acute group A streptococcal pharyngitis in children.", "offsetInBeginSection": 1844, "offsetInEndSection": 2022, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27493985", "text": "In children, Centor Criteria does not cover all the symptoms and signs of acute strep pharyngitis.", "offsetInBeginSection": 175, "offsetInEndSection": 273, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a86ebf2faa1ab7d2e000038", "body": "Which are the main transcriptional activators of circadian oscillations?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30127410", "http://www.ncbi.nlm.nih.gov/pubmed/18084825", "http://www.ncbi.nlm.nih.gov/pubmed/27912059", "http://www.ncbi.nlm.nih.gov/pubmed/20967239", "http://www.ncbi.nlm.nih.gov/pubmed/26229984", "http://www.ncbi.nlm.nih.gov/pubmed/33452240", "http://www.ncbi.nlm.nih.gov/pubmed/26321255", "http://www.ncbi.nlm.nih.gov/pubmed/23217262", "http://www.ncbi.nlm.nih.gov/pubmed/33931447", "http://www.ncbi.nlm.nih.gov/pubmed/28821614"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19917250", "text": "Circadian rhythms in mammals are generated by a transcriptional negative feedback loop that is driven primarily by oscillations of PER and CRY, which inhibit their own transcriptional activators, CLOCK and BMAL1.", "offsetInBeginSection": 0, "offsetInEndSection": 212, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24320178", "text": "In the present study, we demonstrate that Id2 is involved in stabilization of the amplitudes of the circadian oscillations by suppressing transcriptional activation of clock genes Clock and Bmal1.", "offsetInBeginSection": 422, "offsetInEndSection": 618, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24592314", "text": "Recent work, however, has revealed that a subset of the REVEILLE (RVE) family of Myb transcription factors closely related to CCA1 and LHY are transcriptional activators in novel feedback transcription-translation feedback loops.", "offsetInBeginSection": 761, "offsetInEndSection": 990, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254", "text": "In the model of the Neurospora oscillator, FRQ suppresses frq transcription by binding to a complex of the transcriptional activators WC-1 and WC-2, thus yielding negative feedback.", "offsetInBeginSection": 341, "offsetInEndSection": 522, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18177499", "text": "Two basic helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG).", "offsetInBeginSection": 109, "offsetInEndSection": 335, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9115195", "text": "The white collar-1 and white collar-2 genes, both global regulators of photoresponses in Neurospora, encode DNA binding proteins that contain PAS domains and are believed to act as transcriptional activators.", "offsetInBeginSection": 487, "offsetInEndSection": 695, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21533189", "text": "In mammals, cellular circadian rhythms are generated by a transcriptional-translational autoregulatory network that consists of clock genes that encode transcriptional regulators.", "offsetInBeginSection": 0, "offsetInEndSection": 179, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24320178", "text": "We propose that Id2 expression in the SCN contributes to maintenance of dynamic circadian oscillations.", "offsetInBeginSection": 1280, "offsetInEndSection": 1383, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20967239", "text": "Bmal1 is an essential transcriptional activator within the mammalian circadian clock.", "offsetInBeginSection": 0, "offsetInEndSection": 85, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24592314", "text": "To date, the majority of plant transcription factors constituting these loops, including the central oscillator components CIRCADIAN CLOCK ASSOCIATED 1 (CCA1), LATE ELONGATED HYPOCOTYL (LHY), and TIMING OF CAB2 EXPRESSION 1 (TOC1), and the related PSEUDO-RESPONSE REGULATORS (PRRs), are transcriptional repressors, leading to a model of the clock emphasizing repressive interactions.", "offsetInBeginSection": 377, "offsetInEndSection": 760, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a67c8c4b750ff4455000013", "body": "What is the link between TADs and GRBs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11406576", "http://www.ncbi.nlm.nih.gov/pubmed/20867291", "http://www.ncbi.nlm.nih.gov/pubmed/23239730", "http://www.ncbi.nlm.nih.gov/pubmed/35308092", "http://www.ncbi.nlm.nih.gov/pubmed/23368301", "http://www.ncbi.nlm.nih.gov/pubmed/24093241", "http://www.ncbi.nlm.nih.gov/pubmed/16943830", "http://www.ncbi.nlm.nih.gov/pubmed/17293314", "http://www.ncbi.nlm.nih.gov/pubmed/16943831", "http://www.ncbi.nlm.nih.gov/pubmed/25166786"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26957603", "text": "Therefore, lineage-enriched TADs inform cell-specific genome organization during myogenesis.", "offsetInBeginSection": 720, "offsetInEndSection": 812, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482", "text": "Contrary to previous studies, we find that regions between TADs (i.e., the inter-TADs and TAD boundaries) in Drosophila are only weakly enriched with the insulator protein dCTCF, while another insulator protein Su(Hw) is preferentially present within TADs.", "offsetInBeginSection": 625, "offsetInEndSection": 881, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28060840", "text": "This approach revealed that: 1) TADs and LADs correspond to isochores, i.e., isochores are the genomic units that underlie chromatin domains; 2) the conservation of TADs and LADs in mammalian genomes is explained by the evolutionary conservation of isochores; 3) chromatin domains corresponding to GC-poor isochores (e.g., LADs) show not only self-interactions but also intrachromosomal interactions with other domains also corresponding to GC-poor isochores even if located far away; in contrast, chromatin domains corresponding to GC-rich isochores (e.g., TADs) show more localized chromosomal interactions, many of which are inter-chromosomal.", "offsetInBeginSection": 379, "offsetInEndSection": 1025, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27919068", "text": "C-walks that couple 2-4 TADs indicate stochastic associations between transcriptionally active, early replicating loci.", "offsetInBeginSection": 874, "offsetInEndSection": 993, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1448082", "text": "Repression depends on the presence of the transactivation domains (TADs), suggesting that a limiting factor interacting with the TADs is essential to link Jun and the components of the transcriptional machinery.", "offsetInBeginSection": 388, "offsetInEndSection": 599, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26957603", "text": "These lineage-enriched TADs demonstrate an expression-dependent pattern of nuclear organization that influences the positioning of adjacent nonenriched TADs.", "offsetInBeginSection": 562, "offsetInEndSection": 719, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482", "text": "Collectively, our results suggest that TADs are condensed chromatin domains depleted in active chromatin marks, separated by regions of active chromatin.", "offsetInBeginSection": 1275, "offsetInEndSection": 1428, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668", "text": "The close correspondence between extreme noncoding conservation and TADs suggests that these TADs are ancient, revealing a regulatory architecture conserved over hundreds of millions of years.Metazoan genomes contain many clusters of conserved noncoding elements.", "offsetInBeginSection": 902, "offsetInEndSection": 1165, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26544940", "text": "We find that TADs and the regions between them correspond with the bands and interbands of polytene chromosomes of Drosophila.", "offsetInBeginSection": 232, "offsetInEndSection": 358, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482", "text": "However, Drosophila inter-TADs harbor active chromatin and constitutively transcribed (housekeeping) genes.", "offsetInBeginSection": 882, "offsetInEndSection": 989, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7600b983b0d9ea6600000c", "body": "Which clinical trials for psoriasis involved tofacitinib? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30581877", "http://www.ncbi.nlm.nih.gov/pubmed/21171673", "http://www.ncbi.nlm.nih.gov/pubmed/31101342", "http://www.ncbi.nlm.nih.gov/pubmed/28255960", "http://www.ncbi.nlm.nih.gov/pubmed/35297512", "http://www.ncbi.nlm.nih.gov/pubmed/24883332", "http://www.ncbi.nlm.nih.gov/pubmed/33458669", "http://www.ncbi.nlm.nih.gov/pubmed/34045358", "http://www.ncbi.nlm.nih.gov/pubmed/30215633", "http://www.ncbi.nlm.nih.gov/pubmed/31839954"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26889727", "text": "EVIDENCE SYNTHESIS Only randomized controlled trial results or trial results for registration purposes of etanercept, adalimumab, infliximab, ustekinumab, secukinumab, brodalumab, ixekizumab, guselkumab, tofacitinib, and apremilast are included.", "offsetInBeginSection": 569, "offsetInEndSection": 814, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24883332", "text": "In phase III trials for rheumatoid arthritis, tofacitinib was efficacious in patients with inadequate responses to tumor necrosis factor inhibitors, methotrexate monotherapy, or disease-modifying antirheumatic drugs.", "offsetInBeginSection": 684, "offsetInEndSection": 900, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27692733", "text": "BACKGROUND Tofacitinib is an oral Janus kinase inhibitor that improves clinical measures of psoriasis.", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24883332", "text": "Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.", "offsetInBeginSection": 388, "offsetInEndSection": 610, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722", "text": "METHODS We reviewed phase III randomized, placebo-controlled clinical trial results for apremilast and tofacitinib for efficacy and safety in psoriasis.", "offsetInBeginSection": 441, "offsetInEndSection": 593, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26889081", "text": "Tofacitinib is an orally available compound belonging to a novel category of nonbiologic drugs, the \"JAK inhibitors\", which target JAKs.", "offsetInBeginSection": 739, "offsetInEndSection": 875, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27716172", "text": "Tofacitinib is a small molecule Janus kinase inhibitor investigated for the topical treatment of psoriasis.", "offsetInBeginSection": 199, "offsetInEndSection": 306, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236", "text": "Expert opinion: Although tofacitinib plus MTX is statistically more clinically effective, tofacitinib monotherapy is effective in many patients with RA.", "offsetInBeginSection": 1043, "offsetInEndSection": 1195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722", "text": "CONCLUSION Both new oral medications, apremilast and tofacitinib, appear to be effective in treating psoriasis", "offsetInBeginSection": 1042, "offsetInEndSection": 1152, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236", "text": "Tofacitinib is a pan JAK inhibitor with specificity for JAK3 over JAK1 over JAK2, which is approved in many countries for the treatment of rheumatoid arthritis (RA), including the United States and the European Union, either as monotherapy or in combination with conventional synthetic disease modifying anti-arthritis drugs (csDMARDs).", "offsetInBeginSection": 0, "offsetInEndSection": 336, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a551a8fb750ff4455000002", "body": "What is a potential side effect for Tymlos?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21694803", "http://www.ncbi.nlm.nih.gov/pubmed/28695614", "http://www.ncbi.nlm.nih.gov/pubmed/32607602", "http://www.ncbi.nlm.nih.gov/pubmed/20854178", "http://www.ncbi.nlm.nih.gov/pubmed/25982680", "http://www.ncbi.nlm.nih.gov/pubmed/7593734", "http://www.ncbi.nlm.nih.gov/pubmed/15328825", "http://www.ncbi.nlm.nih.gov/pubmed/10463379", "http://www.ncbi.nlm.nih.gov/pubmed/21457289", "http://www.ncbi.nlm.nih.gov/pubmed/25130305"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27836000", "text": "This case highlights the potential side effect of lipodystrophy secondary to leuprolide acetate injections.", "offsetInBeginSection": 481, "offsetInEndSection": 588, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2183167", "text": "A potential side effect of paracetamol is its hepatotoxicity.", "offsetInBeginSection": 0, "offsetInEndSection": 61, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27924737", "text": "However, there is increasing awareness of potential side effects associated with the intra- and peri-articular use of both glucocorticoids and topical analgesics.- In this review we will discuss the effects and side effects of intra-articular glucocorticoid injections in the context of non-rheumatic knee and shoulder conditions.", "offsetInBeginSection": 65, "offsetInEndSection": 395, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055", "text": "The authors review changing from one antipsychotic to another (\"switching\") as a potential treatment strategy for reducing the overall side effect burden of antipsychotic therapy.", "offsetInBeginSection": 429, "offsetInEndSection": 608, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27836000", "text": "The implication of this potential side effect poses difficult management strategies for such patients, and second-line alternatives such as chemotherapy may need to be considered.", "offsetInBeginSection": 1778, "offsetInEndSection": 1957, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055", "text": "Because of the differences in side effect profiles between the newer and older antipsychotic medications, and distinct differences among the newer agents themselves, the spectrum of side effects associated with antipsychotic therapy has changed tremendously.", "offsetInBeginSection": 170, "offsetInEndSection": 428, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27836000", "text": "Leuprolide acetate in commonly used as one of the gonadotrophin-releasing hormone agonists and thus we should be mindful of the potential effect of producing lipodystrophy, especially in patients with cirrhosis, and to watch for any signs and symptoms as appropriate.", "offsetInBeginSection": 1510, "offsetInEndSection": 1777, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24261314", "text": "We hope this case may encourage clinicians to inquire about headache as a potential side effect of indomethacin.", "offsetInBeginSection": 1150, "offsetInEndSection": 1262, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27924737", "text": "In view of the potential (harmful) side effects, it is advisable to use the lowest possible effective dose.", "offsetInBeginSection": 838, "offsetInEndSection": 945, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25119580", "text": "There was a clear effect of the warning in that placebo treated participants who were warned about side effects were much more likely to report the target side effect than those not warned about side effects.", "offsetInBeginSection": 797, "offsetInEndSection": 1005, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a87f44061bb38fb2400000f", "body": "Which disorder has been approved for treatment with Alk inhibitors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35105467", "http://www.ncbi.nlm.nih.gov/pubmed/27912826", "http://www.ncbi.nlm.nih.gov/pubmed/34210658", "http://www.ncbi.nlm.nih.gov/pubmed/35527776", "http://www.ncbi.nlm.nih.gov/pubmed/25979929", "http://www.ncbi.nlm.nih.gov/pubmed/29336091", "http://www.ncbi.nlm.nih.gov/pubmed/28528303", "http://www.ncbi.nlm.nih.gov/pubmed/29856687", "http://www.ncbi.nlm.nih.gov/pubmed/24509625", "http://www.ncbi.nlm.nih.gov/pubmed/26294238"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28065466", "text": "BACKGROUND Second-generation anaplastic lymphoma kinase (ALK) inhibitors, such as alectinib and ceritinib, have recently been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC).", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26294238", "text": "Crizotinib is an oral tyrosine kinase inhibitor approved in 2011 as a first-line therapy for patients with metastatic ALK mutation-driven NSCLC.", "offsetInBeginSection": 440, "offsetInEndSection": 584, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28979145", "text": "Alectinib, a second-generation ALK inhibitor, has recently been approved for ALK-rearranged NSCLC after patients progressed on crizotinib.", "offsetInBeginSection": 527, "offsetInEndSection": 665, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24166094", "text": "Most recently, pediatric phase I testing has been completed for the first approved ALK inhibitor, Crizotinib, showing very encouraging antitumoral results in neuroblastoma patients.", "offsetInBeginSection": 742, "offsetInEndSection": 923, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26294238", "text": "CONCLUSION The tyrosine kinase inhibitors crizotinib and ceritinib provide an effective treatment approach for patients with ALK-mutated NSCLC.", "offsetInBeginSection": 1442, "offsetInEndSection": 1585, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26992917", "text": "Crizotinib is the first anaplastic lymphoma kinase (ALK) inhibitor to have been approved for the treatment of non-small cell lung cancer (NSCLC) harboring an ALK fusion gene, but it has been found that, in the clinic, patients develop resistance to it.", "offsetInBeginSection": 0, "offsetInEndSection": 252, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26992917", "text": "Alectinib and ceritinib are second-generation ALK inhibitors which show remarkable clinical responses in both crizotinib-naive and crizotinib-resistant NSCLC patients harboring an ALK fusion gene.", "offsetInBeginSection": 253, "offsetInEndSection": 449, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27468827", "text": "Crizotinib is approved for the treatment of advanced ALK-positive non-small cell lung cancer (NSCLC).", "offsetInBeginSection": 283, "offsetInEndSection": 384, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28182271", "text": "This review article provides an overview of currently approved ALK inhibitors, other ALK inhibitors in development, and commonly described mechanisms of resistance to ALK inhibitors.", "offsetInBeginSection": 264, "offsetInEndSection": 446, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27122312", "text": "AREAS COVERED Three drugs have been approved for clinical use in ALK-positive patients - crizotinib, ceritinib and alectinib.", "offsetInBeginSection": 263, "offsetInEndSection": 388, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a723edd2dc08e987e00000c", "body": "Is Tofacitinib effective for Ulcerative Colitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32283509", "http://www.ncbi.nlm.nih.gov/pubmed/36185344", "http://www.ncbi.nlm.nih.gov/pubmed/25547087", "http://www.ncbi.nlm.nih.gov/pubmed/33760960", "http://www.ncbi.nlm.nih.gov/pubmed/31101342", "http://www.ncbi.nlm.nih.gov/pubmed/32185360", "http://www.ncbi.nlm.nih.gov/pubmed/30668755", "http://www.ncbi.nlm.nih.gov/pubmed/35307594", "http://www.ncbi.nlm.nih.gov/pubmed/33845581", "http://www.ncbi.nlm.nih.gov/pubmed/33051163"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27663846", "text": "Tofacitinib, an oral janus kinase inhibitor, is a new biologic that has shown promise in the treatment of ulcerative colitis and may be effective in the treatment of Crohn's disease according to phase 2 trials.", "offsetInBeginSection": 199, "offsetInEndSection": 409, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28790099", "text": "Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerative colitis (UC).", "offsetInBeginSection": 0, "offsetInEndSection": 166, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28601639", "text": "Tofacitinib (CP-690,550), an oral small-molecule Janus kinase inhibitor, has been shown to be effective in the treatment of rheumatoid arthritis, autoimmune encephalomyelitis and ulcerative colitis.", "offsetInBeginSection": 96, "offsetInEndSection": 294, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869", "text": "BACKGROUND Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.", "offsetInBeginSection": 0, "offsetInEndSection": 172, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25651782", "text": "BACKGROUND Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC).", "offsetInBeginSection": 0, "offsetInEndSection": 198, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869", "text": "CONCLUSIONS In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.", "offsetInBeginSection": 2249, "offsetInEndSection": 2409, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574", "text": "BACKGROUND Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective.", "offsetInBeginSection": 0, "offsetInEndSection": 136, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27699641", "text": "Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib.", "offsetInBeginSection": 357, "offsetInEndSection": 458, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27699641", "text": "Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) \u03b1 treatments.", "offsetInBeginSection": 0, "offsetInEndSection": 233, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27177233", "text": "INTRODUCTION Management of patients with active ulcerative colitis (UC), one of the most frequent inflammatory bowel diseases in human beings, is mainly based on the use of mesalamine and corticosteroids.", "offsetInBeginSection": 0, "offsetInEndSection": 204, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a85a0f1faa1ab7d2e000032", "body": "What is the definition of General Regulatory Factors (GRFs)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15806593", "http://www.ncbi.nlm.nih.gov/pubmed/23956474", "http://www.ncbi.nlm.nih.gov/pubmed/18431697", "http://www.ncbi.nlm.nih.gov/pubmed/36114005", "http://www.ncbi.nlm.nih.gov/pubmed/31250040", "http://www.ncbi.nlm.nih.gov/pubmed/17497458", "http://www.ncbi.nlm.nih.gov/pubmed/28448767", "http://www.ncbi.nlm.nih.gov/pubmed/30576657", "http://www.ncbi.nlm.nih.gov/pubmed/10705154", "http://www.ncbi.nlm.nih.gov/pubmed/33326253"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27540088", "text": "We found that nucleosomes and specific DNA-binding proteins, including the general regulatory factors (GRFs) Reb1p, Rap1p, and Abf1p, and Pol III transcription factors enhance the efficiency of NNS termination by physically blocking Pol II progression.", "offsetInBeginSection": 328, "offsetInEndSection": 580, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417", "text": "Together with Reb1p and Tbf1p, previously involved in the activity of Saccharomyces cerevisiae subtelomeric insulators, insulating potential emerges as a supplementary common property of General Regulatory Factors (GRFs).", "offsetInBeginSection": 658, "offsetInEndSection": 879, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17158163", "text": "Abf1 and Rap1 are general regulatory factors (GRFs) that contribute to transcriptional activation of a large number of genes, as well as to replication, silencing and telomere structure in yeast.", "offsetInBeginSection": 0, "offsetInEndSection": 195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28158860", "text": "Here, we show that most Ribi gene promoters also contain binding sites for one or more General Regulatory Factors (GRFs), most frequently Abf1 and Reb1, and that these factors are enriched in vivo at Ribi promoters.", "offsetInBeginSection": 304, "offsetInEndSection": 519, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28448767", "text": "This regulon has recently been shown to rely on a small set of transcriptional regulators (mainly Abf1, but also Reb1, Tbf1 and Rap1) previously referred to as general regulatory factors (GRFs) because of their widespread binding and action at many promoters and other specialized genomic regions.", "offsetInBeginSection": 122, "offsetInEndSection": 419, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25215414", "text": "Here, we will focus on the roles of gene regulatory factors (GRFs), in particular transcription factors (TFs) and long non-coding RNAs (lncRNAs) during human evolution.", "offsetInBeginSection": 130, "offsetInEndSection": 298, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25620770", "text": "The expression of several GRFs is controlled by microRNA miR396, and the GRF-miRNA396 regulatory module appears to be central to several of these processes.", "offsetInBeginSection": 390, "offsetInEndSection": 546, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20371324", "text": "Gene-regulation functions (GRF) provide a unique characteristic of a cis-regulatory module (CRM), relating the concentrations of transcription factors (input) to the promoter activities (output).", "offsetInBeginSection": 0, "offsetInEndSection": 195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28158860", "text": "Our observations point to GRFs as new multifaceted players in Ribi gene regulation both during exponential growth and under repressive conditions.", "offsetInBeginSection": 1159, "offsetInEndSection": 1305, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25620770", "text": "Growth-regulating factors (GRFs) are plant-specific transcription factors that were originally identified for their roles in stem and leaf development, but recent studies highlight them to be similarly important for other central developmental processes including flower and seed formation, root development, and the coordination of growth processes under adverse environmental conditions.", "offsetInBeginSection": 0, "offsetInEndSection": 389, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a68a463b750ff4455000014", "body": "Do chromatin features predict genes associated with eQTLs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28825057", "http://www.ncbi.nlm.nih.gov/pubmed/29142228", "http://www.ncbi.nlm.nih.gov/pubmed/28929106", "http://www.ncbi.nlm.nih.gov/pubmed/33575550", "http://www.ncbi.nlm.nih.gov/pubmed/27226577", "http://www.ncbi.nlm.nih.gov/pubmed/34385711", "http://www.ncbi.nlm.nih.gov/pubmed/36243984", "http://www.ncbi.nlm.nih.gov/pubmed/21324173", "http://www.ncbi.nlm.nih.gov/pubmed/36207300", "http://www.ncbi.nlm.nih.gov/pubmed/24013639"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551", "text": "Here, we integrate genome-wide data on TF-binding sites, chromatin markers and functional annotations to predict genes associated with human eQTLs.", "offsetInBeginSection": 382, "offsetInEndSection": 529, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551", "text": "Using the random forest classifier, we found that genomic proximity plus five TF and chromatin features are able to predict >90% of target genes within 1 megabase of eQTLs.", "offsetInBeginSection": 530, "offsetInEndSection": 702, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23935528", "text": "The cell type specificity of eQTLs is associated with eQTL SNP overlap with hundreds of cell type specific CRE classes, including enhancer, promoter, and repressive chromatin marks, regions of open chromatin, and many classes of DNA binding proteins.", "offsetInBeginSection": 1103, "offsetInEndSection": 1353, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24013639", "text": "DeepSAGE RNA sequencing showed that rs4917014 strongly alters the 3' UTR levels of IKZF1 in cis, and chromatin immunoprecipitation and sequencing analysis of the trans-regulated genes implicated IKZF1 as the causal gene.", "offsetInBeginSection": 734, "offsetInEndSection": 954, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551", "text": "Mapping studies for expression quantitative trait loci (eQTLs), transcription factors (TFs) and chromatin markers have become widely used tools for identifying gene regulatory elements, but prediction of target genes remains a major challenge.", "offsetInBeginSection": 138, "offsetInEndSection": 381, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28302177", "text": "By connecting large-scale epigenomic profiles to expression quantitative trait loci (eQTLs) in a wide range of human tissues/cell types, we identify critical chromatin features that predict variant regulatory potential.", "offsetInBeginSection": 138, "offsetInEndSection": 357, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24089144", "text": "This analysis suggests that the large-scale topology of chromatin is coupled with eQTL associations by providing evidence that eQTLs are in general spatially close to their target genes, occur often around topological domain boundaries and preferentially associate with genes across domains.", "offsetInBeginSection": 675, "offsetInEndSection": 966, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27435189", "text": "eQTLs for genes in this network were not dependent on absolute gene expression levels and were not enriched for chromatin marks of active enhancers.", "offsetInBeginSection": 1380, "offsetInEndSection": 1528, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23935528", "text": "Using a random forest classifier with cell specific CRE-SNP overlap as features, we demonstrate the feasibility of predicting the cell type specificity of eQTLs.", "offsetInBeginSection": 1516, "offsetInEndSection": 1677, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27435189", "text": "Using paired gene expression and genetic data, we identified genetic variants associated with gene expression, expression quantitative trait loci (eQTLs), in four peripheral blood cell subsets.", "offsetInBeginSection": 679, "offsetInEndSection": 872, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a760a4183b0d9ea66000016", "body": "What is filgotinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27045723", "http://www.ncbi.nlm.nih.gov/pubmed/27988142", "http://www.ncbi.nlm.nih.gov/pubmed/27988141", "http://www.ncbi.nlm.nih.gov/pubmed/25681059", "http://www.ncbi.nlm.nih.gov/pubmed/27993828", "http://www.ncbi.nlm.nih.gov/pubmed/27993829", "http://www.ncbi.nlm.nih.gov/pubmed/28622463", "http://www.ncbi.nlm.nih.gov/pubmed/28626520", "http://www.ncbi.nlm.nih.gov/pubmed/26693854", "http://www.ncbi.nlm.nih.gov/pubmed/24818516"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28765121", "text": "We summarise the development and recent application of Janus kinase (JAK) inhibitors in the treatment of IMIDs, including first-generation pan-JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib) and second-generation selective JAK inhibitors (decernotinib, filgotinib, upadacitinib).", "offsetInBeginSection": 1255, "offsetInEndSection": 1554, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24818516", "text": "Phase II data for four JAK inhibitors (baricitinib, decernotinib, filgotinib and INCB-039110) are contrasted with that reported for the recently approved JAK inhibitor tofacitinib.", "offsetInBeginSection": 556, "offsetInEndSection": 736, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142", "text": "BACKGROUND Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor.", "offsetInBeginSection": 0, "offsetInEndSection": 122, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25681059", "text": "BACKGROUND AND OBJECTIVES Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease.", "offsetInBeginSection": 0, "offsetInEndSection": 185, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24818516", "text": "JAK inhibitors differ in isoform specificity profiles, with good efficacy achievable by selective inhibition of either JAK1 (filgotinib or INCB-039110) or JAK3 (decernotinib).", "offsetInBeginSection": 1176, "offsetInEndSection": 1351, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28765121", "text": "Emerging strategies to interfere with cellular adhesion processes involved in lymphocyte recruitment are discussed, including both integrin blockade (natalizumab, vedolizumab, etrolizumab) and sphingosine-1-phosphate receptor inhibition (fingolimod, ozanimod).", "offsetInBeginSection": 994, "offsetInEndSection": 1254, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27993828", "text": "OBJECTIVES To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX).", "offsetInBeginSection": 0, "offsetInEndSection": 235, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26693854", "text": "OBJECTIVE The selective Janus kinase 1 inhibitor filgotinib (GLPG0634), which is currently in clinical development for the treatment of rheumatoid arthritis (RA) and Crohn's disease, demonstrated encouraging safety and efficacy profiles in RA patients after 4 weeks of daily dosing.", "offsetInBeginSection": 0, "offsetInEndSection": 282, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28838249", "text": "The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme family which mediate signalling for a cytokine subset important in RA pathogenesis.", "offsetInBeginSection": 168, "offsetInEndSection": 367, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27993829", "text": "OBJECTIVES To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX.", "offsetInBeginSection": 0, "offsetInEndSection": 251, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a74d9980384be9551000008", "body": "What is LHON, also known as Lebers syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21346843", "http://www.ncbi.nlm.nih.gov/pubmed/35008635", "http://www.ncbi.nlm.nih.gov/pubmed/9335011", "http://www.ncbi.nlm.nih.gov/pubmed/19421414", "http://www.ncbi.nlm.nih.gov/pubmed/17562939", "http://www.ncbi.nlm.nih.gov/pubmed/12031765", "http://www.ncbi.nlm.nih.gov/pubmed/7916404", "http://www.ncbi.nlm.nih.gov/pubmed/32387972", "http://www.ncbi.nlm.nih.gov/pubmed/26894521", "http://www.ncbi.nlm.nih.gov/pubmed/9010406"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288", "text": "Leber's hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disorder with bilateral loss of central vision primarily due to mitochondrial DNA (mtDNA) mutations in subunits of complex I in the respiratory chain (primary LHON mutations), while other mtDNA mutations can also be causative.", "offsetInBeginSection": 0, "offsetInEndSection": 309, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11329546", "text": "Wolff-Parkinson-White syndrome, myocardial thickening and ILVAT may be rare manifestations of LHON.", "offsetInBeginSection": 839, "offsetInEndSection": 938, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9309689", "text": "The phenotypic characteristics of the syndrome resemble those found in other mitochondrial (mt)DNA mediated disorders such as Leber's hereditary optic neuropathy (LHON) or maternally inherited diabetes and deafness (MIDD).", "offsetInBeginSection": 286, "offsetInEndSection": 508, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9309689", "text": "Wolfram or DIDMOAD (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness) syndrome, which has long been known as an autosomal-recessive disorder, has recently been proposed to be a mitochondrial-mediated disease with either a nuclear or a mitochondrial genetic background.", "offsetInBeginSection": 0, "offsetInEndSection": 285, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16523300", "text": "BACKGROUND Leber's hereditary optic neuropathy (LHON) is a maternally inherited optic neuropathy caused by mutations in mitochondrial DNA (mtDNA).", "offsetInBeginSection": 0, "offsetInEndSection": 146, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9147893", "text": "The pre-excitation syndrome Wolff-Parkinson-White syndrome or Lown-Ganong-Levine syndrome, is reportedly common in Finns with LHON, being seen in 14 (9%) of the 163 individuals with mitochondrial DNA (mtDNA) mutations.", "offsetInBeginSection": 113, "offsetInEndSection": 331, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7916404", "text": "Mitochondrial DNA causal for LHON may contribute to pre-excitation syndrome.", "offsetInBeginSection": 552, "offsetInEndSection": 628, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7916404", "text": "Pre-excitation syndrome is common in families with Leber's hereditary optic neuropathy (LHON).", "offsetInBeginSection": 0, "offsetInEndSection": 94, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288", "text": "Since the first description, it is known that LHON is not restricted to the eyes but is a multisystem disorder additionally involving the central nervous system, ears, endocrinological organs, heart, bone marrow, arteries, kidneys, or the peripheral nervous system.", "offsetInBeginSection": 310, "offsetInEndSection": 575, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288", "text": "Primary LHON mutations may rarely manifest without ocular compromise but with arterial hypertension, various neurodegenerative diseases, or Leigh syndrome.", "offsetInBeginSection": 825, "offsetInEndSection": 980, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8842a261bb38fb24000015", "body": "List proteins that are targeted by \"immune checkpoints inhibitors\".", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29930003", "http://www.ncbi.nlm.nih.gov/pubmed/30653899", "http://www.ncbi.nlm.nih.gov/pubmed/16409137", "http://www.ncbi.nlm.nih.gov/pubmed/27770382", "http://www.ncbi.nlm.nih.gov/pubmed/30365127", "http://www.ncbi.nlm.nih.gov/pubmed/36189222", "http://www.ncbi.nlm.nih.gov/pubmed/26860624", "http://www.ncbi.nlm.nih.gov/pubmed/31963646", "http://www.ncbi.nlm.nih.gov/pubmed/28000527", "http://www.ncbi.nlm.nih.gov/pubmed/34917131"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27664133", "text": "Cytotoxic-T-lymphocyte antigen (CTLA-4) and programmed cell death protein 1 (PD-1) are the two most commonly targeted immune checkpoint molecules.", "offsetInBeginSection": 164, "offsetInEndSection": 310, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26183909", "text": "Most promising therapeutic approaches to activating antitumor immunity include immune checkpoint inhibitors.", "offsetInBeginSection": 147, "offsetInEndSection": 255, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26680224", "text": "Strategies that hold promise include dual immune checkpoint blockade, as well as the combination of immune checkpoint blockade with costimulatory receptor agonists, enhancers of innate immunity, inhibition of indoleamine 2,3-dioxygenase, adoptive T-cell transfer/T-cell engineering, therapeutic vaccines, small-molecule inhibitors, and radiation therapy.", "offsetInBeginSection": 711, "offsetInEndSection": 1065, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27683114", "text": "Since alterations in DNA repair genes have been connected to the efficacy of checkpoint inhibitors, we investigated associations between methylation of DNA repair genes and CTLA4 and CD274 (PD-L1) expression.A list of DNA repair genes (179 genes) was selected from the literature, methylation status and expression of inflammation-associated genes (The Cancer Genome Atlas data) was correlated in head and neck squamous cell carcinoma (HNSCC), cervical and lung squamous cell carcinoma.A significant positive correlation of the methylation status of 15, 3 and 2 genes with checkpoint expression was identified, respectively.", "offsetInBeginSection": 122, "offsetInEndSection": 746, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26183909", "text": "Immune checkpoints are numerous inhibitory pathways hardwired in the immune system.", "offsetInBeginSection": 256, "offsetInEndSection": 339, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26765776", "text": "Combinations of PD-1 inhibitors with novel immune checkpoints or with molecularly targeted therapies are under investigation and may improve on the considerable progress made.", "offsetInBeginSection": 504, "offsetInEndSection": 679, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27068940", "text": "Combinatorial studies using both anti-CTLA-4 and anti-PD-1 demonstrate synergistic effects of targeting multiple checkpoints, paving the way for other immune checkpoints to be targeted.", "offsetInBeginSection": 477, "offsetInEndSection": 662, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26860624", "text": "Antibodies that block inhibitory checkpoints, such as anti-CTLA-4, anti-PD1 and anti-PD-L1 antibodies have demonstrated delayed tumor growth and increased survival.", "offsetInBeginSection": 564, "offsetInEndSection": 728, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27683114", "text": "Methylation of the candidate genes was also associated with expression of other checkpoints, ligands, MHC- and T-cell associated genes as well as an interferon-inflammatory immune gene signature, predictive for the efficacy of PD-1 inhibition in HNSCC.Homologous recombination deficiency might therefore be mediated by DNA repair gene hypermethylation and linked to an immune-evasive phenotype in SCC.", "offsetInBeginSection": 904, "offsetInEndSection": 1305, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26765776", "text": "Melanoma is at the forefront of development of systemic therapeutics with both molecular targeted therapies and immune checkpoint inhibitors as cornerstones of treatment.", "offsetInBeginSection": 0, "offsetInEndSection": 170, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a736efc3b9d13c708000006", "body": "Which chromosomes are implicated in the Emanuel syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16020785", "http://www.ncbi.nlm.nih.gov/pubmed/23691404", "http://www.ncbi.nlm.nih.gov/pubmed/10325262", "http://www.ncbi.nlm.nih.gov/pubmed/24991435", "http://www.ncbi.nlm.nih.gov/pubmed/8591961", "http://www.ncbi.nlm.nih.gov/pubmed/14623457", "http://www.ncbi.nlm.nih.gov/pubmed/18286821", "http://www.ncbi.nlm.nih.gov/pubmed/18314872", "http://www.ncbi.nlm.nih.gov/pubmed/1532789", "http://www.ncbi.nlm.nih.gov/pubmed/30178914"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18286821", "text": "Emanuel syndrome results from +der(22)t(11q23;22q11).", "offsetInBeginSection": 0, "offsetInEndSection": 53, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22876593", "text": "Emanuel syndrome is an inherited chromosomal abnormality resulting from 3:1 meiotic segregation from parental balanced translocation carrier t(11;22)(q23;q11), mostly of maternal origin.", "offsetInBeginSection": 0, "offsetInEndSection": 186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27617132", "text": "Complex sSMCs consist of chromosomal material derived from more than one chromosome, for example, the derivative der(22)t(11;22)(q23;q11.2) in Emanuel syndrome.", "offsetInBeginSection": 128, "offsetInEndSection": 288, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27785401", "text": "Emanuel syndrome (ES) is a rare chromosomal disorder that is characterized by multiple congenital anomalies and developmental disabilities.", "offsetInBeginSection": 0, "offsetInEndSection": 139, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28075445", "text": "Emanuel syndrome (ES) is the most frequent type of recurrent non\u2011Robertsonian translocation that is characterized by numerous anomalies.", "offsetInBeginSection": 0, "offsetInEndSection": 138, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27973931", "text": "Emanuel syndrome is associated with supernumerary chromosome, which consists of the extra genetic material from chromosome 11 and 22.", "offsetInBeginSection": 0, "offsetInEndSection": 133, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488", "text": "Emanuel syndrome is characterized by multiple congenital anomalies and developmental disability.", "offsetInBeginSection": 0, "offsetInEndSection": 96, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22876593", "text": "Here in, we describe a female patient with supernumerary der(22) syndrome (Emanuel syndrome) due to balanced translocation carrier father t(11;22) (q23;q11).", "offsetInBeginSection": 436, "offsetInEndSection": 593, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24171835", "text": "Complex sSMC consist of chromosomal material derived from more than one chromosome; the best known representative of this group is the derivative chromosome 22 {der(22)t(11;22)} or Emanuel syndrome.", "offsetInBeginSection": 126, "offsetInEndSection": 324, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28981939", "text": "CONCLUSION A fetal case of Emanuel syndrome has been identified.", "offsetInBeginSection": 904, "offsetInEndSection": 968, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a86c938faa1ab7d2e000034", "body": "Which genes belong to the AUX/IAA family of transcription repressors in plants?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27109828", "http://www.ncbi.nlm.nih.gov/pubmed/17900969", "http://www.ncbi.nlm.nih.gov/pubmed/12036261", "http://www.ncbi.nlm.nih.gov/pubmed/9478901", "http://www.ncbi.nlm.nih.gov/pubmed/23603958", "http://www.ncbi.nlm.nih.gov/pubmed/16478940", "http://www.ncbi.nlm.nih.gov/pubmed/11752389", "http://www.ncbi.nlm.nih.gov/pubmed/11115889", "http://www.ncbi.nlm.nih.gov/pubmed/10431823", "http://www.ncbi.nlm.nih.gov/pubmed/31722607"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17430601", "text": "The Arabidopsis gene AXR3/IAA17 encodes a member of the Aux/IAA family of auxin responsive transcriptional repressors.", "offsetInBeginSection": 138, "offsetInEndSection": 256, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27247276", "text": "The coordinated action of the auxin-sensitive Aux/IAA transcriptional repressors and ARF transcription factors produces complex gene-regulatory networks in plants.", "offsetInBeginSection": 0, "offsetInEndSection": 163, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16478940", "text": "In the presence of a low concentration of auxin in the nucleus, members of the Aux/IAA family of transcriptional repressors bind to ARF proteins and inhibit the transcription of specific auxin response genes.", "offsetInBeginSection": 337, "offsetInEndSection": 545, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22409484", "text": "Functional characterization of SlIAA15, a member of the tomato (Solanum lycopersicum) Aux/IAA family, shows that the encoded protein acts as a strong repressor of auxin-dependent transcription.", "offsetInBeginSection": 110, "offsetInEndSection": 303, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27049520", "text": "Auxin/Indole-3-Acetic Acid (Aux/IAA) are early auxin response genes noted as transcriptional repressors in plant auxin signaling.", "offsetInBeginSection": 131, "offsetInEndSection": 260, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16284307", "text": "The AUXIN/INDOLE-3-ACETIC ACID (Aux/IAA) genes encode short-lived transcriptional repressors that are targeted by the TRANSPORT INHIBITOR RESPONSE1/AUXIN RECEPTOR F-BOX proteins.", "offsetInBeginSection": 65, "offsetInEndSection": 243, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22409484", "text": "The Aux/IAA genes encode a large family of short-lived proteins known to regulate auxin signalling in plants.", "offsetInBeginSection": 0, "offsetInEndSection": 109, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17919906", "text": "At the molecular level, auxin induces gene expression through direct physical interaction with the TIR1-like F box proteins, which in turn remove the Aux/IAA family of transcriptional repressors [1-4].", "offsetInBeginSection": 75, "offsetInEndSection": 276, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22368074", "text": "Functional characterization using a dedicated single cell system revealed that tomato Aux/IAA proteins function as active repressors of auxin-dependent gene transcription, with, however, different Aux/IAA members displaying varying levels of repression.", "offsetInBeginSection": 543, "offsetInEndSection": 796, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17077182", "text": "The Aux/IAA genes are best characterized among the early auxin-responsive genes, which encode short-lived transcriptional repressors.", "offsetInBeginSection": 173, "offsetInEndSection": 306, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6a2bbcb750ff4455000022", "body": "What is Cellbase?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11654349", "http://www.ncbi.nlm.nih.gov/pubmed/11789525", "http://www.ncbi.nlm.nih.gov/pubmed/11662648", "http://www.ncbi.nlm.nih.gov/pubmed/11271619", "http://www.ncbi.nlm.nih.gov/pubmed/11824273", "http://www.ncbi.nlm.nih.gov/pubmed/11925667", "http://www.ncbi.nlm.nih.gov/pubmed/11977505", "http://www.ncbi.nlm.nih.gov/pubmed/12077793", "http://www.ncbi.nlm.nih.gov/pubmed/11643613", "http://www.ncbi.nlm.nih.gov/pubmed/10247165"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19035847", "text": "The G protein-coupled receptor (GPCR) family is a major target for drug discovery, and most, if not all, GPCRs can couple to Ca2+ signaling.", "offsetInBeginSection": 0, "offsetInEndSection": 140, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28535294", "text": "HGVA calculates population frequencies for these projects and enriches their data with variant annotation provided by CellBase, a rich and fast annotation solution.", "offsetInBeginSection": 771, "offsetInEndSection": 935, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25912433", "text": "Here, we investigated whether Neurogenin 2 (Ngn2), which is a proneural gene that directs neuronal differentiation of progenitor cells during development, can enhance the generation of patient-specific induced neuronal cells.", "offsetInBeginSection": 351, "offsetInEndSection": 576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220", "text": "CellBase implements a set of RESTful web services that query a centralized database containing the most relevant biological data sources.", "offsetInBeginSection": 998, "offsetInEndSection": 1135, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25912433", "text": "In this study, we transfected Ascl1, Sox2 and Ngn2 into human fibroblasts from the patients' scalp by lentivirus.", "offsetInBeginSection": 577, "offsetInEndSection": 690, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220", "text": "CellBase documentation can be found at http://docs.bioinfo.cipf.es/projects/cellbase.", "offsetInBeginSection": 1200, "offsetInEndSection": 1285, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220", "text": "CellBase provides a solution to the growing necessity of integration by easing the access to biological data.", "offsetInBeginSection": 888, "offsetInEndSection": 997, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25912433", "text": "Ngn2 increase the conversion efficiency from 4% to 13.4%.", "offsetInBeginSection": 886, "offsetInEndSection": 943, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28535294", "text": "HGVA provides an efficient and intuitive web-interface for easy data mining, a comprehensive RESTful API and client libraries in Python, Java and JavaScript for fast programmatic access to its knowledge base.", "offsetInBeginSection": 562, "offsetInEndSection": 770, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19035847", "text": "This exquisite sensitivity, the high signal-to-noise ratios, and the ability to target expression to discrete subcellular sites (in order to detect Ca2+ microdomains) have made photoproteins a principal choice in a wide range of GPCR drug discovery programs.", "offsetInBeginSection": 847, "offsetInEndSection": 1105, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a76155c83b0d9ea6600001e", "body": "Which phase III clinical trials for rheumatoid arthritis involve baricitinib? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17668369", "http://www.ncbi.nlm.nih.gov/pubmed/15264435", "http://www.ncbi.nlm.nih.gov/pubmed/35096866", "http://www.ncbi.nlm.nih.gov/pubmed/20979549", "http://www.ncbi.nlm.nih.gov/pubmed/20140823", "http://www.ncbi.nlm.nih.gov/pubmed/30701418", "http://www.ncbi.nlm.nih.gov/pubmed/31163474", "http://www.ncbi.nlm.nih.gov/pubmed/35330989", "http://www.ncbi.nlm.nih.gov/pubmed/31642025", "http://www.ncbi.nlm.nih.gov/pubmed/32222877"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27577235", "text": "Results of phase III clinical trials using a JAK1/2 inhibitor, baricitinib, have shown feasible efficacy and tolerable safety.", "offsetInBeginSection": 973, "offsetInEndSection": 1099, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962", "text": "Baricitinib (LY-3009104, INCB-028050), a new potent and selective tyrosine-protein kinase JAK1/JAK2 inhibitor, has shown clinical efficacy in patients with RA refractory to aggressive standard-of-care treatment (with both conventional DMARDs and bDMARDs) when administered orally at 4 mg q.d.", "offsetInBeginSection": 535, "offsetInEndSection": 827, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962", "text": "in pivotal phase III clinical trials.", "offsetInBeginSection": 828, "offsetInEndSection": 865, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28923098", "text": "BACKGROUND This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and na\u00efve to biological DMARDs.", "offsetInBeginSection": 0, "offsetInEndSection": 343, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27427830", "text": "Five phase 3 trials of Baricitinib, a JAK1 and JAK2 inhibitor, have been performed and showed high clinical efficacy in patients with active RA and na\u00efve to sDMARDs or an inadequate response to sDMARDs, MTX or bDMARDs.", "offsetInBeginSection": 597, "offsetInEndSection": 816, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28290136", "text": "Baricitinib (Olumiant\u2122) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus.", "offsetInBeginSection": 0, "offsetInEndSection": 254, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27577235", "text": "In addition, clinical phase III trials using filgotinib and ABT-494, specific JAK1 inhibitors, are currently underway.", "offsetInBeginSection": 1218, "offsetInEndSection": 1336, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28290136", "text": "In February 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).", "offsetInBeginSection": 491, "offsetInEndSection": 804, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28255337", "text": "Biologics have changed expectation and outcomes for rheumatoid arthritis (RA).", "offsetInBeginSection": 0, "offsetInEndSection": 78, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27689735", "text": "METHODS In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-na\u00efve patients with rheumatoid arthritis and inadequate response or intolerance to \u22651 conventional synthetic DMARDs were randomly assigned 1:1:1 to placebo or baricitinib (2 or 4\u2005mg) once daily, stratified by region and the presence of joint erosions.", "offsetInBeginSection": 91, "offsetInEndSection": 460, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a87124561bb38fb24000001", "body": "What is cebocephaly", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11643613", "http://www.ncbi.nlm.nih.gov/pubmed/11662648", "http://www.ncbi.nlm.nih.gov/pubmed/11654349", "http://www.ncbi.nlm.nih.gov/pubmed/1144444", "http://www.ncbi.nlm.nih.gov/pubmed/1174023", "http://www.ncbi.nlm.nih.gov/pubmed/1183556", "http://www.ncbi.nlm.nih.gov/pubmed/12077793", "http://www.ncbi.nlm.nih.gov/pubmed/13874423", "http://www.ncbi.nlm.nih.gov/pubmed/115387", "http://www.ncbi.nlm.nih.gov/pubmed/10463269"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16061113", "text": "Here we report on first case of cebocephaly with semilobar holoprosencephaly, hypotelorism, and a single nostril due to intrauterine TORCH infection (Toxoplasmosis, other [syphilis, varicella-zoster, parvovirus B19], Rubella, Cytomegalovirus [CMV], and Herpes infections) in the English language literature.", "offsetInBeginSection": 116, "offsetInEndSection": 423, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180", "text": "Cebocephaly is a very rare congenital anomaly combining with semilobar holoprosencephaly.", "offsetInBeginSection": 137, "offsetInEndSection": 226, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23599105", "text": "We report a case of alobar holoprosencephaly (HPE) and cebocephaly associated with uncontrolled maternal type 1 (insulin-dependent) diabetes mellitus.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9132501", "text": "We report on a female still-birth with cebocephaly, alobar holoprosencephaly, cleft palate, lumbar spina bifida, sirenomelia, a single umbilical artery, and a 46,XX karyotype, but without maternal diabetes mellitus.", "offsetInBeginSection": 171, "offsetInEndSection": 386, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16061113", "text": "Cebocephaly is a very rare congenital anomaly combining a severe midline facial malformation and holoprosencephaly.", "offsetInBeginSection": 0, "offsetInEndSection": 115, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365", "text": "We report here a case of alobar holoprosencephaly with cebocephaly and craniosynostosis.", "offsetInBeginSection": 187, "offsetInEndSection": 275, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180", "text": "Herein we present the first case of cebocephaly with severe semilobar holoprosencephaly and lissencephaly.", "offsetInBeginSection": 383, "offsetInEndSection": 489, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2255999", "text": "Cebocephaly (hypotelorism, single-nostril nose) and ethmocephaly (hypotelorism, interorbital proboscis) lie in the middle of the spectrum of craniofacial changes associated with holoprosencephaly.", "offsetInBeginSection": 0, "offsetInEndSection": 196, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365", "text": "Cebocephaly is a very rare congenital midline facial anomaly characterized by a blind-ended single nostril and ocular hypotelorism, and is usually combined with alobar holoprosencephaly.", "offsetInBeginSection": 0, "offsetInEndSection": 186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9132501", "text": "Cebocephaly and sirenomelia are uncommon birth defects.", "offsetInBeginSection": 0, "offsetInEndSection": 55, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8881118cb19eca6b000006", "body": "Has the proteome of mice hippocampus been analysed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17663576", "http://www.ncbi.nlm.nih.gov/pubmed/26783459", "http://www.ncbi.nlm.nih.gov/pubmed/28374408", "http://www.ncbi.nlm.nih.gov/pubmed/18283665", "http://www.ncbi.nlm.nih.gov/pubmed/15797529", "http://www.ncbi.nlm.nih.gov/pubmed/30590179", "http://www.ncbi.nlm.nih.gov/pubmed/23741028", "http://www.ncbi.nlm.nih.gov/pubmed/35398524", "http://www.ncbi.nlm.nih.gov/pubmed/33591546", "http://www.ncbi.nlm.nih.gov/pubmed/27062398"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17663576", "text": "2D-gel electrophoresis and mass spectrometry were applied to study the proteome difference in denervated hippocampus in wildtype mice and mice lacking intermediate filament proteins glial fibrillary acidic protein (GFAP) and vimentin (GFAP-/-Vim-/-) that show attenuated reactive gliosis and enhanced posttraumatic regeneration.", "offsetInBeginSection": 166, "offsetInEndSection": 494, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15863242", "text": "It was shown recently that Tg-hSOD1 mice develop a characteristic set of neurodegenerative changes in hippocampus and we therefore decided to study differential protein expression patterns, constructing a mouse hippocampal proteome map using two-dimensional electrophoresis (2-DE) with in-gel digestion of spots followed by matrix-assisted laser desorption/ionisation-time of flight (MALDI-TOF) identification and quantitatively compared protein profiles between non-transgenic mice, hemizygous and homozygous Tg-hSOD1 mice.", "offsetInBeginSection": 290, "offsetInEndSection": 814, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27155843", "text": "In order to explore the underlying mechanisms in rabies virus (RABV) and synaptic dysfunctions, a quantitative proteome profiling was carried out on synaptosome samples from mice hippocampus.", "offsetInBeginSection": 133, "offsetInEndSection": 324, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665", "text": "We find that transcriptome and proteome levels of function as well as the topological organization of synaptic protein clusters, detected by toponomics at physiological sites of hippocampus CA3 region, are all largely conserved between different mice.", "offsetInBeginSection": 218, "offsetInEndSection": 469, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23741028", "text": "Although mice are an extensively used model to recapitulate various pathological conditions, the proteome of the normal mouse brain has not been yet reported.", "offsetInBeginSection": 97, "offsetInEndSection": 255, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17663576", "text": "Culture-derived isotope tags (CDIT) and mass spectrometry demonstrated that 14-3-3 epsilon was the major isoform upregulated in denervated hippocampus and that its upregulation was attenuated in GFAP-/-Vim-/- mice and thus most likely connected to reactive gliosis.", "offsetInBeginSection": 700, "offsetInEndSection": 965, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10641757", "text": "Any comparative proteome analysis that can identify proteins important in a disease affecting the hippocampus requires the characterization of the normal hippocampal proteome.", "offsetInBeginSection": 345, "offsetInEndSection": 520, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18648492", "text": "Apparently, the large difference in the hippocampal protein patterns between two-month old APP23 and wildtype mice was caused by the absence of distinct developmental changes in the hippocampal proteome of APP23 mice.", "offsetInBeginSection": 1147, "offsetInEndSection": 1364, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27062398", "text": "We unravel discrete proteome changes in mouse auditory cortex, frontal cortex, hippocampus, and striatum functionally implicated in the learning process.", "offsetInBeginSection": 1635, "offsetInEndSection": 1788, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665", "text": "We have correlated transcriptomics, proteomics and toponomics analyses of hippocampus tissue of inbred C57BL/6 mice to analyse the interrelationship of expressed genes and proteins at different levels of organization.", "offsetInBeginSection": 0, "offsetInEndSection": 217, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a742d620384be9551000002", "body": "Which disease risk can be estimated with the Stop-Bang questionnaire?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24439158", "http://www.ncbi.nlm.nih.gov/pubmed/34495174", "http://www.ncbi.nlm.nih.gov/pubmed/34786269", "http://www.ncbi.nlm.nih.gov/pubmed/32780995", "http://www.ncbi.nlm.nih.gov/pubmed/29685727", "http://www.ncbi.nlm.nih.gov/pubmed/35956020", "http://www.ncbi.nlm.nih.gov/pubmed/32879339", "http://www.ncbi.nlm.nih.gov/pubmed/29426446", "http://www.ncbi.nlm.nih.gov/pubmed/30171191", "http://www.ncbi.nlm.nih.gov/pubmed/31172707"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22270686", "text": "The STOP-BANG questionnaire offers clinicians an efficient and objective tool for improving detection of OSA risk in MS patients.", "offsetInBeginSection": 1295, "offsetInEndSection": 1424, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27938922", "text": "OBJECTIVE The STOP-Bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (OSA) in preoperative clinics.", "offsetInBeginSection": 0, "offsetInEndSection": 147, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22270686", "text": "PURPOSE This study aims: (1) to identify patients with multiple sclerosis (MS) who are at high risk for obstructive sleep apnea (OSA) by utilizing the STOP-BANG questionnaire and (2) to evaluate the relationship between OSA risk as determined by the STOP-BANG questionnaire and self-reported sleepiness and fatigue using the Epworth Sleepiness Scale (ESS) and the Fatigue Severity Scale (FSS), respectively.", "offsetInBeginSection": 0, "offsetInEndSection": 407, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25758298", "text": "This study aimed to evaluate and validate the Arabic version of Stop-Bang questionnaire as a screening tool for patients with OSA symptoms referred to a sleep clinic.", "offsetInBeginSection": 319, "offsetInEndSection": 485, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615", "text": "RESULTS Eighty-three out of 200 patients had a high risk of OSA based on the STOP-Bang questionnaire.", "offsetInBeginSection": 798, "offsetInEndSection": 899, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25758298", "text": "CONCLUSION The Arabic version of STOP-Bang questionnaire is an easy-to-use tool that can be implemented as a reliable, quick screening tool for OSA in patients referred to sleep clinic.", "offsetInBeginSection": 1550, "offsetInEndSection": 1735, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430", "text": "RECENT FINDINGS The STOP-Bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (OSA).", "offsetInBeginSection": 186, "offsetInEndSection": 359, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22270686", "text": "CONCLUSIONS Over 40% of MS patients were identified as high risk for OSA based on the STOP-BANG questionnaire.", "offsetInBeginSection": 1184, "offsetInEndSection": 1294, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27938922", "text": "We aimed to evaluate the validity of the STOP-Bang questionnaire to predict moderate-to-severe and severe OSA in the general population.", "offsetInBeginSection": 148, "offsetInEndSection": 284, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25081584", "text": "STUDY OBJECTIVE To determine if a high score (\u2265 3) on the STOP-Bang screening questionnaire for obstructive sleep apnea (OSA) predicts whether obese patients are at high risk for OSA and increased risk of difficult airway.", "offsetInBeginSection": 0, "offsetInEndSection": 224, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a86ea05faa1ab7d2e000037", "body": "How is CTCF activated post-translationally?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16417510", "http://www.ncbi.nlm.nih.gov/pubmed/8381417", "http://www.ncbi.nlm.nih.gov/pubmed/12052863", "http://www.ncbi.nlm.nih.gov/pubmed/17403684", "http://www.ncbi.nlm.nih.gov/pubmed/24691257", "http://www.ncbi.nlm.nih.gov/pubmed/34643340", "http://www.ncbi.nlm.nih.gov/pubmed/22771116", "http://www.ncbi.nlm.nih.gov/pubmed/10037138", "http://www.ncbi.nlm.nih.gov/pubmed/21912613", "http://www.ncbi.nlm.nih.gov/pubmed/32128389"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25183525", "text": "Functionally, we show that CTCF interacts with TET methylcytosine dioxygenase (TET) enzymes and promotes adipogenic transcriptional enhancer DNA hydroxymethylation.", "offsetInBeginSection": 1100, "offsetInEndSection": 1264, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21912613", "text": "The Bcl-3/p50 complex suppressed CTCF promoter activity to down-regulate CTCF transcription.", "offsetInBeginSection": 818, "offsetInEndSection": 910, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24362533", "text": "CTCF binding, which was found in BCL6-expressing cell lines, correlated with the presence of histone variant H2A.Z and active histone marks, suggesting that CTCF induces chromatin modification at a transcriptionally active BCL6 locus.", "offsetInBeginSection": 972, "offsetInEndSection": 1206, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15361875", "text": "We show that the chromatin insulator protein CTCF carries a post-translational modification: poly(ADP-ribosyl)ation.", "offsetInBeginSection": 136, "offsetInEndSection": 252, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20110362", "text": "CCCTC binding factor (CTCF) controls DNA imprinting, insulates important gene expression, and mediates growth factor- and stress-induced cell fate.", "offsetInBeginSection": 0, "offsetInEndSection": 147, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19170077", "text": "CCCTC-binding factor (CTCF) is a ubiquitous Zn-finger-containing protein with numerous recognized functions, including, but not limited to, gene activation and repression, enhancer-blocking, X-chromosome inactivation, and gene imprinting.", "offsetInBeginSection": 0, "offsetInEndSection": 238, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29077515", "text": "CCCTC-binding factor (CTCF) is a conserved, essential regulator of chromatin architecture containing a unique array of 11 zinc fingers (ZFs).", "offsetInBeginSection": 0, "offsetInEndSection": 141, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24362533", "text": "CCCTC-binding factor (CTCF) is a multi-functional chromatin regulator, which has recently been shown to bind in a methylation-sensitive manner to sites within the BCL6 first intron.", "offsetInBeginSection": 629, "offsetInEndSection": 810, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24362533", "text": "This work demonstrates that, in contexts in which BCL6 is expressed, CTCF binding to BCL6 exon1A associates with epigenetic modifications indicative of transcriptionally open chromatin.", "offsetInBeginSection": 1617, "offsetInEndSection": 1802, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20110362", "text": "EGF-induced formation of a p65/p50 heterodimer activated CTCF transcription to promote cellular proliferation.", "offsetInBeginSection": 548, "offsetInEndSection": 658, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6a2f88b750ff4455000024", "body": "What is Target Explorer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21347154", "http://www.ncbi.nlm.nih.gov/pubmed/24202045", "http://www.ncbi.nlm.nih.gov/pubmed/30128806", "http://www.ncbi.nlm.nih.gov/pubmed/21249219", "http://www.ncbi.nlm.nih.gov/pubmed/16357031", "http://www.ncbi.nlm.nih.gov/pubmed/23493964", "http://www.ncbi.nlm.nih.gov/pubmed/24201739", "http://www.ncbi.nlm.nih.gov/pubmed/30914926", "http://www.ncbi.nlm.nih.gov/pubmed/34002702", "http://www.ncbi.nlm.nih.gov/pubmed/24975290"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372", "text": "Target Explorer is available at http://trantor.bioc.columbia.edu/Target_Explorer/", "offsetInBeginSection": 820, "offsetInEndSection": 901, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372", "text": "Target Explorer automates the entire process from the creation of a customized library of binding sites for known transcription factors through the prediction and annotation of putative target genes that are potentially regulated by these factors.", "offsetInBeginSection": 417, "offsetInEndSection": 664, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24925319", "text": "We found that c-Myc is a global explorer of the nucleus.", "offsetInBeginSection": 285, "offsetInEndSection": 341, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24864210", "text": "Emergence of rapid drug resistance to existing antimalarial drugs in Plasmodium falciparum has created the need for prediction of novel targets as well as leads derived from original molecules with improved activity against a validated drug target.", "offsetInBeginSection": 0, "offsetInEndSection": 248, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21619487", "text": "Knowledge of existing drug targets (both approved and within clinical trials) is highly useful for facilitating target discovery, selection, exploration and tool development.", "offsetInBeginSection": 319, "offsetInEndSection": 493, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21619487", "text": "This review briefly describes the TTD database and illustrates how its data can be explored for facilitating target and drug searches, the study of the mechanism of multi-target drugs and the development of in silico target discovery tools.", "offsetInBeginSection": 833, "offsetInEndSection": 1073, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21619487", "text": "The Therapeutic Target Database (TTD) has been developed and updated to provide information on 358 successful targets, 251 clinical trial targets and 1254 research targets in addition to 1511 approved drugs, 1118 clinical trials drugs and 2331 experimental drugs linked to their primary targets (3257 drugs with available structure data).", "offsetInBeginSection": 494, "offsetInEndSection": 832, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28817602", "text": "The analysis of structural variability through available redundant structures of a target, called multiple target conformations (MTC), obtained using experimental or modeling methods and under different biological conditions or different sources is one way to explore protein flexibility.", "offsetInBeginSection": 288, "offsetInEndSection": 576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28817602", "text": "To facilitate the study of these MTC sets, we have developed an efficient tool, SA-conf, dedicated to capturing and linking the amino acid and local structure variability and analyzing the target structural variability space.", "offsetInBeginSection": 853, "offsetInEndSection": 1078, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24925319", "text": "In contrast, the positive transcription elongation factor P-TEFb is a local explorer that oversamples its environment.", "offsetInBeginSection": 342, "offsetInEndSection": 460, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a772e9dfaa1ab7d2e000001", "body": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16639431", "http://www.ncbi.nlm.nih.gov/pubmed/32686156", "http://www.ncbi.nlm.nih.gov/pubmed/26493492", "http://www.ncbi.nlm.nih.gov/pubmed/30017405", "http://www.ncbi.nlm.nih.gov/pubmed/26009269", "http://www.ncbi.nlm.nih.gov/pubmed/32051399", "http://www.ncbi.nlm.nih.gov/pubmed/24968896", "http://www.ncbi.nlm.nih.gov/pubmed/26591429", "http://www.ncbi.nlm.nih.gov/pubmed/23144237", "http://www.ncbi.nlm.nih.gov/pubmed/21792888"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928", "text": "CONCLUSION Saracatinib is a novel oral Src kinase inhibitor that was well tolerated but failed to meet its primary endpoint of improvement in 4 month progression-free survival as a single agent in previously treated metastatic colorectal cancer patients.", "offsetInBeginSection": 1396, "offsetInEndSection": 1650, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928", "text": "Saracatinib (AZD0530) is a novel selective oral Src kinase inhibitor.", "offsetInBeginSection": 243, "offsetInEndSection": 312, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26271177", "text": "On the basis of the re-analysis it was concluded that solanezumab does show disease-modifying activity and should be considered a promising candidate for treatment of Alzheimer's disease in the near future.", "offsetInBeginSection": 576, "offsetInEndSection": 782, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001", "text": "Targeting Fyn kinase may be a promising therapeutic approach in AD, and a larger Phase IIa clinical trial of AZD0530 for the treatment of patients with AD has recently launched.", "offsetInBeginSection": 2493, "offsetInEndSection": 2670, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21977379", "text": "OBJECTIVE The cholinesterase inhibitor rivastigmine is approved for the treatment of mild to moderate Alzheimer's disease.", "offsetInBeginSection": 0, "offsetInEndSection": 122, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29112196", "text": "A more flexible theoretical framework capable of accommodating the complexity of the APP proteolytic system is required to integrate available evidence.Molecular Psychiatry advance online publication, 7 November 2017; doi:10.1038/mp.2017.218.", "offsetInBeginSection": 1474, "offsetInEndSection": 1716, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001", "text": "Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.", "offsetInBeginSection": 598, "offsetInEndSection": 800, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11763163", "text": "TAK-147 is a CNS-specific acetylcholinesterase inhibitor under development by Takeda as a potential treatment for Alzheimer's disease.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11802333", "text": "METHOD Data were collected from patients with Alzheimer's disease who were treated with rivastigmine between 1 October 1998-30 November 1999 at the Memory Disorders Outpatients Clinic at the Academic Medical Centre or the Slotervaart Hospital, both in Amsterdam, the Netherlands.", "offsetInBeginSection": 116, "offsetInEndSection": 395, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26271177", "text": "A more definite positioning of solanezumab will not be possible until data from the ongoing Expedition III study becomes available in 2017 at the earliest.", "offsetInBeginSection": 865, "offsetInEndSection": 1020, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a897729fcd1d6a10c000009", "body": "What is the asosciation between the  eustachian tube and the uvula?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11944475", "http://www.ncbi.nlm.nih.gov/pubmed/2750871", "http://www.ncbi.nlm.nih.gov/pubmed/24148589", "http://www.ncbi.nlm.nih.gov/pubmed/6586052", "http://www.ncbi.nlm.nih.gov/pubmed/33517248", "http://www.ncbi.nlm.nih.gov/pubmed/18695625", "http://www.ncbi.nlm.nih.gov/pubmed/32694471", "http://www.ncbi.nlm.nih.gov/pubmed/17049625", "http://www.ncbi.nlm.nih.gov/pubmed/16160520", "http://www.ncbi.nlm.nih.gov/pubmed/26901020"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21112097", "text": "CONCLUSION SMCP is often diagnosed very late, though symptoms of velopharyngeal insufficiency (hyper nasal speech, Eustachian tube dysfunction) and bifid uvula are present.", "offsetInBeginSection": 795, "offsetInEndSection": 967, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19644792", "text": "CONCLUSIONS SMCP is often diagnosed very late, though symptoms of velopharyngeal insufficiency such as open nasal speech, Eustachian tube dysfunction and reduced contraction of the palate with bifid uvula are present.", "offsetInBeginSection": 1222, "offsetInEndSection": 1439, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17049625", "text": "A bifid uvula may be considered the earliest form of a cleft palate, and more importantly, it has been shown in the literature to be associated with other anomalies as submucosal cleft, hyoplastic eustachian tube orifice, and absence of the salpingopharyngeal folds.", "offsetInBeginSection": 766, "offsetInEndSection": 1032, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052", "text": "Cleft palate, even in the microform of cleft uvula, was an indicator of large eustachian tube (p less than 0.001).", "offsetInBeginSection": 220, "offsetInEndSection": 334, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26901020", "text": "OBJECTIVE We sought to combine the Valsalva maneuver with MRI to evaluate eustachian tube function in patients with nasopharyngeal carcinoma (NPC) and to correlate the extent of tumor invasion with the presence of middle ear effusion (MEE) and eustachian tube dysfunction (ETD).", "offsetInBeginSection": 0, "offsetInEndSection": 278, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19644792", "text": "BACKGROUND Submucous cleft palate (SMCP) is often diagnosed very late and can cause velopharyngeal insufficiency with open nasal speech and Eustachian tube dysfunction.", "offsetInBeginSection": 0, "offsetInEndSection": 168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052", "text": "Clinical data supported the hypothesis that most otitis media requiring surgery is part of a life-long bilateral process that correlates with small mastoid air system, and with a bougie-assessable large eustachian tube.", "offsetInBeginSection": 0, "offsetInEndSection": 219, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26901020", "text": "ETD was correlated with tumor invasion of the ipsilateral pharyngeal recess (p < 0.001), pharyngeal opening of the eustachian tube (p < 0.001), the cartilaginous eustachian tube (p < 0.001), the eustachian cartilage (p < 0.001), Ostmann fat pad (p < 0.001), the levator veli palatine muscle (p < 0.001), and the tensor veli palatine muscle (p < 0.001).", "offsetInBeginSection": 745, "offsetInEndSection": 1097, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26901020", "text": "The cause of MEE in patients with NPC is dysfunction of the eustachian tube opening, which is associated with tumor invasion around the eustachian tube.", "offsetInBeginSection": 1379, "offsetInEndSection": 1531, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17049625", "text": "A bifid uvula, midline diastasis of the palatal muscles, and notching of the posterior hard palate have classically formed a triad diagnosing submucosal clefts.", "offsetInBeginSection": 0, "offsetInEndSection": 160, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a888b56d543831129000002", "body": "What induces Arabidopsis ROF1 expression?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18219494", "http://www.ncbi.nlm.nih.gov/pubmed/24664204", "http://www.ncbi.nlm.nih.gov/pubmed/31721650", "http://www.ncbi.nlm.nih.gov/pubmed/17012601", "http://www.ncbi.nlm.nih.gov/pubmed/32320660", "http://www.ncbi.nlm.nih.gov/pubmed/9461499", "http://www.ncbi.nlm.nih.gov/pubmed/15980201", "http://www.ncbi.nlm.nih.gov/pubmed/27189192", "http://www.ncbi.nlm.nih.gov/pubmed/32100164", "http://www.ncbi.nlm.nih.gov/pubmed/12410808"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428", "text": "Arabidopsis ROF1 (AtFKBP62) is a peptidyl prolyl cis/trans isomerase and a member of the FKBP (FK506 binding protein) family.", "offsetInBeginSection": 0, "offsetInEndSection": 125, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8914512", "text": "We have isolated clones of an Arabidopsis gene (ROF1, for rotamase FKBP) encoding a high molecular weight member of the FK506 binding protein (FKBP) family.", "offsetInBeginSection": 0, "offsetInEndSection": 156, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14996219", "text": "ROF1 and XERO2).", "offsetInBeginSection": 836, "offsetInEndSection": 852, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25944928", "text": "The Arabidopsis thaliana genome encodes three RNA-binding proteins (RBPs), UBP1-associated protein 2a (UBA2a), UBA2b, and UBA2c, that contain two RNA-recognition motif (RRM) domains.", "offsetInBeginSection": 0, "offsetInEndSection": 182, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22268595", "text": "In the plant Arabidopsis thaliana, we found that intracellular acid stress generated by weak organic acids at normal external pH induces expression of several chaperone genes, including ROF2, which encodes a peptidyl-prolyl cis-trans isomerase of the FK506-binding protein class.", "offsetInBeginSection": 198, "offsetInEndSection": 477, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19876748", "text": "Transient expression of ROF2 together with ROF1 repressed transcription of small HSPs.", "offsetInBeginSection": 1124, "offsetInEndSection": 1210, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23133621", "text": "Our results show that ROF1 plays an important role in the osmotic/salt stress responses of germinating Arabidopsis thaliana seedlings and suggest its involvement in salinity stress responses through a phosphatidylinositol-phosphate related protein quality control pathway.", "offsetInBeginSection": 1315, "offsetInEndSection": 1587, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17080288", "text": "We report the characterization of the Arabidopsis large FKBPs ROF1 (AtFKBP62) and ROF2 (AtFKBP65) expression and protein accumulation patterns.", "offsetInBeginSection": 174, "offsetInEndSection": 317, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428", "text": "Exposure to heat stress induces nuclear localization of the ROF1-HSP90.1 complex, which is dependent upon the presence of the transcription factor HsfA2, which interacts with HSP90.1 but not with ROF1.", "offsetInBeginSection": 363, "offsetInEndSection": 564, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17080288", "text": "The plant co-chaperones FK506-binding proteins (FKBPs) are peptidyl prolyl cis-trans isomerases that function in protein folding, signal transduction and chaperone activity.", "offsetInBeginSection": 0, "offsetInEndSection": 173, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a67a207b750ff4455000008", "body": "List indications for palivizumab for treatment of RSV-induced bronchiolitis. ", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19063700", "http://www.ncbi.nlm.nih.gov/pubmed/20705882", "http://www.ncbi.nlm.nih.gov/pubmed/32288783", "http://www.ncbi.nlm.nih.gov/pubmed/20457017", "http://www.ncbi.nlm.nih.gov/pubmed/26953285", "http://www.ncbi.nlm.nih.gov/pubmed/24231153", "http://www.ncbi.nlm.nih.gov/pubmed/25070304", "http://www.ncbi.nlm.nih.gov/pubmed/16236360", "http://www.ncbi.nlm.nih.gov/pubmed/12171262", "http://www.ncbi.nlm.nih.gov/pubmed/25070315"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20695756", "text": "Prevention of RSV infection includes palivizumab, which is proven to be effective in reducing the overall hospitalization rate for RSV-induced bronchiolitis in preterm neonates.", "offsetInBeginSection": 564, "offsetInEndSection": 741, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20705882", "text": "ANSWER Most infants should not be considered for RSV prophylaxis with palivizumab.", "offsetInBeginSection": 254, "offsetInEndSection": 336, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19811111", "text": "CONCLUSION Palivizumab provides cost-effective prophylaxis against RSV in high-risk infants.", "offsetInBeginSection": 2044, "offsetInEndSection": 2136, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28987219", "text": "There is definitive evidence that RSV-induced bronchiolitis can damage the airways to promote airway obstruction and recurrent wheezing.", "offsetInBeginSection": 602, "offsetInEndSection": 738, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19811111", "text": "OBJECTIVE To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in the indication of preterm infants and infants with preterm/bronchopulmonary dysplasia and in the second indication of children with congenital heart disease in the Dutch healthcare setting.", "offsetInBeginSection": 380, "offsetInEndSection": 769, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28987219", "text": "Treatments that inhibit inflammation have efficacy for RV-induced wheezing, whereas the anti-RSV mAb palivizumab decreases the risk of severe RSV-induced illness and subsequent recurrent wheeze.", "offsetInBeginSection": 1225, "offsetInEndSection": 1419, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20705882", "text": "QUESTION Palivizumab, a specific monoclonal antibody for respiratory syncytial virus (RSV), is available for prevention of pediatric respiratory tract infections.", "offsetInBeginSection": 0, "offsetInEndSection": 162, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262", "text": "The routine use of RSV monoclonal antibody, palivizumab, for RSV prophylaxis was reported by 49% (31/63) of paediatricians.", "offsetInBeginSection": 1049, "offsetInEndSection": 1172, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28987219", "text": "Respiratory syncytial virus (RSV) is the main causative agent of bronchiolitis, whereas rhinovirus (RV) is most commonly detected in wheezing children thereafter.", "offsetInBeginSection": 83, "offsetInEndSection": 245, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358", "text": "Although children with such disorders should be protected from RSV, they are currently excluded from the indication for palivizumab administration as passive immunization against RSV in Japan.", "offsetInBeginSection": 995, "offsetInEndSection": 1187, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a86f074faa1ab7d2e00003a", "body": "With which cancers has the loss of SMARCB1 been associated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33432679", "http://www.ncbi.nlm.nih.gov/pubmed/33451916", "http://www.ncbi.nlm.nih.gov/pubmed/18973917", "http://www.ncbi.nlm.nih.gov/pubmed/18072270", "http://www.ncbi.nlm.nih.gov/pubmed/24525513", "http://www.ncbi.nlm.nih.gov/pubmed/27921248", "http://www.ncbi.nlm.nih.gov/pubmed/25007146", "http://www.ncbi.nlm.nih.gov/pubmed/32380731", "http://www.ncbi.nlm.nih.gov/pubmed/28825187", "http://www.ncbi.nlm.nih.gov/pubmed/28824165"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22797305", "text": "Here we sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early childhood characterized by biallelic loss of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex.", "offsetInBeginSection": 374, "offsetInEndSection": 569, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25490678", "text": "Differences in mutation profiles and patterns of gene gains/losses are seen between BRCA2 (associated with TP53/PTEN mutations, loss of RB1 and gain of HRAS, STK11 and SMARCB1) and BRCAX (associated with PIK3CA mutations) tumours, suggesting that BRCA2 and BRCAX MBCs may be distinct and arise from different tumour pathways.", "offsetInBeginSection": 1194, "offsetInEndSection": 1519, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26941181", "text": "Since discovering genetic alterations of the SMARCB1 gene in malignant rhabdoid tumours, the family of tumours harbouring loss of SMARCB1 expression has been steadily expanding.", "offsetInBeginSection": 158, "offsetInEndSection": 335, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28974397", "text": "In the course of clinical care, we encountered a patient with a complete loss of SMARCB1 (switch/sucrose nonfermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1), which encodes INI-1 (integrase interactor 1), as the sole detected driver of their urinary tract tumor.", "offsetInBeginSection": 93, "offsetInEndSection": 404, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23851500", "text": "SMARCB1 (Snf5/Ini1/Baf47) is a potent tumor suppressor, the loss of which serves as the diagnostic feature in malignant rhabdoid tumors (MRT) and atypical teratoid/rhabdoid tumors (AT/RT), two highly aggressive forms of pediatric neoplasms.", "offsetInBeginSection": 0, "offsetInEndSection": 240, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23851500", "text": "SMARCB1 is a core subunit of Swi/Snf chromatin remodeling complexes, and loss of SMARCB1 or other subunits of these complexes has been observed in a variety of tumor types.", "offsetInBeginSection": 241, "offsetInEndSection": 413, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23432645", "text": "SMARCB1 is a core subunit of the SWI/SNF chromatin remodeling complex, and the recent emergence of frequent mutations in genes that encode subunits of this complex across a wide variety of cancers suggests that perturbation of this chromatin remodeling complex constitutes a key driver of cancer formation.", "offsetInBeginSection": 192, "offsetInEndSection": 498, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23174932", "text": "About 10% of epithelioid sarcomas have biallelic mutation of the SMARCB1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1) gene resulting in a lack of this nuclear protein.", "offsetInBeginSection": 0, "offsetInEndSection": 222, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24853101", "text": "Consequently, investigation of the mechanisms by which SMARCB1 mutation causes cancer has relevance not only for rhabdoid tumors, but also potentially for the wide variety of SWI/SNF mutant cancers.", "offsetInBeginSection": 669, "offsetInEndSection": 867, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26743474", "text": "An expanded survey of other members of the SWI/SNF complex showed SMARCB1 loss in the undifferentiated component of two SMARCA4-intact tumors, and all SMARCA4- or SMARCB1-deficient tumors showed concomitant loss of expression of SMARCA2.", "offsetInBeginSection": 653, "offsetInEndSection": 890, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6d022ab750ff445500002a", "body": "Is there any linear-time and linear-space algorithm for the computation of avoided words in biological sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19894615", "http://www.ncbi.nlm.nih.gov/pubmed/29658774", "http://www.ncbi.nlm.nih.gov/pubmed/36385911", "http://www.ncbi.nlm.nih.gov/pubmed/18233508", "http://www.ncbi.nlm.nih.gov/pubmed/17446914", "http://www.ncbi.nlm.nih.gov/pubmed/30315586", "http://www.ncbi.nlm.nih.gov/pubmed/15971771", "http://www.ncbi.nlm.nih.gov/pubmed/17369637", "http://www.ncbi.nlm.nih.gov/pubmed/18002786", "http://www.ncbi.nlm.nih.gov/pubmed/21096585"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277", "text": "We present a linear-time and linear-space algorithm for the computation of avoided words of length k in a given sequence x.", "offsetInBeginSection": 1647, "offsetInEndSection": 1770, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25526884", "text": "In this article, we present a new linear-time and linear-space algorithm for the computation of minimal absent words based on the suffix array.", "offsetInBeginSection": 1697, "offsetInEndSection": 1840, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038", "text": "There exists an O(n) -time and O(n) -space algorithm for computing all minimal absent words of a sequence of length n on a fixed-sized alphabet based on suffix arrays.", "offsetInBeginSection": 231, "offsetInEndSection": 398, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11694179", "text": "Berman and Hannenhalli avoided the explicit computation of the overlap graph and gave an O(nalpha(n)) algorithm, based on a Union-Find structure, to find its connected components, where alpha is the inverse Ackerman function.", "offsetInBeginSection": 537, "offsetInEndSection": 762, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25526884", "text": "RESULTS Our contribution in this article is twofold: first, we bridge this unpleasant gap by presenting an [Formula: see text]-time and [Formula: see text]-space algorithm for computing all minimal absent words based on the construction of suffix arrays; and second, we provide the respective implementation of this algorithm.", "offsetInBeginSection": 905, "offsetInEndSection": 1231, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25526884", "text": "There exists an [Formula: see text]-time and [Formula: see text]-space algorithm for computing all minimal absent words on a fixed-sized alphabet based on the construction of suffix automata (Crochemore et al., 1998).", "offsetInBeginSection": 345, "offsetInEndSection": 562, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11694179", "text": "In this paper, we present a new linear-time algorithm for computing the connected components, which is more efficient than that of Berman and Hannenhalli in both theory and practice.", "offsetInBeginSection": 905, "offsetInEndSection": 1087, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18283030", "text": "The kTST algorithm creates a k-deep tree in linear time that allows rapid searches for short patterns of length of up to k characters.", "offsetInBeginSection": 519, "offsetInEndSection": 653, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28407038", "text": "Results We present emMAW, the first external-memory algorithm for computing minimal absent words.", "offsetInBeginSection": 645, "offsetInEndSection": 742, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277", "text": "Hence, computing all such words na\u00efvely can be a very time-consuming procedure, in particular for large k.   RESULTS In this article, we propose an [Formula: see text]-time and [Formula: see text]-space algorithm to compute all [Formula: see text]-avoided words of length k in a given sequence of length n over a fixed-sized alphabet.", "offsetInBeginSection": 608, "offsetInEndSection": 943, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a735b383b9d13c708000002", "body": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30829617", "http://www.ncbi.nlm.nih.gov/pubmed/31452021", "http://www.ncbi.nlm.nih.gov/pubmed/35218869", "http://www.ncbi.nlm.nih.gov/pubmed/25604431", "http://www.ncbi.nlm.nih.gov/pubmed/25229269", "http://www.ncbi.nlm.nih.gov/pubmed/31639841", "http://www.ncbi.nlm.nih.gov/pubmed/30598431", "http://www.ncbi.nlm.nih.gov/pubmed/26611723", "http://www.ncbi.nlm.nih.gov/pubmed/25672679", "http://www.ncbi.nlm.nih.gov/pubmed/27033334"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208", "text": "BACKGROUND Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality.", "offsetInBeginSection": 0, "offsetInEndSection": 239, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25003808", "text": "INTRODUCTION Transthyretin (TTR)-related hereditary amyloidosis is an adult-onset, dominantly inherited, systemic neurodegenerative disease endemic in some populations.", "offsetInBeginSection": 0, "offsetInEndSection": 168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707", "text": "p53, caspase 2, PKN3, \u03b22-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral).", "offsetInBeginSection": 1020, "offsetInEndSection": 1302, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25604431", "text": "TTR protein destabilised by TTR gene mutation is prone to dissociate from its native tetramer to monomer, and to then misfold and aggregate into amyloid fibrils, resulting in autosomal dominant hereditary amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy and familial leptomeningeal amyloidosis.", "offsetInBeginSection": 181, "offsetInEndSection": 514, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25604431", "text": "Analogous misfolding of wild-type TTR results in senile systemic amyloidosis, now termed wild-type ATTR amyloidosis, characterised by acquired amyloid disease in the elderly.", "offsetInBeginSection": 515, "offsetInEndSection": 689, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25604431", "text": "Recently, the clinical effects of TTR tetramer stabilisers, diflunisal and tafamidis, were demonstrated in randomised clinical trials, and tafamidis has been approved for treatment of hereditary ATTR amyloidosis in European countries and in Japan.", "offsetInBeginSection": 1189, "offsetInEndSection": 1436, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26611723", "text": "The TTR stabilizers tafamidis and diflunisal slow disease progression in some patients with ATTR amyloidosis with polyneuropathy, and the postulated synergistic effect of doxycycline and tauroursodeoxycholic acid on dissolution of amyloid is under investigation.", "offsetInBeginSection": 784, "offsetInEndSection": 1046, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334", "text": "RNA interference (RNAi) is a clinically validated technology that may be a promising approach to the treatment of ATTR amyloidosis.", "offsetInBeginSection": 115, "offsetInEndSection": 246, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10137064", "text": "The entries include generic/chemical name, investigational drug number, synonyms, trade names, manufacturers, clinical trial status, predicted approval year, indications or drug class, whether the drug has been developed through biotechnology, and references.", "offsetInBeginSection": 243, "offsetInEndSection": 502, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10137850", "text": "The entries include generic/chemical name, investigational drug number, synonyms, trade names, manufacturers, clinical trial status, predicted approval year, indications or drug class, whether the drug has been developed through biotechnology, and references.", "offsetInBeginSection": 320, "offsetInEndSection": 579, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a67b48cb750ff4455000010", "body": "SGOT is an abbreviation for an enzyme other wise known as alanine amino transferase, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9805367", "http://www.ncbi.nlm.nih.gov/pubmed/5636816", "http://www.ncbi.nlm.nih.gov/pubmed/22056425", "http://www.ncbi.nlm.nih.gov/pubmed/7703229", "http://www.ncbi.nlm.nih.gov/pubmed/24469580", "http://www.ncbi.nlm.nih.gov/pubmed/16658147", "http://www.ncbi.nlm.nih.gov/pubmed/8566704", "http://www.ncbi.nlm.nih.gov/pubmed/2760064", "http://www.ncbi.nlm.nih.gov/pubmed/2991884", "http://www.ncbi.nlm.nih.gov/pubmed/8555180"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/589307", "text": "Mean values of glutamate dehydrogenase (GDH), serum aspartate and alanine transferase (SGOT and SGPT), ornithine carbamoyltransferase (OCT), and gamma-glutamyltranspeptidase (gamma-GTP) tended to rise with increasing liver cell necrosis, though values of SGOT, SGPT, OCT, and gamma-GTP showed considerable overlap between the 32 patients with histologically proved hepatitis and the 68 without.", "offsetInBeginSection": 156, "offsetInEndSection": 550, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17904308", "text": "The ethanolic extract of C. inerme significantly (P<0.001) decreases the serum enzyme alanine amino transferase (ALT), asparate amino transferase (AST), alkaline phosphates (ALP), triglycerides (TGL), total cholesterol (TC) and significantly increased the glutathione level.", "offsetInBeginSection": 195, "offsetInEndSection": 469, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1678364", "text": "DEC inhibited activities of monoamine oxidase, aspartate amino transferase and alanine amino transferase and enhanced those of cathepsin and glutamate dehydrogenase.", "offsetInBeginSection": 419, "offsetInEndSection": 584, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17880731", "text": "Complete blood picture, differential leukocyte count, and serum levels of Estrogen, Alanine amino transferase (SGPT), Aspartate amino transferase (SGOT), total protein and albumin were estimated.", "offsetInBeginSection": 293, "offsetInEndSection": 488, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21375200", "text": "The study excluded by screening for AntiHCV, HBsAg and patients with aspartate amino transferase (SGOT), alanine amino transferase (SGPT), GGT levels more than three times the normal and subject with a total leukocyte count more than 10,000/microl.", "offsetInBeginSection": 379, "offsetInEndSection": 627, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/5470040", "text": "Serum aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT), creatinine phosphokinase (CPK), and butyric acid dehydrogenase (BDH) were determined in 94 patients before, 1(1/2) hours, and 24 hours after cardioversion.", "offsetInBeginSection": 0, "offsetInEndSection": 229, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16877991", "text": "An increase in alanine amino transferase (ALT) and ALT/aspartate aminotransferase ratio was associated with the mutation (F = 4.46, P = 0.016 and F = 5.92, P = 0.0049, respectively).", "offsetInBeginSection": 938, "offsetInEndSection": 1120, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/5349302", "text": "When synthetic oestrogens were given, raised values of serum aspartate and alanine amino-transferase (S.G.O.T.", "offsetInBeginSection": 118, "offsetInEndSection": 228, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1681419", "text": "Glucagon increased alanine amino transferase (AAT) activity in perfused rat liver by about 90% over control.", "offsetInBeginSection": 0, "offsetInEndSection": 108, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21375200", "text": "Subjects were measured for waist/hip ratio, BMI and serum levels of ALT, AST, Alk phosphatase and glutamyl transferase (GGT).", "offsetInBeginSection": 253, "offsetInEndSection": 378, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a893da7bc7bade53a000001", "body": "Is CREB a key memory protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12058167", "http://www.ncbi.nlm.nih.gov/pubmed/17553985", "http://www.ncbi.nlm.nih.gov/pubmed/16980541", "http://www.ncbi.nlm.nih.gov/pubmed/32161734", "http://www.ncbi.nlm.nih.gov/pubmed/25031400", "http://www.ncbi.nlm.nih.gov/pubmed/22564082", "http://www.ncbi.nlm.nih.gov/pubmed/10377374", "http://www.ncbi.nlm.nih.gov/pubmed/9126327", "http://www.ncbi.nlm.nih.gov/pubmed/10964952", "http://www.ncbi.nlm.nih.gov/pubmed/10652539"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12006982", "text": "The cyclic AMP responsive element binding protein (CREB) is a key transcription factor in synaptic plasticity and memory consolidation.", "offsetInBeginSection": 112, "offsetInEndSection": 247, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23504989", "text": "The transcription factor cAMP response element binding protein (CREB) is a key protein implicated in memory, synaptic plasticity and structural plasticity in mammals.", "offsetInBeginSection": 0, "offsetInEndSection": 166, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22267118", "text": "The transcription factor cyclic AMP-response element binding protein (CREB) is a key regulator of many neuronal processes, including brain development, circadian rhythm and long-term memory.", "offsetInBeginSection": 0, "offsetInEndSection": 190, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15988467", "text": "Moreover, Rolipram treatments have been shown to increase expression and phosphorylation of a key factor for hippocampal memory consolidation, the cAMP-dependent response element-binding protein, CREB.", "offsetInBeginSection": 115, "offsetInEndSection": 316, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21712073", "text": "The transcription factor cAMP response element binding protein (CREB) is a key player in synaptic plasticity and learning.", "offsetInBeginSection": 0, "offsetInEndSection": 122, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19110430", "text": "Mechanistically, DREAM functions as a negative regulator of the key memory factor CREB in a Ca(2+)-dependent manner, and loss of DREAM facilitates CREB-dependent transcription during learning.", "offsetInBeginSection": 927, "offsetInEndSection": 1119, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9530494", "text": "The cAMP responsive element binding protein (CREB) is a nuclear protein that modulates the transcription of genes with cAMP responsive elements in their promoters.", "offsetInBeginSection": 0, "offsetInEndSection": 163, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283", "text": "The cAMP responsive element binding protein (CREB) is a nuclear transcription factor that modulates transcription of genes containing cAMP responsive elements (CRE sites) in their promoters.", "offsetInBeginSection": 233, "offsetInEndSection": 423, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28017136", "text": "Moreover, sumoylation, an important post-translational modification of protein, plays a key role in sustaining CREB activation in the rat hippocampus in order to enhance the long-term memory and other aspects.", "offsetInBeginSection": 319, "offsetInEndSection": 528, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21734652", "text": "As the transcription factor CREB (cAMP/Ca(2+) responsive element-binding protein) is critical for memory formation across species, we investigated the role of CREB in a mouse model of AD.", "offsetInBeginSection": 81, "offsetInEndSection": 268, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a67ade5b750ff445500000c", "body": "Does erythromycin increase risk of hypertrophic pyloric stenosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2358993", "http://www.ncbi.nlm.nih.gov/pubmed/15368696", "http://www.ncbi.nlm.nih.gov/pubmed/17101376", "http://www.ncbi.nlm.nih.gov/pubmed/1378938", "http://www.ncbi.nlm.nih.gov/pubmed/469469", "http://www.ncbi.nlm.nih.gov/pubmed/10770691", "http://www.ncbi.nlm.nih.gov/pubmed/984599", "http://www.ncbi.nlm.nih.gov/pubmed/33140632", "http://www.ncbi.nlm.nih.gov/pubmed/2223531", "http://www.ncbi.nlm.nih.gov/pubmed/17934821"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18358279", "text": "BACKGROUND Erythromycin treatment before 2 weeks of age has been shown to increase the risk of infantile hypertrophic pyloric stenosis (IHPS) up to 10 times.", "offsetInBeginSection": 0, "offsetInEndSection": 157, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27655365", "text": "PURPOSE Macrolide antibiotics, erythromycin, in particular, have been linked to the development of infantile hypertrophic pyloric stenosis (IHPS).", "offsetInBeginSection": 0, "offsetInEndSection": 146, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559", "text": "A case report has suggested that exposure to erythromycin through breast milk might cause infantile hypertrophic pyloric stenosis.", "offsetInBeginSection": 0, "offsetInEndSection": 130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11562617", "text": "OBJECTIVES To evaluate the risk for infantile hypertrophic pyloric stenosis (IHPS) among infants prescribed systemic erythromycin, infants prescribed a course of erythromycin ophthalmic ointment, and infants whose mothers were prescribed a macrolide antibiotic during pregnancy.", "offsetInBeginSection": 0, "offsetInEndSection": 278, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25687145", "text": "BACKGROUND AND OBJECTIVE Use of oral erythromycin in infants is associated with infantile hypertrophic pyloric stenosis (IHPS).", "offsetInBeginSection": 0, "offsetInEndSection": 127, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559", "text": "The use of macrolides during breast-feeding increases the risk of infantile hypertrophic pyloric stenosis.", "offsetInBeginSection": 895, "offsetInEndSection": 1001, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12381214", "text": "One of the more serious of these is infantile hypertrophic pyloric stenosis (IHPS).", "offsetInBeginSection": 115, "offsetInEndSection": 198, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559", "text": "This study therefore examined whether macrolides, transmitted via breast milk, increase the risk of infantile hypertrophic pyloric stenosis in neonates.", "offsetInBeginSection": 131, "offsetInEndSection": 283, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23558266", "text": "Early exposure to oral erythromycin in young infants, particularly in the first 2 weeks of life, has previously been associated with the development of hypertrophic pyloric stenosis.", "offsetInBeginSection": 0, "offsetInEndSection": 182, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12100810", "text": "Causal inference from the association between prenatal nonerythromycin macrolides and infantile hypertrophic pyloric stenosis is limited by the small number of affected children and the evidence of other differences between users of nonerythromycin macrolides and controls.", "offsetInBeginSection": 1442, "offsetInEndSection": 1715, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a870b7bfaa1ab7d2e00003d", "body": "What is the function of STAR elements in yeast telomeres?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25453752", "http://www.ncbi.nlm.nih.gov/pubmed/10090726", "http://www.ncbi.nlm.nih.gov/pubmed/16713250", "http://www.ncbi.nlm.nih.gov/pubmed/6350893", "http://www.ncbi.nlm.nih.gov/pubmed/19026778", "http://www.ncbi.nlm.nih.gov/pubmed/11676924", "http://www.ncbi.nlm.nih.gov/pubmed/7548843", "http://www.ncbi.nlm.nih.gov/pubmed/7809947", "http://www.ncbi.nlm.nih.gov/pubmed/17715303", "http://www.ncbi.nlm.nih.gov/pubmed/25225329"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687", "text": "The fragments have a 1.18-kb region homologous with the type X regions at yeast telomeres that contain ARS elements that allow the autonomous replication of plasmids in yeast.", "offsetInBeginSection": 227, "offsetInEndSection": 402, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16132818", "text": "Telomeres are multifunctional genetic elements that cap chromosome ends, playing essential roles in genome stability, chromosome higher-order organization and proliferation control.", "offsetInBeginSection": 0, "offsetInEndSection": 181, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21949764", "text": "Thus the STAR and TEF2-UASrpg boundary elements inhibit chromatin silencing through an antisilencing activity independently of their position or orientation in S. cerevisiae minichromosomes rather than by creating a position-specific barrier as seen in the genome.", "offsetInBeginSection": 1122, "offsetInEndSection": 1386, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21949764", "text": "We found that both HML-E and HML-I silencers can efficiently repress the URA3 reporter on a multi-copy yeast minichromosome and we further showed that two distinct heterochromatin boundary elements STAR and TEF2-UASrpg are able to limit the heterochromatin spreading in circular minichromosomes.", "offsetInBeginSection": 519, "offsetInEndSection": 814, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8720065", "text": "Most of the 'core' X elements also contain an Abf1p binding site and a URS1-like element, which may have consequences for the chromatin structure, nuclear architecture and transcription of native telomeres.", "offsetInBeginSection": 1409, "offsetInEndSection": 1615, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21437278", "text": "We also show that the deletion of Histone-Acetyltransferase genes reduce the silencing activity of an ACS proto-silencer, but also reduce the anti-silencing activity of a STAR.", "offsetInBeginSection": 660, "offsetInEndSection": 836, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687", "text": "DNA fragments isolated from the left end of chromosome III in the yeast Saccharomyces cerevisiae are recognized as telomeres in yeast, since plasmids constructed with such fragments are replicated as linear molecules in yeast.", "offsetInBeginSection": 0, "offsetInEndSection": 226, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166", "text": "Overall, our results suggest that the silencing emanating from telomeres can be propagated in a discontinuous manner via a series of subtelomeric relay elements.", "offsetInBeginSection": 1098, "offsetInEndSection": 1259, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21437278", "text": "Telomere Position Effect (TPE) is governed by strong repression signals emitted by telomeres via the Sir2/3/4 Histone Deacetylase complex.", "offsetInBeginSection": 0, "offsetInEndSection": 138, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9188726", "text": "The two proximal SF-1 response elements were shown to be critical for StAR promoter function in human granulosalutein cells, which express SF-1 and respond to cAMP with increased transcription of the StAR gene.", "offsetInBeginSection": 872, "offsetInEndSection": 1082, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6d13fbb750ff445500002f", "body": "What is MINDY (motif interacting with Ub-containing novel DUB family)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20181693", "http://www.ncbi.nlm.nih.gov/pubmed/15701692", "http://www.ncbi.nlm.nih.gov/pubmed/12859687", "http://www.ncbi.nlm.nih.gov/pubmed/34989313", "http://www.ncbi.nlm.nih.gov/pubmed/28786561", "http://www.ncbi.nlm.nih.gov/pubmed/10524205", "http://www.ncbi.nlm.nih.gov/pubmed/28133767", "http://www.ncbi.nlm.nih.gov/pubmed/22846990", "http://www.ncbi.nlm.nih.gov/pubmed/15483401", "http://www.ncbi.nlm.nih.gov/pubmed/21282113"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798", "text": "Here we report the discovery of a new family of DUBs, which we have named MINDY (motif interacting with Ub-containing novel DUB family).", "offsetInBeginSection": 139, "offsetInEndSection": 275, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15483401", "text": "The inference of the likely DUB function of the PPPDE superfamily proteins is based on the fusions of the catalytic domain to Ub-binding PUG (PUB)/UBA domains and a novel alpha-helical Ub-associated domain (the PUL domain, after PLAP, Ufd3p and Lub1p).", "offsetInBeginSection": 691, "offsetInEndSection": 943, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28786561", "text": "HPV16 E6 was found to bind to the homology to E6AP C terminus-type Ub ligase (E6AP), three really interesting new gene (RING)-type Ub ligases (MGRN1, LNX3, LNX4), and the DUB Ub-specific protease 15 (USP15).", "offsetInBeginSection": 615, "offsetInEndSection": 822, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28786561", "text": "HPV16 E7 was found to bind to several broad-complex tramtrack and bric-a-brac domain-containing proteins (such as TNFAIP1/KCTD13) that are potential substrate adaptors of Cullin 3-RING Ub ligases, to RING-type Ub ligases implicated in innate immunity (RNF135, TRIM32, TRAF2, TRAF5), to the substrate adaptor DCAF15 of Cullin 4-RING Ub ligase and to some DUBs (USP29, USP33).", "offsetInBeginSection": 1032, "offsetInEndSection": 1406, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26115687", "text": "USP47 released Ub from Ub-aminoacyl-4-metheylcoumaryl-7-amide and Ub-tagged granzyme B.", "offsetInBeginSection": 490, "offsetInEndSection": 577, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798", "text": "Found in all eukaryotes, MINDY-family DUBs are highly selective at cleaving K48-linked polyUb, a signal that targets proteins for degradation.", "offsetInBeginSection": 276, "offsetInEndSection": 418, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26115687", "text": "In this study, the physicochemical and enzymatic properties of recombinant human ubiquitin (Ub)-specific protease (USP) 47, a novel member of the C19 family of de-ubiquitinating enzymes (DUB), were characterized for the first time.", "offsetInBeginSection": 0, "offsetInEndSection": 231, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18980247", "text": "In addition, structural and immunoprecipitation analyses revealed that DUB-1 contains a putative PEST motif and is polyubiquitinated, indicating that DUB-1 is also regulated by the ubiquitin-proteasome pathway.", "offsetInBeginSection": 868, "offsetInEndSection": 1078, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12704427", "text": "Two novel proteins were isolated from HeLa cells by affinity purification using the DUB-specific inhibitor, Ub aldehyde (Ubal).", "offsetInBeginSection": 589, "offsetInEndSection": 716, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28082312", "text": "The recently discovered deubiquitinase MINDY-1/FAM63A contains a tandem MIU repeat (tMIU) that is highly selective at binding to K48-linked polyUb.", "offsetInBeginSection": 401, "offsetInEndSection": 548, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a735c143b9d13c708000003", "body": "Is patisiran currently (November 2017) in clinical phase II trials?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/14983981", "http://www.ncbi.nlm.nih.gov/pubmed/7986106", "http://www.ncbi.nlm.nih.gov/pubmed/14983983", "http://www.ncbi.nlm.nih.gov/pubmed/18729008", "http://www.ncbi.nlm.nih.gov/pubmed/12625032", "http://www.ncbi.nlm.nih.gov/pubmed/16100702", "http://www.ncbi.nlm.nih.gov/pubmed/29637216", "http://www.ncbi.nlm.nih.gov/pubmed/16499282", "http://www.ncbi.nlm.nih.gov/pubmed/24173686", "http://www.ncbi.nlm.nih.gov/pubmed/26958930"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/14983983", "text": "In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction.", "offsetInBeginSection": 240, "offsetInEndSection": 439, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094", "text": "Patisiran 0.3\u00a0mg/kg Q3W is currently in phase III development.", "offsetInBeginSection": 1672, "offsetInEndSection": 1735, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707", "text": "The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3).", "offsetInBeginSection": 582, "offsetInEndSection": 727, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707", "text": "p53, caspase 2, PKN3, \u03b22-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral).", "offsetInBeginSection": 1020, "offsetInEndSection": 1302, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28043166", "text": "Phase III trials are currently underway with an estimated accrual end date of 2017.", "offsetInBeginSection": 842, "offsetInEndSection": 925, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14983981", "text": "Phase I clinical trials of NC-531 were ongoing in November 1999, and by October 2002 phase II trials were underway.", "offsetInBeginSection": 177, "offsetInEndSection": 292, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28591872", "text": "Two international phase III trials evaluate an adjuvant immunotherapy with nivolumab and atezolizumab.", "offsetInBeginSection": 974, "offsetInEndSection": 1076, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21740357", "text": "Among these are the armed oncolytic adenoviruses such as H103 (expressing the heat shock protein) currently has finished phase I trial, and KH901 (expressing GM-CSF) now launched in phase II trial In this review, we will discuss the current status of ongoing oncolytic virus projects being conducted at various clinical stages in China, including the preliminary market response for Oncorine after it was launched into the Chinese market in 2006.", "offsetInBeginSection": 385, "offsetInEndSection": 831, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707", "text": "This review addresses nine small-interfering RNAs (siRNAs) and one unique microRNA (miRNA) inhibitor, which entered the phase 2-3 clinical trials.", "offsetInBeginSection": 435, "offsetInEndSection": 581, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29134822", "text": "This article will review the available phase II and phase III guselkumab clinical trial data.", "offsetInBeginSection": 159, "offsetInEndSection": 252, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a787544faa1ab7d2e00000b", "body": "Is Kummell\u2019s disease an avascular necrosis of the vertebral body?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3726582", "http://www.ncbi.nlm.nih.gov/pubmed/10855321", "http://www.ncbi.nlm.nih.gov/pubmed/2250061", "http://www.ncbi.nlm.nih.gov/pubmed/6491222", "http://www.ncbi.nlm.nih.gov/pubmed/2656842", "http://www.ncbi.nlm.nih.gov/pubmed/19967016", "http://www.ncbi.nlm.nih.gov/pubmed/9604106", "http://www.ncbi.nlm.nih.gov/pubmed/3180615", "http://www.ncbi.nlm.nih.gov/pubmed/19124637", "http://www.ncbi.nlm.nih.gov/pubmed/21409500"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23814399", "text": "Kummell disease, or avascular necrosis of a vertebral body, presents as vertebral osteonecrosis typically affecting a thoracic vertebra with compression deformity, intravertebral vacuum cleft, and exaggerated kyphosis weeks to months after a minor traumatic injury.", "offsetInBeginSection": 0, "offsetInEndSection": 265, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28913640", "text": "INTRODUCTION Kummell's disease is an avascular necrosis of the vertebral body, secondary to a vertebral compression fracture.", "offsetInBeginSection": 0, "offsetInEndSection": 125, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19124637", "text": "Kummel disease is the eponym for avascular necrosis of the vertebral body after a vertebral compression fracture.", "offsetInBeginSection": 0, "offsetInEndSection": 113, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22220246", "text": "Kummell's disease is a spinal disorder characterized by delayed post-traumatic collapse of a vertebral body with avascular necrosis.", "offsetInBeginSection": 0, "offsetInEndSection": 132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19321060", "text": "Avascular necrosis of a vertebral body, a relatively uncommon entity, is caused by malignancy, infection, radiation, systemic steroid treatment, trauma, and the like.1 Vertebral osteonecrosis induced by trauma is called Kvmell's disease, because it was initially described by Hermann Kvmell of Germany in 1891.2 This paper reported a young female with posttraumatic vertebral osteonecrosis and analyzed the causes.", "offsetInBeginSection": 0, "offsetInEndSection": 414, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031", "text": "SUMMARY OF BACKGROUND DATA Avascular necrosis of a vertebral body is an uncommon entity.", "offsetInBeginSection": 276, "offsetInEndSection": 364, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10966213", "text": "In most cases of infectious spondylodiscitis, avascular necrosis of the vertebral body, nontraumatic vertebral compression fractures, and insufficiency fractures of the sacrum characteristic findings on MRI suggest the correct diagnosis.", "offsetInBeginSection": 935, "offsetInEndSection": 1172, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19214087", "text": "Surgical treatment is required in avascular necrosis of a vertebral body with progressive collapse and neurologic compromise secondary to osteoporotic fracture adjacent to a wedge-shaped vertebra at the thoracolumbar junction.", "offsetInBeginSection": 1027, "offsetInEndSection": 1253, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031", "text": "The intravertebral vacuum cleft phenomenon seen on plain films has been strongly associated with vertebral body avascular necrosis.", "offsetInBeginSection": 534, "offsetInEndSection": 665, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12865850", "text": "The indicators of the condition included spinal instability associated with avascular necrosis, which was diagnosed by a vacuum phenomenon or by fluid collection in the vertebral body as found from imaging studies.", "offsetInBeginSection": 810, "offsetInEndSection": 1024, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a895a96fcd1d6a10c000003", "body": "Can a circRNA be translated into protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29643274", "http://www.ncbi.nlm.nih.gov/pubmed/30367041", "http://www.ncbi.nlm.nih.gov/pubmed/34342387", "http://www.ncbi.nlm.nih.gov/pubmed/35379558", "http://www.ncbi.nlm.nih.gov/pubmed/30091402", "http://www.ncbi.nlm.nih.gov/pubmed/25449546", "http://www.ncbi.nlm.nih.gov/pubmed/32955563", "http://www.ncbi.nlm.nih.gov/pubmed/35936754", "http://www.ncbi.nlm.nih.gov/pubmed/6131379", "http://www.ncbi.nlm.nih.gov/pubmed/36151789"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28344082", "text": "Circ-ZNF609 is associated with heavy polysomes, and it is translated into a protein in a splicing-dependent and cap-independent manner, providing an example of a protein-coding circRNA in eukaryotes.", "offsetInBeginSection": 910, "offsetInEndSection": 1109, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25449546", "text": "The resulting circRNA can be translated to generate functional proteins.", "offsetInBeginSection": 792, "offsetInEndSection": 864, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28223408", "text": "This subsequently results in back-splicing of the 5' cleavage product into a circRNA that can translate a reporter protein from an internal ribosomal entry site (IRES).", "offsetInBeginSection": 698, "offsetInEndSection": 866, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28223408", "text": "Here we describe a switch for inducing back-splicing of an engineered circRNA that relies on the CRISPR endoribonuclease, Csy4, as an activator of circularization.", "offsetInBeginSection": 271, "offsetInEndSection": 434, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28705773", "text": "Third, they can be translated into protein driven by N6-methyladenosine modification.", "offsetInBeginSection": 446, "offsetInEndSection": 531, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29028266", "text": "To gain insights into the new area of circRNA translation, we introduce an integrated tool capable of detecting circRNAs with protein-coding potential from high-throughput sequencing data.", "offsetInBeginSection": 645, "offsetInEndSection": 833, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28344080", "text": "In addition, we found that a circRNA generated from the muscleblind locus encodes a protein, which we detected in fly head extracts by mass spectrometry.", "offsetInBeginSection": 466, "offsetInEndSection": 619, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29036403", "text": "We constructed a cancer-specific circRNA database (CSCD, http://gb.whu.edu.cn/CSCD).", "offsetInBeginSection": 643, "offsetInEndSection": 727, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29036403", "text": "Circular RNA (circRNA) is a large group of RNA family extensively existed in cells and tissues.", "offsetInBeginSection": 0, "offsetInEndSection": 95, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25449546", "text": "Here we constructed a single exon minigene containing split GFP, and found that the pre-mRNA indeed produces circRNA through efficient backsplicing in human and Drosophila cells.", "offsetInBeginSection": 305, "offsetInEndSection": 483, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a67afb7b750ff445500000d", "body": "List main clinical features of the POEMS syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/6505218", "http://www.ncbi.nlm.nih.gov/pubmed/3363376", "http://www.ncbi.nlm.nih.gov/pubmed/2227242", "http://www.ncbi.nlm.nih.gov/pubmed/34341211", "http://www.ncbi.nlm.nih.gov/pubmed/10378364", "http://www.ncbi.nlm.nih.gov/pubmed/7640197", "http://www.ncbi.nlm.nih.gov/pubmed/25984208", "http://www.ncbi.nlm.nih.gov/pubmed/11274880", "http://www.ncbi.nlm.nih.gov/pubmed/22479298", "http://www.ncbi.nlm.nih.gov/pubmed/19863172"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27208909", "text": "POEMS is an acronym for the main clinical features of the syndrome, namely, Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin abnormalities.", "offsetInBeginSection": 137, "offsetInEndSection": 293, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27208909", "text": "POEMS syndrome is a paraneoplastic manifestation associated with hematopoietic disorders such as multiple myeloma and Castleman disease.", "offsetInBeginSection": 0, "offsetInEndSection": 136, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16136774", "text": "Although the etiology of type 2 autoimmune polyendocrine syndrome and POEMS syndrome are not as well characterized as that of the aforementioned monogenic diseases, considering their clinical importance, the authors summarize the main features of these syndromes, as well.", "offsetInBeginSection": 582, "offsetInEndSection": 854, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27208909", "text": "Glomeruloid hemangiomas are considered to be a specific clinical marker of POEMS syndrome.", "offsetInBeginSection": 294, "offsetInEndSection": 384, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25984208", "text": "POEMS syndrome is a rare conglomeration of disorders associated with plasma cell dyscrasia.", "offsetInBeginSection": 0, "offsetInEndSection": 91, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25984208", "text": "The acronym POEMS is derived from main features of the syndrome namely 'polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin lesions'.", "offsetInBeginSection": 92, "offsetInEndSection": 250, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364", "text": "The patient had many clinical features of the described POEMS syndrome including sclerotic bone lesions, a persistent lambda-paraprotein and refractory ascites.", "offsetInBeginSection": 541, "offsetInEndSection": 701, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25984208", "text": "Myeloma is the most common plasma cell dyscrasia associated with POEMS syndrome.", "offsetInBeginSection": 422, "offsetInEndSection": 502, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21221584", "text": "POEMS syndrome is a rare plasma cell dyscrasia characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes.", "offsetInBeginSection": 0, "offsetInEndSection": 138, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8699962", "text": "The POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy, and skin changes) syndrome is a rare variant of plasma cell dyscrasia with multisystemic manifestations.", "offsetInBeginSection": 0, "offsetInEndSection": 184, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a89528dfcd1d6a10c000001", "body": "Where do centromeres locate according to the Rabl orientation of eukaryotic nuclei?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21357674", "http://www.ncbi.nlm.nih.gov/pubmed/9813109", "http://www.ncbi.nlm.nih.gov/pubmed/15753566", "http://www.ncbi.nlm.nih.gov/pubmed/18541703", "http://www.ncbi.nlm.nih.gov/pubmed/24015880", "http://www.ncbi.nlm.nih.gov/pubmed/3395988", "http://www.ncbi.nlm.nih.gov/pubmed/14555468", "http://www.ncbi.nlm.nih.gov/pubmed/11453558", "http://www.ncbi.nlm.nih.gov/pubmed/15289660", "http://www.ncbi.nlm.nih.gov/pubmed/25277538"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/11559751", "text": "The Rabl orientation is an example of the non-random arrangement of chromosomes, centromeres are grouped in a limited area near the nuclear periphery and telomeres are located apart from centromeres.", "offsetInBeginSection": 52, "offsetInEndSection": 251, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20501974", "text": "Small genome species have chromosomes in their interphase nuclei disposed in diffuse chromosome territories, without any Rabl arrangement, while in large genomes the chromosomes run string-like through the nucleus with a Rabl orientation following through the cell cycle.", "offsetInBeginSection": 211, "offsetInEndSection": 482, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25060696", "text": "The global RNAPII distribution within nuclei is not influenced by interphase chromatin organization such as Rabl (rye) versus non-Rabl (Arabidopsis thaliana) orientation.", "offsetInBeginSection": 531, "offsetInEndSection": 701, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774", "text": "Both Rabl and non-Rabl distribution patterns of centromeres and telomeres were consistent in interphase nuclei derived from meristematic root tip cells, microspore mother cells and differentiated leaf cells.", "offsetInBeginSection": 659, "offsetInEndSection": 866, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15102067", "text": "In wheat and its close relatives, the interphase chromosomes adopt a highly regular Rabl configuration, with the two chromosome arms lying next to each other and the centromeres and telomeres located at opposite poles of the nuclei.", "offsetInBeginSection": 343, "offsetInEndSection": 575, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21674259", "text": "Applying fluorescence in situ hybridization, we found that both rye A and B chromosomes added to hexaploid wheat showed in meristematic nuclei a string-like shape and a clear Rabl orientation.", "offsetInBeginSection": 259, "offsetInEndSection": 451, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3395988", "text": "No polarization of heterochromatin in a Rabl orientation is seen in the trophoblast nuclei.", "offsetInBeginSection": 391, "offsetInEndSection": 482, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11559751", "text": "The existence of the triplex structure (centromere-microtubule-Sad1 body) suggests that the clustering of centromeres is controlled by a cytoplasmic microtubular system.", "offsetInBeginSection": 944, "offsetInEndSection": 1113, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7789185", "text": "The observed orientation of the centromeres is reminiscent of the Rabl polarization of chromosomes; this is the first mammalian cell substrate in which such an higher-order chromosomal organization has been observed.", "offsetInBeginSection": 665, "offsetInEndSection": 881, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15102067", "text": "By contrast, the chromosomes in most rice nuclei clearly do not show a Rabl configuration.", "offsetInBeginSection": 576, "offsetInEndSection": 666, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e18d8b750ff4455000038", "body": "Are Conserved Nonexonic Elements (CNEEs) important in phylogenomics research?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30517151", "http://www.ncbi.nlm.nih.gov/pubmed/16806968", "http://www.ncbi.nlm.nih.gov/pubmed/7312050", "http://www.ncbi.nlm.nih.gov/pubmed/23357263", "http://www.ncbi.nlm.nih.gov/pubmed/10388814", "http://www.ncbi.nlm.nih.gov/pubmed/19344491", "http://www.ncbi.nlm.nih.gov/pubmed/26362138", "http://www.ncbi.nlm.nih.gov/pubmed/29449857", "http://www.ncbi.nlm.nih.gov/pubmed/21852499", "http://www.ncbi.nlm.nih.gov/pubmed/17096848"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21852499", "text": "These putative regulatory regions are conserved nonexonic elements (CNEEs), which are evolutionarily conserved yet do not overlap any coding or noncoding mature transcript.", "offsetInBeginSection": 323, "offsetInEndSection": 495, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293", "text": "Here we analyze and study the evolutionary properties of a new type of noncoding marker, conserved nonexonic elements (CNEEs), which consists of noncoding elements that are estimated to evolve slower than the neutral rate across a set of species.", "offsetInBeginSection": 290, "offsetInEndSection": 536, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17463089", "text": "Recent work has highlighted a handful of cases where mobile element insertions have resulted in the introduction of novel conserved nonexonic elements.", "offsetInBeginSection": 317, "offsetInEndSection": 468, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15802507", "text": "We present bioinformatic, phylogenetic, and experimental evidence in Drosophila for a mechanism that subdivides many large introns by recursive splicing at nonexonic elements and alternative exons.", "offsetInBeginSection": 167, "offsetInEndSection": 364, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18832441", "text": "Here, we present a global evolutionary analysis of mammalian conserved nonexonic elements (CNEs), and find strong evidence to the contrary.", "offsetInBeginSection": 373, "offsetInEndSection": 512, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15802507", "text": "Mutation of nonexonic site RP3 within Ultrabithorax also confirmed that recursive splicing is the predominant processing pathway even with a shortened version of the intron.", "offsetInBeginSection": 1254, "offsetInEndSection": 1427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22952639", "text": "These putative regulatory regions are conserved non-exonic elements (CNEEs), which show considerable cross-species constraint and signatures of continued negative selection in humans, yet do not appear in a known mature transcript.", "offsetInBeginSection": 685, "offsetInEndSection": 916, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19371447", "text": "Strikingly, conservation of expression correlates poorly with the amount of conserved nonexonic sequence, even using a sequence alignment technique that accounts for non-collinearity in conserved elements.", "offsetInBeginSection": 867, "offsetInEndSection": 1072, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28417603", "text": "Target capture for vertebrate animals is currently dominated by two approaches-anchored hybrid enrichment (AHE) and ultraconserved elements (UCE)-and both approaches have proven useful for addressing questions in phylogenomics, phylogeography and population genomics.", "offsetInBeginSection": 316, "offsetInEndSection": 583, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11076855", "text": "In addition to these coding elements, we identified 33 CpG islands and 49 orthologous nonexonic, nonisland sequences that met our criteria as being conserved, and making up 4.1% of the total sequence.", "offsetInBeginSection": 803, "offsetInEndSection": 1003, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7361d83b9d13c708000005", "body": "What is miravirsen?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11654349", "http://www.ncbi.nlm.nih.gov/pubmed/11789525", "http://www.ncbi.nlm.nih.gov/pubmed/11662648", "http://www.ncbi.nlm.nih.gov/pubmed/11271619", "http://www.ncbi.nlm.nih.gov/pubmed/11824273", "http://www.ncbi.nlm.nih.gov/pubmed/11925667", "http://www.ncbi.nlm.nih.gov/pubmed/12077793", "http://www.ncbi.nlm.nih.gov/pubmed/12082812", "http://www.ncbi.nlm.nih.gov/pubmed/11643613", "http://www.ncbi.nlm.nih.gov/pubmed/10247165"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103", "text": "Combination studies of miravirsen with interferon \u03b12b, ribavirin, and nonnucleoside (VX-222) and nucleoside (2'-methylcytidine) inhibitors of NS5B, NS5A (BMS-790052), or NS3 (telaprevir) indicated additive interactions.", "offsetInBeginSection": 461, "offsetInEndSection": 681, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103", "text": "Miravirsen is a \u03b2-D-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide targeting the liver-specific microRNA-122 (miR-122).", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24385319", "text": "Currently, the most advanced miR-122 targeting therapy is SPC3649 (miravirsen), a locked nucleic acid-modified oligonucleotide antagonizing miR-122.", "offsetInBeginSection": 388, "offsetInEndSection": 536, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27805315", "text": "Miravirsen, a locked-nucleic acid oligonucleotide, sequesters miR-122 and inhibits HCV replication.", "offsetInBeginSection": 207, "offsetInEndSection": 306, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553", "text": "Miravirsen is composed of locked nucleic acid (LNAs) ribonucleotides interspaced throughout a DNA phosphorothioate sequence complementary to mature miR-122.", "offsetInBeginSection": 522, "offsetInEndSection": 678, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23534542", "text": "Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function.", "offsetInBeginSection": 176, "offsetInEndSection": 364, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22545703", "text": "Miravirsen, an oligonucleotide with locked nucleic acid, binds to miR-122, potently inhibiting its activity.", "offsetInBeginSection": 126, "offsetInEndSection": 234, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23109665", "text": "The most advanced of these programs targets the liver-expressed miRNA-122 using the locked nucleic acid (LNA)-modified antisense oligonucleotide miravirsen.", "offsetInBeginSection": 272, "offsetInEndSection": 428, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553", "text": "It is the target of miravirsen (SPC3649), an antimiR drug candidate currently in clinical testing for treatment of HCV infections.", "offsetInBeginSection": 391, "offsetInEndSection": 521, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27805315", "text": "In conclusion, miravirsen delivery during NEVLP is a potential strategy to prevent HCV reinfection after LT.", "offsetInBeginSection": 1095, "offsetInEndSection": 1203, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7a44b4faa1ab7d2e000010", "body": "Is Loss of function one of the cardinal signs of inflammation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1699987", "http://www.ncbi.nlm.nih.gov/pubmed/6360096", "http://www.ncbi.nlm.nih.gov/pubmed/1617392", "http://www.ncbi.nlm.nih.gov/pubmed/35258243", "http://www.ncbi.nlm.nih.gov/pubmed/29135930", "http://www.ncbi.nlm.nih.gov/pubmed/28728825", "http://www.ncbi.nlm.nih.gov/pubmed/26372222", "http://www.ncbi.nlm.nih.gov/pubmed/32501622", "http://www.ncbi.nlm.nih.gov/pubmed/15871350", "http://www.ncbi.nlm.nih.gov/pubmed/25411856"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21218013", "text": "An arthritic joint exhibits cardinal signs of joint inflammation, such as swelling, pain, heat, and loss of function; any joint can be arthritic, but large joints are more frequently affected.", "offsetInBeginSection": 514, "offsetInEndSection": 706, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12776909", "text": "The concept of the four cardinal signs of acute inflammation comes from antiquity as rubor et tumor cum calore et dolore, (redness and swelling with heat and pain) extended later by functio laesa (loss of function).", "offsetInBeginSection": 0, "offsetInEndSection": 215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851", "text": "It was Galen who added the disturbance of function (functio laesa) as the fifth cardinal sign of inflammation to the four well-known cardinal signs of Celsus (rubor, calor, tumor, dolor).", "offsetInBeginSection": 1008, "offsetInEndSection": 1195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22412193", "text": "This lipid mediator can induce the cardinal signs of inflammation, and the beneficial actions of nonsteroidal anti-inflammatory drugs are attributed to inhibition of cyclooxygenase (COX)-1 and COX-2, enzymes essential in the biosynthesis of PGE(2) from arachidonic acid.", "offsetInBeginSection": 60, "offsetInEndSection": 330, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930", "text": "As early as 2000 years ago, the Roman encyclopaedist Aulus Cornelius Celsus recognised four cardinal signs of this response-redness, heat, swelling and pain; a fifth sign is loss of function.[...", "offsetInBeginSection": 60, "offsetInEndSection": 255, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354", "text": "The cardinal signs of inflammation dolor, calor, tumor and rubor are intrinsically associated with events including vasodilatation, edema and leukocyte trafficking into the site of inflammation.", "offsetInBeginSection": 246, "offsetInEndSection": 440, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14662892", "text": "PGs and leukotrienes (LTs) mediate cardinal signs of inflammation; hence, their enzymes are targets of current anti-inflammatory therapies.", "offsetInBeginSection": 0, "offsetInEndSection": 139, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1617392", "text": "These changes contribute to the cardinal signs of inflammation (i.e.", "offsetInBeginSection": 530, "offsetInEndSection": 598, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10874776", "text": "Treatment is directed at the cardinal signs and is largely palliative.", "offsetInBeginSection": 646, "offsetInEndSection": 716, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14662892", "text": "These results indicate that overexpression of 15-LO type I and LXA(4) is associated with dampened PMN-mediated tissue degradation and bone loss, suggesting that enhanced anti-inflammation status is an active process.", "offsetInBeginSection": 1614, "offsetInEndSection": 1830, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a89a20ffcd1d6a10c00000e", "body": "List factors that promote lymphangiogenesis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17419947", "http://www.ncbi.nlm.nih.gov/pubmed/18497750", "http://www.ncbi.nlm.nih.gov/pubmed/24115038", "http://www.ncbi.nlm.nih.gov/pubmed/9162011", "http://www.ncbi.nlm.nih.gov/pubmed/28804221", "http://www.ncbi.nlm.nih.gov/pubmed/19958632", "http://www.ncbi.nlm.nih.gov/pubmed/30007095", "http://www.ncbi.nlm.nih.gov/pubmed/16557570", "http://www.ncbi.nlm.nih.gov/pubmed/26968383", "http://www.ncbi.nlm.nih.gov/pubmed/12070340"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796", "text": "Here, we report that sine oculis homeobox homolog 1 (SIX1), expressed in tumor cells, can promote tumor lymphangiogenesis and lymph node metastasis by coordinating with TGF\u03b2 to increase the expression of VEGF-C. Lymphangiogenesis and lymph node metastasis in cervical cancer were closely correlated with higher expression of SIX1 in tumor cells.", "offsetInBeginSection": 210, "offsetInEndSection": 556, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22967508", "text": "Here we show that FGF-2 and VEGF-C, two lymphangiogenic factors, collaboratively promote angiogenesis and lymphangiogenesis in the tumor microenvironment, leading to widespread pulmonary and lymph-node metastases.", "offsetInBeginSection": 133, "offsetInEndSection": 346, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18519975", "text": "Other signaling molecules that have been reported to promote lymphangiogenesis and/or lymphatic metastasis in cancer include VEGF-A, platelet-derived growth factor-BB, and hepatocyte growth factor.", "offsetInBeginSection": 809, "offsetInEndSection": 1006, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19958632", "text": "Several members of vascular endothelial growth factor (VEGF) family, such as VEGF-C, VEGF-D, and VEGF receptor-3 (VEGFR-3), have been found to promote lymphangiogenesis in breast cancer.", "offsetInBeginSection": 253, "offsetInEndSection": 439, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26968383", "text": "CONCLUSIONS This study suggested that HCM from MSCs contain high levels of secreted lymphangiogenic factors and promote lymphangiogenesis by regulating mitochondrial-related factors.", "offsetInBeginSection": 1112, "offsetInEndSection": 1294, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796", "text": "Malignant tumors release growth factors such as VEGF-C to induce lymphangiogenesis, thereby promoting lymph node metastasis.", "offsetInBeginSection": 85, "offsetInEndSection": 209, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570", "text": "More recent studies have identified other signaling molecules that can also promote lymphangiogenesis in vivo, including hepatocyte growth factor and members of the fibroblast growth factor, angiopoietin, platelet-derived growth factor and insulin-like growth factor families of secreted proteins.", "offsetInBeginSection": 806, "offsetInEndSection": 1103, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26706909", "text": "The most extensively accepted signaling pathways promoting lymphangiogenesis in tumors include the secreted lymphangiogenic proteins: vascular endothelial growth factor-C (VEGF-C) and VEGF-D, and their cognate receptor on lymphatic endothelium VEGF receptor-3 (VEGFR-3).", "offsetInBeginSection": 555, "offsetInEndSection": 825, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16793912", "text": "Our recent findings indicate that VEGF-A also acts as a potent tumor lymphangiogenesis factor that promotes lymphatic tumor spread.", "offsetInBeginSection": 698, "offsetInEndSection": 829, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26706909", "text": "Recent research has identified a range of lymphangiogenic growth factors that could conceivably play a great role in promoting tumor lymphangiogenesis and lymphatic metastasis.", "offsetInBeginSection": 378, "offsetInEndSection": 554, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a68f448b750ff4455000018", "body": "Which bacteria causes erythrasma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28397528", "http://www.ncbi.nlm.nih.gov/pubmed/9614412", "http://www.ncbi.nlm.nih.gov/pubmed/6859802", "http://www.ncbi.nlm.nih.gov/pubmed/26951251", "http://www.ncbi.nlm.nih.gov/pubmed/3310884", "http://www.ncbi.nlm.nih.gov/pubmed/23210102", "http://www.ncbi.nlm.nih.gov/pubmed/9801290", "http://www.ncbi.nlm.nih.gov/pubmed/1885917", "http://www.ncbi.nlm.nih.gov/pubmed/3465494", "http://www.ncbi.nlm.nih.gov/pubmed/3965026"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/6859802", "text": "Corynebacteria causes erythrasma, trichomycosis or pitted keratolysis.", "offsetInBeginSection": 403, "offsetInEndSection": 473, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12010076", "text": "Corynebacterium minutissimum is the bacteria that leads to cutaneous eruptions of erythrasma and is the most common cause of interdigital foot infections.", "offsetInBeginSection": 0, "offsetInEndSection": 154, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9614412", "text": "Bacterial skin infections caused by corynebacteria include erythrasma, trichomycosis axillaris and pitted keratolysis.", "offsetInBeginSection": 215, "offsetInEndSection": 333, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3965026", "text": "It is a common mucocutaneous inhabitant which causes erythrasma.", "offsetInBeginSection": 258, "offsetInEndSection": 322, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21393451", "text": "Erythrasma is a superficial skin disease caused by Gram-positive Corynebacterium species.", "offsetInBeginSection": 0, "offsetInEndSection": 89, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9614412", "text": "The many dermatomycoses (skin infections caused by fungi or yeasts) include tinea capitis, tinea barbae, tinea cruris, tinea manus, tinea pedis and tinea unguium (onychomycosis).", "offsetInBeginSection": 630, "offsetInEndSection": 808, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25477907", "text": "Erythrasma caused by Corynebacterium minutissimum can be confused with superficial mycoses.", "offsetInBeginSection": 115, "offsetInEndSection": 206, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15189194", "text": "Pityriasis versicolor (PV) is a widespread dermatomycosis caused by yeasts.", "offsetInBeginSection": 0, "offsetInEndSection": 75, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9614412", "text": "Skin infections are common and may be caused by bacteria, fungi or viruses.", "offsetInBeginSection": 0, "offsetInEndSection": 75, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25477907", "text": "Interdigital foot infections are mostly caused initially by dermatophytes, yeasts and less frequently by bacteria.", "offsetInBeginSection": 0, "offsetInEndSection": 114, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a89537cfcd1d6a10c000002", "body": "Are mouse chromosomes acrocentric?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2832136", "http://www.ncbi.nlm.nih.gov/pubmed/3248380", "http://www.ncbi.nlm.nih.gov/pubmed/7606923", "http://www.ncbi.nlm.nih.gov/pubmed/1601422", "http://www.ncbi.nlm.nih.gov/pubmed/6177004", "http://www.ncbi.nlm.nih.gov/pubmed/100785", "http://www.ncbi.nlm.nih.gov/pubmed/35835815", "http://www.ncbi.nlm.nih.gov/pubmed/7789187", "http://www.ncbi.nlm.nih.gov/pubmed/6299509", "http://www.ncbi.nlm.nih.gov/pubmed/9263450"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/2832136", "text": "Among centromeric C-bands, the heterochromatin in Robertsonian fusion biarmed chromosomes was more resistant to DNase I action than was the centromeric heterochromatin of the acrocentric chromosomes.", "offsetInBeginSection": 518, "offsetInEndSection": 717, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11387219", "text": "Human ribosomal gene repeats are distributed among five nucleolar organizer regions (NORs) on the p arms of acrocentric chromosomes.", "offsetInBeginSection": 0, "offsetInEndSection": 132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7606923", "text": "Chromosome 19 and the sex chromosomes are the only acrocentric chromosomes.", "offsetInBeginSection": 574, "offsetInEndSection": 649, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846", "text": "The resulting metacentric chromosomes are very different in size and in morphology from normal mouse acrocentric chromosomes.", "offsetInBeginSection": 327, "offsetInEndSection": 452, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/100785", "text": "The two mouse stocks exhibit karyotypes consisting of nine pairs of metacentric chromosomes as a result of centric fusions of acrocentric chromosomes in different combinations.", "offsetInBeginSection": 240, "offsetInEndSection": 416, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/100785", "text": "In the hybrid cells these metacentric chromosomes can be distinguished from the acrocentric chromosomes of myeloma origin, permitting correlation of Ig chain expression with mitotic loss of individual metacentric chromosomes.", "offsetInBeginSection": 417, "offsetInEndSection": 642, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23030344", "text": "In an Rb heterozygote, DNA probes from laboratory mouse chromosomes (MMUs) 1 and 10 were simultaneously hybridized to the long arm of a metacentric and a medium-sized acrocentric chromosome and to the short arm of the metacentric and a small acrocentric chromosome, respectively.", "offsetInBeginSection": 388, "offsetInEndSection": 667, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1733676", "text": "As in V. faba, all acrocentric mouse chromosomes were labeled by in situ hybridization with a vertebrate telomeric probe at both ends of each chromatid exclusively.", "offsetInBeginSection": 393, "offsetInEndSection": 557, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2832136", "text": "These were the centromeric heterochromatin of acro- and metacentric chromosomes and an interstitial C-band on chromosome 1 of wild mice, IS(HSR;1C5D)1Lub.", "offsetInBeginSection": 227, "offsetInEndSection": 381, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8528584", "text": "It seems likely that the breakpoints required for a Robertsonian process do not include telomeric sites exclusively but extend to the adjacent pericentromeric regions of the original acrocentric chromosomes.", "offsetInBeginSection": 597, "offsetInEndSection": 804, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e1db0b750ff4455000039", "body": "What is Q-nexus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11339496", "http://www.ncbi.nlm.nih.gov/pubmed/12420040", "http://www.ncbi.nlm.nih.gov/pubmed/12313418", "http://www.ncbi.nlm.nih.gov/pubmed/10739331", "http://www.ncbi.nlm.nih.gov/pubmed/14630669", "http://www.ncbi.nlm.nih.gov/pubmed/17356722", "http://www.ncbi.nlm.nih.gov/pubmed/17392915", "http://www.ncbi.nlm.nih.gov/pubmed/17559666", "http://www.ncbi.nlm.nih.gov/pubmed/10814645", "http://www.ncbi.nlm.nih.gov/pubmed/10623056"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676", "text": "An implementation of Q-nexus is available at http://charite.github.io/Q/ .", "offsetInBeginSection": 1550, "offsetInEndSection": 1624, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/401506", "text": "What constitutes the minimum size of a nexus is discussed.", "offsetInBeginSection": 551, "offsetInEndSection": 609, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20298777", "text": "The second nexus is enriched in genes of metazoan origin, which are expressed more narrowly and have organism-centred functions.", "offsetInBeginSection": 382, "offsetInEndSection": 510, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20298777", "text": "The first nexus contains mostly genes of pre-metazoan origin, which are widely expressed and have cell-centred functions.", "offsetInBeginSection": 260, "offsetInEndSection": 381, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20298777", "text": "Within the metazoan nexus, there is a subnexus that is more pronounced in the nervous tissues and is enriched in gene regulatory complexity.", "offsetInBeginSection": 621, "offsetInEndSection": 761, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/5815840", "text": "Squamous carcinoma cells are deficient in nexuses although a rare nexus is seen.", "offsetInBeginSection": 137, "offsetInEndSection": 217, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/874001", "text": "Also, the granulosa cells of mature follicles have a slightly greater number of surface nexuses (without a change in nexus length), and more interiorized nexuses, compared to immature follicles.", "offsetInBeginSection": 350, "offsetInEndSection": 544, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20298777", "text": "Besides gene coexpression, each nexus is characterized by a combination of gene evolutionary origin, function and among-tissues expression breadth.", "offsetInBeginSection": 112, "offsetInEndSection": 259, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676", "text": "CONCLUSIONS The Q-nexus software is efficient and easy to use.", "offsetInBeginSection": 1046, "offsetInEndSection": 1108, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/401506", "text": "Many nexuses in the guinea pig sphincter pupillae, chicken gizzard, and toad stomach show a close relationship with sarcoplasmic reticulum.", "offsetInBeginSection": 1030, "offsetInEndSection": 1169, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a74a8a70384be9551000005", "body": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27863199", "http://www.ncbi.nlm.nih.gov/pubmed/36158269", "http://www.ncbi.nlm.nih.gov/pubmed/28440296", "http://www.ncbi.nlm.nih.gov/pubmed/21331750", "http://www.ncbi.nlm.nih.gov/pubmed/28423924", "http://www.ncbi.nlm.nih.gov/pubmed/27316377", "http://www.ncbi.nlm.nih.gov/pubmed/35967289", "http://www.ncbi.nlm.nih.gov/pubmed/34969758", "http://www.ncbi.nlm.nih.gov/pubmed/34274449", "http://www.ncbi.nlm.nih.gov/pubmed/32438692"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27316377", "text": "We hope that Nek2 siRNA will be a novel therapeutic strategy for pancreatic cancer with liver metastasis and peritoneal dissemination.", "offsetInBeginSection": 1304, "offsetInEndSection": 1438, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27147553", "text": "LOcal Drug EluteR (LODER(TM)) is a novel biodegradable polymeric matrix that shields drugs against enzymatic degradation and releases small interfering RNA (siRNA) against G12D-mutated KRAS (siG12D).", "offsetInBeginSection": 170, "offsetInEndSection": 369, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26000366", "text": "Additionally, potential of target based therapeutic agents and nanomedicines in clinical trials for the pancreatic cancer therapy are highlighted.", "offsetInBeginSection": 1075, "offsetInEndSection": 1221, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21330062", "text": "Although gemcitabine has been established as the standard first-line treatment for advanced pancreatic cancer, gemcitabine-based combination chemotherapy showed either marginal or no improvement in survival.", "offsetInBeginSection": 197, "offsetInEndSection": 404, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19853645", "text": "Using liposomes, nanoparticles, and carbon nanotubes to deliver cancer drugs and other therapeutic agents such as siRNA, suicide gene, oncolytic virus, small molecule inhibitor, and antibody has been a success in recent preclinical trials.", "offsetInBeginSection": 301, "offsetInEndSection": 540, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27316377", "text": "Taken together, Nek2 is an effective therapeutic target in pancreatic cancer.", "offsetInBeginSection": 969, "offsetInEndSection": 1046, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27316377", "text": "Nek2 siRNA inhibited tumor growth in a subcutaneous xenograft mouse model of pancreatic cancer, prolonged the survival time in an intraperitoneal xenograft mouse model and efficiently prevented the progression of liver metastasis using a portal venous port-catheter system.", "offsetInBeginSection": 695, "offsetInEndSection": 968, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28423924", "text": "Herein, we review the barriers, potential siRNA drug delivery systems, and application of siRNA in clinical trials for cancer therapy.", "offsetInBeginSection": 528, "offsetInEndSection": 662, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27316377", "text": "We reported the efficiency of Nek2 siRNA in several cancer xenograft models using cholangiocarcinoma, breast cancer and colorectal cancer.", "offsetInBeginSection": 130, "offsetInEndSection": 268, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033", "text": "Despite significant preclinical data, there are currently very few clinical trials involving pancreatic cancer targeted drug delivery.", "offsetInBeginSection": 1019, "offsetInEndSection": 1153, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a678d63b750ff4455000003", "body": "What are the 4 cardinal signs of inflammation according to Celsus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1699987", "http://www.ncbi.nlm.nih.gov/pubmed/29241539", "http://www.ncbi.nlm.nih.gov/pubmed/15584868", "http://www.ncbi.nlm.nih.gov/pubmed/6360096", "http://www.ncbi.nlm.nih.gov/pubmed/29135930", "http://www.ncbi.nlm.nih.gov/pubmed/28284331", "http://www.ncbi.nlm.nih.gov/pubmed/18437628", "http://www.ncbi.nlm.nih.gov/pubmed/35258243", "http://www.ncbi.nlm.nih.gov/pubmed/26372222", "http://www.ncbi.nlm.nih.gov/pubmed/23820116"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851", "text": "It was Galen who added the disturbance of function (functio laesa) as the fifth cardinal sign of inflammation to the four well-known cardinal signs of Celsus (rubor, calor, tumor, dolor).", "offsetInBeginSection": 1008, "offsetInEndSection": 1195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15041917", "text": "In fact it has been understood that behind the typical signs of inflammation (the famous four cardinal signs of Celsus: pain, redness, swelling, heat) no abstract entities or strange alchemies are concealed, but a series of well-known, classified substance, the so-called \"inflammation mediators\", namely a variety of substances of cellular or plasmatic origin united by the fact that exist, in stationary state conditions, in the form of inactive precursors, or sequestered in intracellular sites where they are unable to carry out their action.", "offsetInBeginSection": 936, "offsetInEndSection": 1482, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930", "text": "As early as 2000 years ago, the Roman encyclopaedist Aulus Cornelius Celsus recognised four cardinal signs of this response-redness, heat, swelling and pain; a fifth sign is loss of function.[...", "offsetInBeginSection": 60, "offsetInEndSection": 255, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7734328", "text": "He bases his observations on the four cardinal signs of Celsus (redness, heat, swelling and pain).", "offsetInBeginSection": 575, "offsetInEndSection": 673, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11131905", "text": "Perhaps the use of the systemic correlates of the cardinal manifestations of inflammation developed by Galen and Celsus would provide a more satisfactory clinical characterization of the clinical disorder.", "offsetInBeginSection": 848, "offsetInEndSection": 1053, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26372222", "text": "Mastitis always manifests clinically by three cardinal signs of inflammation, which are redness, heat and pain.", "offsetInBeginSection": 308, "offsetInEndSection": 419, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15629264", "text": "In this study, the anti-inflammatory (in reference to the cardinal signs of inflammation) and other related pharmacological activities of the hot water extract of black tea (Camellia sinensis, Sikkim variety) were evaluated along with certain standard drugs.", "offsetInBeginSection": 0, "offsetInEndSection": 258, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278", "text": "Tumor, calor, rubor, and dolor describe four cardinal signs of inflammation.", "offsetInBeginSection": 0, "offsetInEndSection": 76, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9120866", "text": "The four cardinal signs of inflammation are redness, swelling, heat, and pain, phenomena explained at the cellular level.", "offsetInBeginSection": 468, "offsetInEndSection": 589, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6360096", "text": "The emergence of all cardinal signs of inflammation is associated with damage of different components of the microcirculatory bed.", "offsetInBeginSection": 411, "offsetInEndSection": 541, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8a9abdfcd1d6a10c000019", "body": "List polyubiquitin binding proteins involved in NF-kappaB signaling.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18347055", "http://www.ncbi.nlm.nih.gov/pubmed/12701623", "http://www.ncbi.nlm.nih.gov/pubmed/11418127", "http://www.ncbi.nlm.nih.gov/pubmed/12692549", "http://www.ncbi.nlm.nih.gov/pubmed/11262403", "http://www.ncbi.nlm.nih.gov/pubmed/19675569", "http://www.ncbi.nlm.nih.gov/pubmed/18456659", "http://www.ncbi.nlm.nih.gov/pubmed/18369152", "http://www.ncbi.nlm.nih.gov/pubmed/11262181", "http://www.ncbi.nlm.nih.gov/pubmed/18029035"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19815658", "text": "The inhibitor of kB kinase (IKK) complex, a critical positive regulator of nuclear factor kappaB (NF-kappaB) signaling and immune function, can be activated in vitro by polyubiquitin chains.", "offsetInBeginSection": 0, "offsetInEndSection": 190, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159", "text": "Protein array screening using polyubiquitin enabled rapid identification of many known and novel polyubiquitin binding proteins and the identification of novel NF-kappaB regulators.", "offsetInBeginSection": 1136, "offsetInEndSection": 1317, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159", "text": "We have used protein arrays to identify polyubiquitin binding proteins that regulate NF-kappaB activity.", "offsetInBeginSection": 358, "offsetInEndSection": 462, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18456659", "text": "The results show that TAB4 binds TAK1 and polyubiquitin chains to promote specific sites of phosphorylation in TAK1-TAB1, which activates IKK signaling to NF-kappaB.", "offsetInBeginSection": 1473, "offsetInEndSection": 1638, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159", "text": "Novel polyubiquitin binders AWP1, CALCOCO2, N4BP1, RIO3, TEX27, TTC3, UBFD1 and ZNF313 were identified using this approach, while known NF-kappaB regulators including NEMO, A20, ABIN-1, ABIN-2, optineurin and p62 were also identified.", "offsetInBeginSection": 559, "offsetInEndSection": 793, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19772915", "text": "Firstly, Malt1 directly cleaves and inactivates A20, a negative regulator of the antigen receptor-to-NF-kappaB pathway.", "offsetInBeginSection": 1493, "offsetInEndSection": 1612, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19136968", "text": "The ubiquitin pathway is crucial in regulating the NF-kappaB pathway.", "offsetInBeginSection": 118, "offsetInEndSection": 187, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19136968", "text": "Here, we demonstrate that LUBAC activates the canonical NF-kappaB pathway by binding to NEMO (NF-kappaB essential modulator, also called IKKgamma) and conjugates linear polyubiquitin chains onto specific Lys residues in the CC2-LZ domain of NEMO in a Ubc13-independent manner.", "offsetInBeginSection": 367, "offsetInEndSection": 643, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16603398", "text": "The receptor interacting protein kinase 1 (RIP1) is essential for the activation of nuclear factor kappaB (NF-kappaB) by tumor necrosis factor alpha (TNFalpha).", "offsetInBeginSection": 0, "offsetInEndSection": 160, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19136968", "text": "Nuclear factor-kappaB (NF-kappaB) is a key transcription factor in inflammatory, anti-apoptotic and immune processes.", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a690487b750ff445500001f", "body": "Which virus can be diagnosed with the monospot test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1295944", "http://www.ncbi.nlm.nih.gov/pubmed/26275628", "http://www.ncbi.nlm.nih.gov/pubmed/2992429", "http://www.ncbi.nlm.nih.gov/pubmed/29514339", "http://www.ncbi.nlm.nih.gov/pubmed/32965330", "http://www.ncbi.nlm.nih.gov/pubmed/17217023", "http://www.ncbi.nlm.nih.gov/pubmed/20086647", "http://www.ncbi.nlm.nih.gov/pubmed/22451758", "http://www.ncbi.nlm.nih.gov/pubmed/21731914", "http://www.ncbi.nlm.nih.gov/pubmed/18063553"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20086647", "text": "Subsequent clinical, laboratory, and serologic evaluation revealed that he, in fact, had a latent infection with Epstein-Barr virus (EBV), a current viral syndrome, and a false-positive Monospot test.", "offsetInBeginSection": 143, "offsetInEndSection": 343, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17217023", "text": "Infectious mononucleosis cases were diagnosed by clinical triad of fever, pharyngitis and cervical lymphadenopathy, relative lymphocytosis, monocytosis and positive monospot test.", "offsetInBeginSection": 784, "offsetInEndSection": 963, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17217023", "text": "Patients were subjected to careful history, thorough clinical examination, complete blood picture, tuberculin test, chest x-ray, Monospot test, indirect fluorescent antibody test for toxoplasmosis, detection of cytomegalovirus antibodies and lymph node biopsy with histopathological examination.", "offsetInBeginSection": 153, "offsetInEndSection": 448, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17217023", "text": "Cytomegalovirus case was diagnosed by lymphocytosis, monocytosis and negative monospot test.", "offsetInBeginSection": 964, "offsetInEndSection": 1056, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11369969", "text": "His septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus.", "offsetInBeginSection": 243, "offsetInEndSection": 355, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396", "text": "Heterophile antibody tests, including the Monospot test, are red cell or latex agglutination assays, which detect antired cell antibodies produced as part of a polyclonal antibody response occurring during EBV infection.", "offsetInBeginSection": 199, "offsetInEndSection": 419, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628", "text": "Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result.", "offsetInBeginSection": 103, "offsetInEndSection": 237, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396", "text": "Epstein-Barr virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents.", "offsetInBeginSection": 0, "offsetInEndSection": 198, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628", "text": "This case conveys that monospot test can yield false-positive result in the setting of acute CMV infection.", "offsetInBeginSection": 697, "offsetInEndSection": 804, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628", "text": "Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection.", "offsetInBeginSection": 238, "offsetInEndSection": 547, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a896a06fcd1d6a10c000006", "body": "What is the phenomenon of gene kissing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24770514", "http://www.ncbi.nlm.nih.gov/pubmed/26063576", "http://www.ncbi.nlm.nih.gov/pubmed/26370077", "http://www.ncbi.nlm.nih.gov/pubmed/10203681", "http://www.ncbi.nlm.nih.gov/pubmed/24922478", "http://www.ncbi.nlm.nih.gov/pubmed/17141947", "http://www.ncbi.nlm.nih.gov/pubmed/8287462", "http://www.ncbi.nlm.nih.gov/pubmed/23099887", "http://www.ncbi.nlm.nih.gov/pubmed/16650596", "http://www.ncbi.nlm.nih.gov/pubmed/21507887"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26063576", "text": "Here, we show that the replication terminator protein Fob1 of Saccharomyces cerevisiae promoted chromosome kissing that initiated rDNA recombination and controlled the replicative life span (RLS).", "offsetInBeginSection": 252, "offsetInEndSection": 448, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27785578", "text": "Ictal kissing is a rare semiological manifestation in patients with epilepsy.", "offsetInBeginSection": 0, "offsetInEndSection": 77, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23099887", "text": "This positioning can also result in the clustering of genes with similar expression patterns, a phenomenon sometimes called \"gene kissing.\"", "offsetInBeginSection": 135, "offsetInEndSection": 274, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25918627", "text": "But, phenomenon of kissing molars is an extremely rare phenomenon.", "offsetInBeginSection": 66, "offsetInEndSection": 132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26063576", "text": "Oligomerization of Fob1 caused synaptic (kissing) interactions between pairs of terminator (Ter) sites that initiated recombination in rDNA.", "offsetInBeginSection": 449, "offsetInEndSection": 589, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26063576", "text": "Protein-mediated \"chromosome kissing\" between two DNA sites in trans (or in cis) is known to facilitate three-dimensional control of gene expression and DNA replication.", "offsetInBeginSection": 0, "offsetInEndSection": 169, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27721082", "text": "Kissing occurred at a median time of 71s (1-95s) after the onset of seizure, and ictal epileptiform discharges usually involved TL during kissing episode.", "offsetInBeginSection": 920, "offsetInEndSection": 1074, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509", "text": "Nevertheless, several contacts between different chromosomal loci have been documented, a phenomenon called chromosome kissing.", "offsetInBeginSection": 133, "offsetInEndSection": 260, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27403349", "text": "In some cases kissing molars can be seen but occurrence of bilateral kissing molars is extremely rare phenomenon in the dental literature and the aetiology of this phenomenon is still unknown.", "offsetInBeginSection": 198, "offsetInEndSection": 390, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27785578", "text": "The most common underlying etiology for ictal kissing is hippocampal sclerosis.", "offsetInBeginSection": 1116, "offsetInEndSection": 1195, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e24a5b750ff445500003c", "body": "Which workflow in Bioconductor has been developed for accessing human RNA-seq samples?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30378071", "http://www.ncbi.nlm.nih.gov/pubmed/34059827", "http://www.ncbi.nlm.nih.gov/pubmed/28899397", "http://www.ncbi.nlm.nih.gov/pubmed/31316748", "http://www.ncbi.nlm.nih.gov/pubmed/28416950", "http://www.ncbi.nlm.nih.gov/pubmed/21937664", "http://www.ncbi.nlm.nih.gov/pubmed/29509844", "http://www.ncbi.nlm.nih.gov/pubmed/27650223", "http://www.ncbi.nlm.nih.gov/pubmed/26847232", "http://www.ncbi.nlm.nih.gov/pubmed/34381207"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27508061", "text": "This article demonstrates a computational workflow for the detection of DE genes and pathways from RNA-seq data by providing a complete analysis of an RNA-seq experiment profiling epithelial cell subsets in the mouse mammary gland.", "offsetInBeginSection": 288, "offsetInEndSection": 519, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26674615", "text": "Here we walk through an end-to-end gene-level RNA-Seq differential expression\u00a0workflow using Bioconductor packages.", "offsetInBeginSection": 0, "offsetInEndSection": 116, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26692761", "text": "Here, we present the first step-by-step protocol for cross-species RNA-seq analysis with a concise workflow that is largely based on the free open-source R language and Bioconductor packages.", "offsetInBeginSection": 520, "offsetInEndSection": 711, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23975260", "text": "This protocol presents a state-of-the-art computational and statistical RNA-seq differential expression analysis workflow largely based on the free open-source R language and Bioconductor software and, in particular, on two widely used tools, DESeq and edgeR.", "offsetInBeginSection": 735, "offsetInEndSection": 994, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27913729", "text": "Additionally, we generated a clinically relevant benchmark data set consisting of methylation enrichment experiments (MeDIP-seq), BS-based validation experiments (Methyl-seq) as well as gene expression experiments (RNA-seq) derived from non-small cell lung cancer patients, and show that the workflow retrieves well-known lung tumour methylation markers that are causative for gene expression changes, demonstrating the applicability of QSEA for clinical studies.", "offsetInBeginSection": 1040, "offsetInEndSection": 1503, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27650223", "text": "To simplify the analysis of widely used NGS applications, the package provides pre-configured workflows and reporting templates for RNA-Seq, ChIP-Seq, VAR-Seq and Ribo-Seq.", "offsetInBeginSection": 1378, "offsetInEndSection": 1550, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27909575", "text": "This article describes a computational workflow for low-level analyses of scRNA-seq data, based primarily on software packages from the open-source Bioconductor project.", "offsetInBeginSection": 557, "offsetInEndSection": 726, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27913729", "text": "In this work, we present QSEA, Quantitative Sequence Enrichment Analysis, a comprehensive workflow for the modelling and subsequent quantification of MeDIP-seq data.", "offsetInBeginSection": 347, "offsetInEndSection": 512, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067", "text": "The recount2 resource is composed of over 70,000 uniformly processed human RNA-seq samples spanning TCGA and SRA, including GTEx.", "offsetInBeginSection": 0, "offsetInEndSection": 129, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27678198", "text": "RESULTS To address the challenges in RNA-seq data analysis, we developed a web portal that offers three integrated workflows that can perform end-to-end compute and analysis, including sequence quality control, read-mapping, transcriptome assembly, reconstruction and quantification, and differential analysis.", "offsetInBeginSection": 367, "offsetInEndSection": 677, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a74b1730384be9551000007", "body": "Which retinal dystrophy related gene is targeted by the AAV2-hRPE65v2 drug?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11135496", "http://www.ncbi.nlm.nih.gov/pubmed/18004402", "http://www.ncbi.nlm.nih.gov/pubmed/25306972", "http://www.ncbi.nlm.nih.gov/pubmed/18633446", "http://www.ncbi.nlm.nih.gov/pubmed/11556484", "http://www.ncbi.nlm.nih.gov/pubmed/28369829", "http://www.ncbi.nlm.nih.gov/pubmed/28840994", "http://www.ncbi.nlm.nih.gov/pubmed/26568297", "http://www.ncbi.nlm.nih.gov/pubmed/21697530", "http://www.ncbi.nlm.nih.gov/pubmed/34884916"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191", "text": "Among many clinical trials of gene therapy for hereditary retinal diseases, a phase 3 clinical trial of voretigene neparvovec (AAV2-hRPE65v2, Luxturna) recently showed significant efficacy for RPE65-mediated inherited retinal dystrophy including Leber congenital amaurosis and RP.", "offsetInBeginSection": 1047, "offsetInEndSection": 1327, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040", "text": "BACKGROUND Safety and efficacy have been shown in a phase 1 dose-escalation study involving a unilateral subretinal injection of a recombinant adeno-associated virus (AAV) vector containing the RPE65 gene (AAV2-hRPE65v2) in individuals with inherited retinal dystrophy caused by RPE65 mutations.", "offsetInBeginSection": 0, "offsetInEndSection": 295, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21606598", "text": "A recent gene therapy trial in patients with LCA2, who have mutations in RPE65, demonstrated that subretinal injection of an adeno-associated virus (AAV) carrying the normal cDNA of that gene (AAV2-hRPE65v2) could markedly improve vision.", "offsetInBeginSection": 111, "offsetInEndSection": 349, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23474247", "text": "PARTICIPANTS Five LCA2 patients with RPE65 gene mutations.", "offsetInBeginSection": 272, "offsetInEndSection": 330, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28712537", "text": "BACKGROUND Phase 1 studies have shown potential benefit of gene replacement in RPE65-mediated inherited retinal dystrophy.", "offsetInBeginSection": 0, "offsetInEndSection": 122, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28712537", "text": "INTERPRETATION Voretigene neparvovec gene replacement improved functional vision in RPE65-mediated inherited retinal dystrophy previously medically untreatable.", "offsetInBeginSection": 2517, "offsetInEndSection": 2677, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20712582", "text": "A recent milestone has been the safety and efficacy observed using recombinant AAV2 expressing retinal pigment epithelial associated 65KDa protein for Leber Congenital Amaurosis.", "offsetInBeginSection": 142, "offsetInEndSection": 320, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19953081", "text": "The safety and efficacy of gene therapy for inherited retinal diseases is being tested in humans affected with Leber's congenital amaurosis (LCA), an autosomal recessive blinding disease.", "offsetInBeginSection": 0, "offsetInEndSection": 187, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28369829", "text": "Although Ccdc66 mutations have been proposed to cause retinal disease in dogs, our results and public databases challenge CCDC66 as a candidate gene for human retinal dystrophy.", "offsetInBeginSection": 975, "offsetInEndSection": 1152, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28369829", "text": "To uncover the genotype underlying early-onset cone-rod dystrophy and central nummular macular atrophic lesion in 2 siblings from an endogamous Arab family, we performed targeted next-generation sequencing (NGS) of 44 retinal dystrophy genes, whole-exome sequencing (WES) and genome-wide linkage analysis.", "offsetInBeginSection": 0, "offsetInEndSection": 305, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a679875b750ff4455000004", "body": "Do bacteria from the genus Morexella cause respiratory infections?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16295189", "http://www.ncbi.nlm.nih.gov/pubmed/2042239", "http://www.ncbi.nlm.nih.gov/pubmed/12225258", "http://www.ncbi.nlm.nih.gov/pubmed/17907902", "http://www.ncbi.nlm.nih.gov/pubmed/19177780", "http://www.ncbi.nlm.nih.gov/pubmed/8829338", "http://www.ncbi.nlm.nih.gov/pubmed/25549373", "http://www.ncbi.nlm.nih.gov/pubmed/29444729", "http://www.ncbi.nlm.nih.gov/pubmed/11738335", "http://www.ncbi.nlm.nih.gov/pubmed/9673324"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28059171", "text": "Bacteria of the genus Legionella cause water-based infections resulting in severe pneumonia.", "offsetInBeginSection": 0, "offsetInEndSection": 92, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24786571", "text": "RESULTS Some plant species, such as Alchornea floribunda, Musanga cecropioides (both leaves and stem bark), Tetracera potatoria and Xylopia aethiopica (stem bark), were effective in inhibiting Morexella cattarhalis, having MIC values between 65 and 250 \u03bcg/mL.", "offsetInBeginSection": 1221, "offsetInEndSection": 1481, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28369241", "text": "The Gram-negative bacteria genus Neisseria includes both pathogenic and commensal species that are found primarily in the upper respiratory tract of humans and animals.", "offsetInBeginSection": 0, "offsetInEndSection": 168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22358396", "text": "The strains of the genus Streptococcus isolated from respiratory infections are still sensitive to penicillin.", "offsetInBeginSection": 1046, "offsetInEndSection": 1156, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629", "text": "The most common species recovered from the sputum specimens of these patients were Haemophilus influenzae, followed by Streptococcus pneumoniae (S. pneumoniae), Staphylococcus aureus (S. aureus), Gram positive cocci unidentified, Pseudomonas aeruginosa (P. aeruginosa), Morexella catarrhalis, Streptococcus epidermidis, and another Haemophilus species in this order.", "offsetInBeginSection": 146, "offsetInEndSection": 512, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22358396", "text": "The gram-positive bacteria frequently responsible for infections in humans are for the most part cocci: staphylococci, streptococci (including pneumococci), and enterococci, in both community and hospital settings.", "offsetInBeginSection": 263, "offsetInEndSection": 477, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019", "text": "are opportunistic bacteria, which usually cause infections of the biliary tract, pneumonia and bacteraemia in oncologic and with lower immunity patients.", "offsetInBeginSection": 522, "offsetInEndSection": 675, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22358396", "text": "Among the nonfermenting gram-negative bacilli, while Pseudomonas aeruginosa strains remain the leading cause of bacteremia, infections caused by strains of Acinetobacter spp.", "offsetInBeginSection": 1511, "offsetInEndSection": 1685, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1795663", "text": "Branhamella catarrhalis is an important pathogen of upper and lower respiratory tract.", "offsetInBeginSection": 0, "offsetInEndSection": 86, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25362808", "text": "At the concentration recommended by the producer, the preparation showed biocidal activity (MBC, MFC) against the strains of the pathogenic microorganisms, which cause respiratory infections most frequently, including, among others, Peptostreptococcus anaerobius, Parvimonas micra, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus anginosus, Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa and Candida albicans, already after 15 min.", "offsetInBeginSection": 631, "offsetInEndSection": 1124, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8aa253fcd1d6a10c00001b", "body": "Which is the specificity of deubiquitinase USP25?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15125567", "http://www.ncbi.nlm.nih.gov/pubmed/28134560", "http://www.ncbi.nlm.nih.gov/pubmed/30579117", "http://www.ncbi.nlm.nih.gov/pubmed/27425610", "http://www.ncbi.nlm.nih.gov/pubmed/33241111", "http://www.ncbi.nlm.nih.gov/pubmed/27364472", "http://www.ncbi.nlm.nih.gov/pubmed/30745998", "http://www.ncbi.nlm.nih.gov/pubmed/23042150", "http://www.ncbi.nlm.nih.gov/pubmed/23674823", "http://www.ncbi.nlm.nih.gov/pubmed/33202887"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23754700", "text": "Ubiquitin Specific Protease 25 (USP25), a member of the deubiquitinase family, is involved in several disease-related signal pathways including myogenesis, immunity and protein degradation.", "offsetInBeginSection": 0, "offsetInEndSection": 189, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28538147", "text": "Ubiquitin-specific protease 25 (Usp25) is a deubiquitinase that is involved in multiple biological processes.", "offsetInBeginSection": 0, "offsetInEndSection": 109, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26305951", "text": "Here, we found that a viral infection-induced deubiquitinase (DUB), ubiquitin-specific protease 25 (USP25) was required for host defense against RNA and DNA viruses.", "offsetInBeginSection": 210, "offsetInEndSection": 375, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23042150", "text": "Thus, our results demonstrate that USP25 is a deubiquitinating enzyme (DUB) that negatively regulates IL-17-triggered signaling.", "offsetInBeginSection": 887, "offsetInEndSection": 1015, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23754700", "text": "USP25 contains one ubiquitin-associated domain and two ubiquitin-interacting motifs (UIMs) in its N-terminal region, which interact with ubiquitin and play a role in substrate recognition.", "offsetInBeginSection": 283, "offsetInEndSection": 471, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28538147", "text": "The N-terminal ubiquitin-binding region (UBR) of Usp25 contains one ubiquitin-associated domain, one small ubiquitin-like modifier (SUMO)-interacting motif and two ubiquitin-interacting motifs.", "offsetInBeginSection": 110, "offsetInEndSection": 303, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29131570", "text": "Here we describe the discovery of the first reported inhibitors of USP28, which we demonstrate are able to bind to and inhibit USP28, and whilst displaying a dual activity against the closest homologue USP25, these inhibitors show a high degree of selectivity over other deubiquitinases.", "offsetInBeginSection": 474, "offsetInEndSection": 761, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18538649", "text": "A USP25 SUMO interaction motif directs SUMO2/3 specificity, and SUMO modification diminishes USP25's ability to bind and degrade polyubiquitin chains.", "offsetInBeginSection": 122, "offsetInEndSection": 272, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26305951", "text": "Host pathogen-recognition receptors detect nucleic acid from invading viruses and initiate a series of signaling pathways that lead to the production of type I interferons (IFNs) and proinflammatory cytokines.", "offsetInBeginSection": 0, "offsetInEndSection": 209, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18538659", "text": "In a screen for SUMO2/3 binding proteins, we identified Ubiquitin Specific Protease 25 (USP25).", "offsetInBeginSection": 270, "offsetInEndSection": 365, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70dbe599e2c3af26000004", "body": "Which two genes are implicated in Juvenile polyposis syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22920200", "http://www.ncbi.nlm.nih.gov/pubmed/7405200", "http://www.ncbi.nlm.nih.gov/pubmed/15264272", "http://www.ncbi.nlm.nih.gov/pubmed/12136244", "http://www.ncbi.nlm.nih.gov/pubmed/11052475", "http://www.ncbi.nlm.nih.gov/pubmed/9060832", "http://www.ncbi.nlm.nih.gov/pubmed/9661881", "http://www.ncbi.nlm.nih.gov/pubmed/29634562", "http://www.ncbi.nlm.nih.gov/pubmed/16629258", "http://www.ncbi.nlm.nih.gov/pubmed/28484856"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27326320", "text": "These include familial adenomatous polyposis (FAP), Lynch syndromes (LS), Juvenile polyposis syndrome, Peutz-Jeghers syndrome, Crohn's disease (CD) and celiac disease.", "offsetInBeginSection": 359, "offsetInEndSection": 526, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21465659", "text": "Juvenile polyposis syndrome (JPS) is caused by heterozygous mutations in either SMAD4 or BMPR1A.", "offsetInBeginSection": 0, "offsetInEndSection": 96, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25841492", "text": "Other polyposis syndromes include the hamartomatous polyp syndromes, including juvenile polyposis syndrome, Peutz-Jeghers syndrome, Cowden syndrome, and Bannayan-Ruvalcaba-Riley syndrome.", "offsetInBeginSection": 1975, "offsetInEndSection": 2162, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22171123", "text": "Juvenile polyposis syndrome is a rare autosomal dominant syndrome characterized by multiple distinct juvenile polyps in the gastrointestinal tract and an increased risk of colorectal cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 190, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17873119", "text": "BACKGROUND In patients with juvenile polyposis syndrome (JPS) the frequency of large genomic deletions in the SMAD4 and BMPR1A genes was unknown.", "offsetInBeginSection": 0, "offsetInEndSection": 145, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21834858", "text": "Juvenile polyposis (JP) is an autosomal dominant hamartomatous polyposis syndrome that carries a significant risk for the development of colorectal cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 155, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648", "text": "SMAD4 germline mutations are responsible for a more aggressive digestive phenotype in patients with juvenile polyposis.", "offsetInBeginSection": 1007, "offsetInEndSection": 1126, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21834858", "text": "Microdeletions of one of the two predisposing genes to JP, BMPR1A, have been associated with a severe form of JP called juvenile polyposis of infancy.", "offsetInBeginSection": 156, "offsetInEndSection": 306, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322", "text": "The findings in this patient with a constitutional 10q23 deletion raise the issue of whether there are separate genes in this region that are involved in Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, juvenile polyposis, and tumor progression, or whether all of these entities could be due to a single gene.", "offsetInBeginSection": 758, "offsetInEndSection": 1070, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22171123", "text": "In about 50%-60% of patients diagnosed with juvenile polyposis syndrome a germline mutation in the SMAD4 or BMPR1A gene is found.", "offsetInBeginSection": 754, "offsetInEndSection": 883, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a86bf2efaa1ab7d2e000033", "body": "What is the mechanism of the auxin-inducible degron system?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26149575", "http://www.ncbi.nlm.nih.gov/pubmed/28335590", "http://www.ncbi.nlm.nih.gov/pubmed/23539280", "http://www.ncbi.nlm.nih.gov/pubmed/27618443", "http://www.ncbi.nlm.nih.gov/pubmed/30375036", "http://www.ncbi.nlm.nih.gov/pubmed/31467088", "http://www.ncbi.nlm.nih.gov/pubmed/36043049", "http://www.ncbi.nlm.nih.gov/pubmed/25181302", "http://www.ncbi.nlm.nih.gov/pubmed/34739048", "http://www.ncbi.nlm.nih.gov/pubmed/19915560"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21314938", "text": "RESULTS We constructed an auxin-inducible degron (AID) system, which utilizes auxin-dependent poly-ubiquitination of Aux/IAA proteins by SCFTIR1 in plants, in fission yeast.", "offsetInBeginSection": 584, "offsetInEndSection": 757, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27010248", "text": "To this end, a degradation system was developed in yeast exploiting TIR1, a plant F box protein, which can recruit proteins with an auxin-inducible degron to an E3 ubiquitin ligase complex, but only in the presence of the phytohormone auxin.", "offsetInBeginSection": 837, "offsetInEndSection": 1078, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25248749", "text": "Taking advantage of the auxin-inducible degron (AID) system, we have developed a suicide system with which ICAD is rapidly degraded in living cells in response to the plant hormone auxin.", "offsetInBeginSection": 419, "offsetInEndSection": 606, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28680098", "text": "The auxin-inducible degron harbors great potential for dynamic protein depletion in yeast.", "offsetInBeginSection": 73, "offsetInEndSection": 163, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26081484", "text": "Strategies that use ubiquitin-mediated protein degradation to eliminate the product of a gene of interest, such as heat-inducible degron (td) and auxin-inducible degron (AID), are powerful methods for constructing conditional mutants.", "offsetInBeginSection": 130, "offsetInEndSection": 364, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714", "text": "We now report the construction of a series of vectors that significantly enhance the versatility of this auxin-inducible degron (AID) system in Saccharomyces cerevisiae.", "offsetInBeginSection": 260, "offsetInEndSection": 429, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560", "text": "Other eukaryotes lack the auxin response but share the SCF degradation pathway, allowing us to transplant the auxin-inducible degron (AID) system into nonplant cells and use a small molecule to conditionally control protein stability.", "offsetInBeginSection": 205, "offsetInEndSection": 439, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27010248", "text": "Neither auxin nor TIR1 expression have obvious toxic effects in this organism, and in combination they result in rapid degradation of a target protein fused to the auxin-inducible degron.", "offsetInBeginSection": 1198, "offsetInEndSection": 1385, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560", "text": "Plants have evolved a unique system in which the plant hormone auxin directly induces rapid degradation of the AUX/IAA family of transcription repressors by a specific form of the SCF E3 ubiquitin ligase.", "offsetInBeginSection": 0, "offsetInEndSection": 204, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25181302", "text": "The auxin-inducible degron (AID) system allows the rapid and reversible proteolysis of proteins of interest, and enables the generation of conditional mutants of budding yeast.", "offsetInBeginSection": 0, "offsetInEndSection": 176, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e3155b750ff445500003f", "body": "Which R/Bioconductor package has been developed for cancer subtype identification?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26607490", "http://www.ncbi.nlm.nih.gov/pubmed/31821408", "http://www.ncbi.nlm.nih.gov/pubmed/21398674", "http://www.ncbi.nlm.nih.gov/pubmed/29092936", "http://www.ncbi.nlm.nih.gov/pubmed/29668835", "http://www.ncbi.nlm.nih.gov/pubmed/35266509", "http://www.ncbi.nlm.nih.gov/pubmed/35134827", "http://www.ncbi.nlm.nih.gov/pubmed/33459772", "http://www.ncbi.nlm.nih.gov/pubmed/21159174", "http://www.ncbi.nlm.nih.gov/pubmed/22113085"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490", "text": "Here, we present the genefu R/Bioconductor package, a multi-tiered compendium of bioinformatics algorithms and gene signatures for molecular subtyping and prognostication in breast cancer.", "offsetInBeginSection": 476, "offsetInEndSection": 664, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24700319", "text": "SUMMARY rTANDEM is an R/Bioconductor package that interfaces the X!Tandem protein identification algorithm.", "offsetInBeginSection": 0, "offsetInEndSection": 107, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "text": "RESULTS We combined a previously published implementation of a triplex DNA search algorithm with visualization to create a versatile R/Bioconductor package 'triplex'.", "offsetInBeginSection": 92, "offsetInEndSection": 258, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519", "text": "We introduce CancerSubtypes, an R package for identifying cancer subtypes using multi-omics data, including gene expression, miRNA expression and DNA methylation data.", "offsetInBeginSection": 119, "offsetInEndSection": 286, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24700319", "text": "Together, those two packages form an entry point for a general MS/MS-based proteomic pipeline in R/Bioconductor.", "offsetInBeginSection": 464, "offsetInEndSection": 576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28110480", "text": "In conclusion, CAsubtype is a flexible and well-integrated tool in the R environment to identify gene sets for cancer subtype identification and clinical outcome prediction.", "offsetInBeginSection": 1631, "offsetInEndSection": 1804, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "text": "AVAILABILITY R package 'triplex' is available from Bioconductor (bioconductor.org).", "offsetInBeginSection": 833, "offsetInEndSection": 916, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28110480", "text": "By integrating more than 13,000 annotated gene sets, CAsubtype provides a comprehensive repertoire of candidates for new cancer subtype identification.", "offsetInBeginSection": 699, "offsetInEndSection": 850, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23648477", "text": "In this study we identified a subset of 20 mRNA differentially regulated in breast cancer analyzing several publicly available array gene expression data using R/Bioconductor package.", "offsetInBeginSection": 194, "offsetInEndSection": 377, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519", "text": "The package is useful for inferring cancer subtypes from an input genomic dataset, comparing the predictions from different well-known methods and testing new subtype discovery methods, as shown with different application scenarios in the Supplementary Material.", "offsetInBeginSection": 723, "offsetInEndSection": 985, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a75fbf383b0d9ea6600000a", "body": "Name the phase 3 clinical trials for tofacitinib in colitis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24883332", "http://www.ncbi.nlm.nih.gov/pubmed/34045358", "http://www.ncbi.nlm.nih.gov/pubmed/32816215", "http://www.ncbi.nlm.nih.gov/pubmed/25110261", "http://www.ncbi.nlm.nih.gov/pubmed/32365634", "http://www.ncbi.nlm.nih.gov/pubmed/26376350", "http://www.ncbi.nlm.nih.gov/pubmed/28329404", "http://www.ncbi.nlm.nih.gov/pubmed/31101342", "http://www.ncbi.nlm.nih.gov/pubmed/34020693", "http://www.ncbi.nlm.nih.gov/pubmed/29051788"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25651782", "text": "BACKGROUND Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC).", "offsetInBeginSection": 0, "offsetInEndSection": 198, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26669566", "text": "BACKGROUND Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).", "offsetInBeginSection": 0, "offsetInEndSection": 104, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869", "text": "BACKGROUND Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.", "offsetInBeginSection": 0, "offsetInEndSection": 172, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26669566", "text": "Serious infections have been reported in tofacitinib RA trials.", "offsetInBeginSection": 324, "offsetInEndSection": 387, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869", "text": "METHODS We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis.", "offsetInBeginSection": 262, "offsetInEndSection": 407, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29051788", "text": "For example, the JAK1 blocker filgotinib was tested in Crohn's disease, whereas the JAK1/3 inhibitor tofacitinib was tested in clinical trials for both Crohn's disease and ulcerative colitis.", "offsetInBeginSection": 1695, "offsetInEndSection": 1886, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236", "text": "Expert opinion: Although tofacitinib plus MTX is statistically more clinically effective, tofacitinib monotherapy is effective in many patients with RA.", "offsetInBeginSection": 1043, "offsetInEndSection": 1195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25110261", "text": "Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.", "offsetInBeginSection": 322, "offsetInEndSection": 568, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236", "text": "Phase 2, 3 and 4 clinical trials have investigated the efficacy and safety of tofacitinib given either as monotherapy or in combination with csDMARDs.", "offsetInBeginSection": 337, "offsetInEndSection": 487, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27177233", "text": "Tofacitinib, an oral inhibitor of the cytokine-driven JAK-STAT signalling cascade, has recently been proposed for the treatment of moderate-to-severe UC.", "offsetInBeginSection": 665, "offsetInEndSection": 818, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a679be1b750ff4455000005", "body": "Are organisms in the genus Morexella associated with sepsis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7890896", "http://www.ncbi.nlm.nih.gov/pubmed/35983067", "http://www.ncbi.nlm.nih.gov/pubmed/549184", "http://www.ncbi.nlm.nih.gov/pubmed/6954635", "http://www.ncbi.nlm.nih.gov/pubmed/9587088", "http://www.ncbi.nlm.nih.gov/pubmed/7066660", "http://www.ncbi.nlm.nih.gov/pubmed/10403734", "http://www.ncbi.nlm.nih.gov/pubmed/23419040", "http://www.ncbi.nlm.nih.gov/pubmed/19870409", "http://www.ncbi.nlm.nih.gov/pubmed/2649316"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24786571", "text": "RESULTS Some plant species, such as Alchornea floribunda, Musanga cecropioides (both leaves and stem bark), Tetracera potatoria and Xylopia aethiopica (stem bark), were effective in inhibiting Morexella cattarhalis, having MIC values between 65 and 250 \u03bcg/mL.", "offsetInBeginSection": 1221, "offsetInEndSection": 1481, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633", "text": "Acinetobacter species, Staphylococcus epidermidis, Klebseila, Streptococci, Enterobacter cloacae and Morexella species were found in 17 (13.1%), 17 (13.1%), 13 (10%), 7 (5.4%), 6 (4.6%), and 5 (3.8%) cases respectively.", "offsetInBeginSection": 1173, "offsetInEndSection": 1392, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9587088", "text": "The genus Citrobacter includes three species of organisms that are uncommonly associated with human infection.", "offsetInBeginSection": 0, "offsetInEndSection": 110, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18696148", "text": "Species of Aeromonas (A. hydrophila, A. caviae, A. veronii) have been shown to be associated with food borne gastroenteritis, with wound infections acquired via water or with sepsis, peritonitis or meningitis.", "offsetInBeginSection": 923, "offsetInEndSection": 1132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9587088", "text": "The authors report a case of Citrobacter freundii empyema in a patient with occult pulmonary histoplasmosis.", "offsetInBeginSection": 440, "offsetInEndSection": 548, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/549184", "text": "Organisms of the genus Bacteroides represent the major group of obligate anaerobes involved in human infections.", "offsetInBeginSection": 0, "offsetInEndSection": 112, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6954635", "text": "Organisms of the genus Bacterioides represent the major group of obligate anaerobes involved in human infections.", "offsetInBeginSection": 0, "offsetInEndSection": 113, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18696148", "text": "Members of the mesophilic genus Aeromonas spp.", "offsetInBeginSection": 233, "offsetInEndSection": 279, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633", "text": "CONCLUSION Staphylococcus aureus are the most common gram positive bacteria and Escherichia coli are the most common gram negative bacteria causing neonatal sepsis.", "offsetInBeginSection": 1934, "offsetInEndSection": 2098, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1078783", "text": "Although Hemophilus influenzae is a common cause of meningitis, other members of the Hemophilus genus are rarely the infecting organism.", "offsetInBeginSection": 0, "offsetInEndSection": 136, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70e1d999e2c3af26000007", "body": "Is Solanezumab effective for Alzheimer's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28649604", "http://www.ncbi.nlm.nih.gov/pubmed/22277519", "http://www.ncbi.nlm.nih.gov/pubmed/24445401", "http://www.ncbi.nlm.nih.gov/pubmed/28219449", "http://www.ncbi.nlm.nih.gov/pubmed/25459121", "http://www.ncbi.nlm.nih.gov/pubmed/23582316", "http://www.ncbi.nlm.nih.gov/pubmed/24733588", "http://www.ncbi.nlm.nih.gov/pubmed/34443678", "http://www.ncbi.nlm.nih.gov/pubmed/33575481", "http://www.ncbi.nlm.nih.gov/pubmed/21501112"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27239538", "text": "INTRODUCTION Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD).", "offsetInBeginSection": 0, "offsetInEndSection": 160, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121", "text": "Results from amyloid-based immunotherapy studies in clinical trials indicate that intervention appears to be more effective in early stages of amyloid accumulation in particular solanezumab with a potential impact at mild Alzheimer's disease, highlighting the importance of diagnosing Alzheimer's disease as early as possible and undertaking clinical trials at this stage.", "offsetInBeginSection": 883, "offsetInEndSection": 1255, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451", "text": "Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of \u03b2-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimer's disease (AD).", "offsetInBeginSection": 0, "offsetInEndSection": 193, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121", "text": "So a new third phase 3 clinical trial for solanezumab, called Expedition 3, in patients with mild Alzheimer's disease and evidence of amyloid burden has been started.", "offsetInBeginSection": 1487, "offsetInEndSection": 1653, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21504387", "text": "Solanezumab is a monoclonal antibody that binds to \u03b2-amyloid (A\u03b2), a protein that plays a key role in the pathogenesis of AD.", "offsetInBeginSection": 126, "offsetInEndSection": 253, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451", "text": "While there is a strong hope that solanezumab may represent the first effective passive vaccine for AD treatment, skepticism still exists on the ability of the drug to slow the rate of deterioration in patients with fully established disease.", "offsetInBeginSection": 790, "offsetInEndSection": 1032, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451", "text": "Eli Lilly & Co is developing an intravenous formulation of solanezumab for the treatment of mild-to-moderate AD.", "offsetInBeginSection": 194, "offsetInEndSection": 306, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463", "text": "The results of the large, ongoing Phase III trials with bapineuzumab and solanezumab will tell us if monoclonal anti-A\u03b2 antibodies may slow down the rate of deterioration of AD.", "offsetInBeginSection": 1956, "offsetInEndSection": 2134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27025080", "text": "Solanezumab is now on a large scale phase III trial in mild AD cases in the world.", "offsetInBeginSection": 604, "offsetInEndSection": 686, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463", "text": "Anti-A\u03b2 monoclonal antibodies (bapineuzumab and solanezumab) are now being developed.", "offsetInBeginSection": 1005, "offsetInEndSection": 1091, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a86ecc7faa1ab7d2e000039", "body": "What is the function of the H19 (ICR) locus in the human genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34921234", "http://www.ncbi.nlm.nih.gov/pubmed/17948025", "http://www.ncbi.nlm.nih.gov/pubmed/16575185", "http://www.ncbi.nlm.nih.gov/pubmed/24023912", "http://www.ncbi.nlm.nih.gov/pubmed/12960026", "http://www.ncbi.nlm.nih.gov/pubmed/17048991", "http://www.ncbi.nlm.nih.gov/pubmed/16006531", "http://www.ncbi.nlm.nih.gov/pubmed/26165656", "http://www.ncbi.nlm.nih.gov/pubmed/12806090", "http://www.ncbi.nlm.nih.gov/pubmed/23230275"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16575185", "text": "Genomic imprinting at the H19/Igf2 locus is governed by a cis-acting Imprinting-Control Region (ICR), located 2 kb upstream of the H19 gene.", "offsetInBeginSection": 0, "offsetInEndSection": 140, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16006531", "text": "A maternally inherited H19 ICR inhibits Igf2 gene activation by the downstream enhancer due to its insulator function while it suppresses H19 gene transcription by promoter DNA methylation when paternally inherited.", "offsetInBeginSection": 305, "offsetInEndSection": 520, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912", "text": "Mono-allelic expression at the mouse IGF2/H19 locus is controlled by differential allelic DNA methylation of the imprinting control region (ICR).", "offsetInBeginSection": 0, "offsetInEndSection": 145, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20047949", "text": "Imprinted expression of the mouse Igf2/H19 locus is controlled by parent-of-origin-specific methylation of the imprinting control region (ICR).", "offsetInBeginSection": 0, "offsetInEndSection": 143, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16006531", "text": "Thus, the ICR autonomously recapitulated imprinting within the normally nonimprinted transgenic beta-globin gene locus, but the temporal establishment of imprinting methylation differs from that at the endogenous Igf2/H19 locus.", "offsetInBeginSection": 1560, "offsetInEndSection": 1788, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19546235", "text": "By grafting a 2.9-kbp H19 ICR fragment into a human beta-globin yeast artificial chromosome in transgenic mice, we previously showed that the ICR could recapitulate imprinted methylation and expression at a heterologous locus, suggesting that the H19 ICR in the beta-globin locus contained sufficient information to maintain the methylation mark (K. Tanimoto, M. Shimotsuma, H. Matsuzaki, A. Omori, J. Bungert, J. D. Engel, and A. Fukamizu, Proc.", "offsetInBeginSection": 262, "offsetInEndSection": 708, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21600199", "text": "Individually, both mutant alleles (H19(ICR\u2206IVS) and H19(ICR-8nrCG)) show loss of imprinted repression of paternal H19.", "offsetInBeginSection": 891, "offsetInEndSection": 1011, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16815976", "text": "It is thought that the H19 imprinting control region (ICR) directs the silencing of the maternally inherited Igf2 allele through a CTCF-dependent chromatin insulator.", "offsetInBeginSection": 0, "offsetInEndSection": 166, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16815976", "text": "Mutation of CTCF binding sites in the H19 ICR leads to loss of CTCF binding and de novo methylation of a CTCF target site within Igf2 DMR1, showing that CTCF can coordinate regional epigenetic marks.", "offsetInBeginSection": 990, "offsetInEndSection": 1189, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21600199", "text": "Like most imprinted genes, H19 and Igf2 are regulated by a differentially methylated imprinting control region (ICR).", "offsetInBeginSection": 104, "offsetInEndSection": 221, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e354fb750ff4455000042", "body": "Which R/bioconductor package has been developed to aid in epigenomic analysis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22113085", "http://www.ncbi.nlm.nih.gov/pubmed/18245128", "http://www.ncbi.nlm.nih.gov/pubmed/19505942", "http://www.ncbi.nlm.nih.gov/pubmed/22923296", "http://www.ncbi.nlm.nih.gov/pubmed/20688976", "http://www.ncbi.nlm.nih.gov/pubmed/29092936", "http://www.ncbi.nlm.nih.gov/pubmed/19654119", "http://www.ncbi.nlm.nih.gov/pubmed/21398674", "http://www.ncbi.nlm.nih.gov/pubmed/17623700", "http://www.ncbi.nlm.nih.gov/pubmed/33325493"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28334349", "text": "Results To make public epigenomic data conveniently available for analysis in R, we developed an R/Bioconductor package that connects to the DeepBlue Epigenomic Data Server, enabling users to quickly gather and transform epigenomic data from selected experiments for analysis in the Bioconductor ecosystem.", "offsetInBeginSection": 343, "offsetInEndSection": 649, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058", "text": "We therein provide here a detailed and easy-to-use protocol of using exomePeak R/Bioconductor package along with other software programs for analysis of MeRIP-Seq data, which covers raw reads alignment, RNA methylation site detection, motif discovery, differential RNA methylation analysis, and functional analysis.", "offsetInBeginSection": 983, "offsetInEndSection": 1298, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26374744", "text": "Here we present an R/Bioconductor package that implements a hybrid gene selection method along with a bunch of functions to facilitate a thorough and convenient gene expression profiling analysis.", "offsetInBeginSection": 434, "offsetInEndSection": 630, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058", "text": "We have previously developed an R/Bioconductor package 'exomePeak' for detecting RNA methylation sites under a specific experimental condition or the identifying the differential RNA methylation sites in a case control study from MeRIP-Seq data.", "offsetInBeginSection": 488, "offsetInEndSection": 733, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24222209", "text": "Here we introduce tRanslatome, a new R/Bioconductor package, which is a complete platform for the simultaneous pairwise analysis of transcriptome, translatome and proteome data.", "offsetInBeginSection": 764, "offsetInEndSection": 941, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22684628", "text": "Here, we introduce an R/Bioconductor software package that enables the identification of candidate functional SNPs by integrating information from tagSNP locations, lists of linked SNPs from the 1000 genomes project and locations of chromatin features which may have functional significance.", "offsetInBeginSection": 983, "offsetInEndSection": 1274, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973", "text": "We developed an R/Bioconductor package called TCGAbiolinks to address these challenges and offer bioinformatics solutions by using a guided workflow to allow users to query, download and perform integrative analyses of TCGA data.", "offsetInBeginSection": 728, "offsetInEndSection": 957, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27239475", "text": "The newly developed Guitar R/Bioconductor package achieves stable performance on the data tested and revealed novel biological insights.", "offsetInBeginSection": 1181, "offsetInEndSection": 1317, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27239475", "text": "We developed here an open source Guitar R/Bioconductor package for sketching the transcriptomic view of RNA-related biological features represented by genome based coordinates.", "offsetInBeginSection": 492, "offsetInEndSection": 668, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26374744", "text": "Detailed instructions and example data are provided in the R package, which is freely available at Bioconductor under the GPL-2 or later license http://www.bioconductor.org/packages/3.1/bioc/html/mAPKL.html.", "offsetInBeginSection": 1730, "offsetInEndSection": 1937, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a76dd749e632bc066000008", "body": "What does VBP15 do to skeletal muscle?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/6131839", "http://www.ncbi.nlm.nih.gov/pubmed/10456253", "http://www.ncbi.nlm.nih.gov/pubmed/7173421", "http://www.ncbi.nlm.nih.gov/pubmed/6361516", "http://www.ncbi.nlm.nih.gov/pubmed/33369797", "http://www.ncbi.nlm.nih.gov/pubmed/9578387", "http://www.ncbi.nlm.nih.gov/pubmed/27916343", "http://www.ncbi.nlm.nih.gov/pubmed/21996779", "http://www.ncbi.nlm.nih.gov/pubmed/32503899", "http://www.ncbi.nlm.nih.gov/pubmed/3042002"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26511361", "text": "Herein, we benchmarked traditional glucocorticoids against the ability of a new clinical-stage dissociative steroidal drug, VBP15, for mitotic resynchronization and associated anti-inflammatory activity in asthmatic airway epithelial cells.", "offsetInBeginSection": 491, "offsetInEndSection": 731, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27133900", "text": "These data demonstrate that VBP15 is a novel anti-mucin agent that mediates the reduction of MUC5AC gene expression differently than the classical glucocorticoid, Dex.", "offsetInBeginSection": 1695, "offsetInEndSection": 1862, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25392236", "text": "Furthermore, treatment with prednisolone-but not VBP15-increased expression of genes associated with bone loss and muscle atrophy, suggesting lack of side effects of VBP15.", "offsetInBeginSection": 1151, "offsetInEndSection": 1323, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23498916", "text": "VBP15 is currently under development for treatment of Duchenne muscular dystrophy.", "offsetInBeginSection": 1922, "offsetInEndSection": 2004, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26511361", "text": "CONCLUSION VBP15 improves mitotic asynchrony and injury-induced pro-inflammatory and fibrogenic responses in asthmatic airway epithelial cultures with efficacy comparable to traditional glucocorticoids.", "offsetInBeginSection": 1469, "offsetInEndSection": 1671, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23667681", "text": "These findings suggest that VBP15 may represent a potent and safer alternative to traditional glucocorticoids in the treatment of asthma and other inflammatory diseases.", "offsetInBeginSection": 1647, "offsetInEndSection": 1816, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378", "text": "We find VBP15 protects and promotes efficient repair of skeletal muscle cells upon laser injury, in opposition to prednisolone.", "offsetInBeginSection": 617, "offsetInEndSection": 744, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378", "text": "Absence of dystrophin makes skeletal muscle more susceptible to injury, resulting in breaches of the plasma membrane and chronic inflammation in Duchenne muscular dystrophy (DMD).", "offsetInBeginSection": 0, "offsetInEndSection": 179, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25392236", "text": "These findings suggest that VBP15 may represent a potentially safer alternative to traditional glucocorticoids in the treatment of multiple sclerosis and other inflammatory diseases.", "offsetInBeginSection": 1324, "offsetInEndSection": 1506, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23936073", "text": "Myosin binding protein-C (MyBP-C) exists in three major isoforms: slow skeletal, fast skeletal, and cardiac.", "offsetInBeginSection": 0, "offsetInEndSection": 108, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6a02a3b750ff4455000021", "body": "What protein is the most common cause of hereditary  renal amyloidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17577690", "http://www.ncbi.nlm.nih.gov/pubmed/22261745", "http://www.ncbi.nlm.nih.gov/pubmed/30829617", "http://www.ncbi.nlm.nih.gov/pubmed/25331409", "http://www.ncbi.nlm.nih.gov/pubmed/21728005", "http://www.ncbi.nlm.nih.gov/pubmed/2564248", "http://www.ncbi.nlm.nih.gov/pubmed/21820994", "http://www.ncbi.nlm.nih.gov/pubmed/15645642", "http://www.ncbi.nlm.nih.gov/pubmed/28078835", "http://www.ncbi.nlm.nih.gov/pubmed/29020719"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29142973", "text": "Introduction Fibrinogen A alpha chain amyloidosis is an autosomal dominant disease associated with mutations in the fibrinogen A alpha chain (FGA) gene, and it is the most common cause of hereditary renal amyloidosis in the UK.", "offsetInBeginSection": 0, "offsetInEndSection": 227, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25331409", "text": "Mutations in the fibrinogen A\u03b1-chain genes are the most common cause of hereditary renal amyloidosis.", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22967253", "text": "Amyloid-A (AA) amyloidosis is the most common form of systemic amyloidosis worldwide, AA amyloidosis occurs in the course of chronic inflammatory diseases, hereditary periodic fevers, and with certain neoplasms such as Hodgkin disease and renal cell carcinoma.", "offsetInBeginSection": 459, "offsetInEndSection": 719, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19073821", "text": "Mutations in the fibrinogen A alpha-chain gene are the most common cause of hereditary renal amyloidosis in the United Kingdom.", "offsetInBeginSection": 0, "offsetInEndSection": 127, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22540225", "text": "Fibrinogen A \u03b1-chain (AFib) and apolipoprotein AI (AApoAI) amyloidosis due to variants in the AFib and ApoAI genes are the most common types of hereditary amyloidosis in Europe and the United States.", "offsetInBeginSection": 0, "offsetInEndSection": 200, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174", "text": "Hereditary renal amyloidosis is an autosomal dominant condition with considerable overlap with other amyloidosis types.", "offsetInBeginSection": 0, "offsetInEndSection": 119, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8560604", "text": "In developed countries, rheumatoid arthritis is the most common cause of renal amyloidosis, while in developing countries patients with familial Mediterranean fever (FMF) (untreated) and chronic suppurative infections constitute a large proportion of renal amyloidosis cases.", "offsetInBeginSection": 1088, "offsetInEndSection": 1363, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174", "text": "We suspected amyloidosis with fibrinogen A alpha chain deposits, which is the most frequent cause of hereditary amyloidosis in Europe, with a glomerular preferential affectation.", "offsetInBeginSection": 427, "offsetInEndSection": 605, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22967253", "text": "Kidney biopsy revealed AA renal amyloidosis.", "offsetInBeginSection": 1191, "offsetInEndSection": 1235, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28153807", "text": "Less common is the hereditary amyloidosis.", "offsetInBeginSection": 571, "offsetInEndSection": 613, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7234352dc08e987e000007", "body": "What is the most common histological diagnosis of \"butterfly glioma\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8967188", "http://www.ncbi.nlm.nih.gov/pubmed/9095625", "http://www.ncbi.nlm.nih.gov/pubmed/21046313", "http://www.ncbi.nlm.nih.gov/pubmed/36208578", "http://www.ncbi.nlm.nih.gov/pubmed/10616096", "http://www.ncbi.nlm.nih.gov/pubmed/14628201", "http://www.ncbi.nlm.nih.gov/pubmed/12672213", "http://www.ncbi.nlm.nih.gov/pubmed/35263137", "http://www.ncbi.nlm.nih.gov/pubmed/23806375", "http://www.ncbi.nlm.nih.gov/pubmed/29732524"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17854667", "text": "Glioblastoma multiforme (GBM), the most common malignant brain tumor of adults, is relatively rare in children.", "offsetInBeginSection": 0, "offsetInEndSection": 111, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27521725", "text": "When a tumor with adenoid histological features and a \"butterfly\" phenotype grows in the corpus callosum in a patient with known parotid ACC, both metastasis and adenoid variant GBM should be considered.", "offsetInBeginSection": 1420, "offsetInEndSection": 1623, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18669409", "text": "RESULTS Magnetic resonance imaging (MRI) of the brain revealed a mass lesion involving both hemispheres, which on positron emission tomography (PET) scan and magnetic resonance-spectroscopy (MR-SPECT) appeared to be a butterfly glioma.", "offsetInBeginSection": 171, "offsetInEndSection": 406, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27458589", "text": "Although rare, GBM should be considered a differential diagnosis in dogs with an MRI evidence of asymmetric or symmetric bilateral, intra-axial cerebral mass lesions with signal characteristics compatible with glioma.", "offsetInBeginSection": 1355, "offsetInEndSection": 1572, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164", "text": "Other neoplastic and non-neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma, as well as associated imaging features, are discussed.", "offsetInBeginSection": 448, "offsetInEndSection": 616, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18669409", "text": "CONCLUSION This is the first case of a localized central nervous system vascular amyloid to imitate a butterfly glioma on MRI and PET scan studies.", "offsetInBeginSection": 507, "offsetInEndSection": 654, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27458589", "text": "This particular tumor manifestation has been coined a \"butterfly\" glioma (BG).", "offsetInBeginSection": 159, "offsetInEndSection": 237, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17854667", "text": "In a GBM affecting a 16-year-old boy, the tumor spread across the corpus callosum (butterfly glioma).", "offsetInBeginSection": 112, "offsetInEndSection": 213, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27521725", "text": "BACKGROUND Intracranial spread of an adenoid cystic carcinoma (ACC) of the parotid gland is rare, and metastatic ACC to the splenium of the corpus callosum mimicking butterfly glioblastoma (GBM) has not been reported previously.", "offsetInBeginSection": 0, "offsetInEndSection": 228, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290", "text": "A previous steroid medication over several weeks for treatment of increased intracranial pressure may be considered as an important factor in the origin of the pulmonary aspergillosis complicating the butterfly glioma.", "offsetInBeginSection": 779, "offsetInEndSection": 997, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a86fd5bfaa1ab7d2e00003b", "body": "Is a CpG island methylator phenotype involved in ependymomas?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22122704", "http://www.ncbi.nlm.nih.gov/pubmed/21507361", "http://www.ncbi.nlm.nih.gov/pubmed/31701771", "http://www.ncbi.nlm.nih.gov/pubmed/18546260", "http://www.ncbi.nlm.nih.gov/pubmed/21037082", "http://www.ncbi.nlm.nih.gov/pubmed/12957287", "http://www.ncbi.nlm.nih.gov/pubmed/15767794", "http://www.ncbi.nlm.nih.gov/pubmed/35131383", "http://www.ncbi.nlm.nih.gov/pubmed/23417071", "http://www.ncbi.nlm.nih.gov/pubmed/26702883"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142", "text": "CpG island methylator phenotype-positive hindbrain ependymomas are responsive to clinical drugs that target either DNA or H3K27 methylation both in vitro and in vivo.", "offsetInBeginSection": 822, "offsetInEndSection": 988, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10411935", "text": "In contrast, methylation of the cancer-specific clones was found exclusively in a subset of colorectal cancers, which appear to display a CpG island methylator phenotype (CIMP).", "offsetInBeginSection": 721, "offsetInEndSection": 898, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19136926", "text": "In hepatocellular carcinomas, hypermethylation of CpG islands, and CpG island methylator phenotype status seems to correlate with levels of long interspersed nuclear element-1 hypomethylation.", "offsetInBeginSection": 1541, "offsetInEndSection": 1733, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25182241", "text": "Although no recurrently mutated genes were found throughout these groups of ependymomas, PFA exhibited a CpG island methylator phenotype, PFB was associated with extensive chromosomal aberrations, and the C11orf95-RELA fusion gene was frequently observed in supratentorial ependymomas.", "offsetInBeginSection": 309, "offsetInEndSection": 594, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142", "text": "Although devoid of recurrent single nucleotide variants and focal copy number aberrations, poor-prognosis hindbrain ependymomas exhibit a CpG island methylator phenotype.", "offsetInBeginSection": 444, "offsetInEndSection": 614, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23619990", "text": "Neuroblastomas with the CpG island methylator phenotype include almost all neuroblastomas with MYCN amplification, and, even among neuroblastomas without MYCN amplification, have worse prognosis.", "offsetInBeginSection": 107, "offsetInEndSection": 302, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23619990", "text": "OBJECTIVE The CpG island methylator phenotype is strongly associated with poor survival in neuroblastomas.", "offsetInBeginSection": 0, "offsetInEndSection": 106, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24674026", "text": "In colorectal cancer, the CpG island methylator phenotype (CIMP) is defined as widespread and elevated levels of DNA methylation and CIMP+ tumors have distinctive clinicopathological and molecular features.", "offsetInBeginSection": 140, "offsetInEndSection": 346, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28548123", "text": "Of the 34 miRNAs associated with CpG island methylator phenotype-high tumors, 16 were more likely to have a CpG island methylator phenotype-high tumor and 19 were less likely to be CpG island methylator phenotype-high.", "offsetInBeginSection": 1130, "offsetInEndSection": 1348, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23619990", "text": "CONCLUSION The CpG island methylator phenotype is likely to have stronger prognostic power than methylation of individual genes in neuroblastomas.", "offsetInBeginSection": 1556, "offsetInEndSection": 1702, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e4814b750ff445500004a", "body": "Are loop domains preserved upon cohesin loss?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31753851", "http://www.ncbi.nlm.nih.gov/pubmed/21708976", "http://www.ncbi.nlm.nih.gov/pubmed/36129789", "http://www.ncbi.nlm.nih.gov/pubmed/26878753", "http://www.ncbi.nlm.nih.gov/pubmed/33767413", "http://www.ncbi.nlm.nih.gov/pubmed/35811175", "http://www.ncbi.nlm.nih.gov/pubmed/29346962", "http://www.ncbi.nlm.nih.gov/pubmed/34297911", "http://www.ncbi.nlm.nih.gov/pubmed/35136067", "http://www.ncbi.nlm.nih.gov/pubmed/35959892"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24185899", "text": "Post-mitotic nuclei deficient for functional cohesin exhibit global architectural changes associated with loss of cohesin/CTCF contacts and relaxation of topological domains.", "offsetInBeginSection": 647, "offsetInEndSection": 821, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28467304", "text": "The insulator protein CTCF and cohesin control domain location by folding domains into loop structures, which are widely thought to be stable.", "offsetInBeginSection": 83, "offsetInEndSection": 225, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24335803", "text": "The boundary sequences between domains are enriched for binding sites of CTCC-binding factor (CTCF) and the cohesin complex, implicating these two factors in the establishment or maintenance of topological domains.", "offsetInBeginSection": 152, "offsetInEndSection": 366, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29077530", "text": "We discuss how loop extrusion models can explain TAD formation and evidence that TADs are formed by the ring-shaped protein complex, cohesin, and that TAD boundaries are established by the DNA-binding protein, CTCF.", "offsetInBeginSection": 250, "offsetInEndSection": 465, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562", "text": "\"Loop domains\" form because of tethering between two loci-almost always bound by CTCF and cohesin-lying on the same chromosome.", "offsetInBeginSection": 142, "offsetInEndSection": 269, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21502535", "text": "Loss of OCT4 in the committed and differentiated neuronal progenitor cells results in loading of cohesin and chromosome looping, which contributes to heterochromatin partitioning and selective gene activation across the HOXA locus.", "offsetInBeginSection": 831, "offsetInEndSection": 1062, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24335803", "text": "We observed a general loss of local chromatin interactions upon disruption of cohesin, but the topological domains remain intact.", "offsetInBeginSection": 629, "offsetInEndSection": 758, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26686465", "text": "The CTCF-CTCF loops we identified form a chromosomal framework of insulated neighborhoods, which in turn form topologically associating domains (TADs) that are largely preserved during the transition between the naive and primed states.", "offsetInBeginSection": 306, "offsetInEndSection": 542, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28467304", "text": "Since CTCF and cohesin are required for loop domain formation, our results suggest that chromatin loops are dynamic and frequently break and reform throughout the cell cycle.", "offsetInBeginSection": 780, "offsetInEndSection": 954, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21502535", "text": "The insulator protein CCCTC-binding factor (CTCF) is involved in creating boundaries that segregate chromatin and functional domains and in organizing higher-order chromatin structures by promoting chromosomal loops across the vertebrate genome.", "offsetInBeginSection": 102, "offsetInEndSection": 347, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7723b79e632bc06600000b", "body": "What are the prednisone side effects in DMD patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24068153", "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/23846963", "http://www.ncbi.nlm.nih.gov/pubmed/36289662", "http://www.ncbi.nlm.nih.gov/pubmed/8313930", "http://www.ncbi.nlm.nih.gov/pubmed/9260858", "http://www.ncbi.nlm.nih.gov/pubmed/16980656", "http://www.ncbi.nlm.nih.gov/pubmed/26701140", "http://www.ncbi.nlm.nih.gov/pubmed/31552055", "http://www.ncbi.nlm.nih.gov/pubmed/17222213"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "text": "The results suggest that (i) DFC and PRED in equal anti-inflammatory dosage are similarly or equally efficient in slowing down the decline of muscle strength in DMD; (ii) benefits outweigh the side effects.", "offsetInBeginSection": 1274, "offsetInEndSection": 1480, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9128400", "text": "In 1974 Drachman and his colleagues first raised the possibility of beneficial effect of glucocorticoid in an uncontrolled trial of Duchenne muscular dystrophy (DMD) patients.", "offsetInBeginSection": 0, "offsetInEndSection": 175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "text": "Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents na\u00efve to corticosteroids (DMD).", "offsetInBeginSection": 321, "offsetInEndSection": 499, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16980656", "text": "BACKGROUND Steroid administration is beneficial in Duchenne muscular dystrophy (DMD), but the response, incidence, and the severity of side effects are variable.", "offsetInBeginSection": 0, "offsetInEndSection": 161, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12548530", "text": "Because steroids are effective in prolonging function, but not in recovering lost function, we propose that treatment be started with low-dose prednisone in DMD patients as soon as the diagnosis is definite.", "offsetInBeginSection": 719, "offsetInEndSection": 926, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "text": "Deflazacort (DFC) is supposed to have fewer side effects than prednisone (PRED).", "offsetInBeginSection": 144, "offsetInEndSection": 224, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "text": "Steroid treatment with deflazacort appears to cause fewer side effects than with prednisone, particularly weight gain, which could be important to maximize motor performances.", "offsetInBeginSection": 1190, "offsetInEndSection": 1365, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "text": "The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups.", "offsetInBeginSection": 500, "offsetInEndSection": 584, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16980656", "text": "RESULTS Mutation studies revealed an heterozygous A to G mutation at GRL cDNA position 1220 in three DMD patients resulting in an asparagine to serine amino acid change at amino acid position 363 (N363S).", "offsetInBeginSection": 434, "offsetInEndSection": 638, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e42f1b750ff4455000046", "body": "What gene is mutated in Familial Mediterranean Fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12387810", "http://www.ncbi.nlm.nih.gov/pubmed/18386244", "http://www.ncbi.nlm.nih.gov/pubmed/31139696", "http://www.ncbi.nlm.nih.gov/pubmed/15070275", "http://www.ncbi.nlm.nih.gov/pubmed/18824843", "http://www.ncbi.nlm.nih.gov/pubmed/15720243", "http://www.ncbi.nlm.nih.gov/pubmed/23838413", "http://www.ncbi.nlm.nih.gov/pubmed/16941262", "http://www.ncbi.nlm.nih.gov/pubmed/10667038", "http://www.ncbi.nlm.nih.gov/pubmed/36299850"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28690860", "text": "Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease that is inherited in an autosomal recessive manner and is caused by mutations in the MEFV gene.", "offsetInBeginSection": 0, "offsetInEndSection": 171, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18347298", "text": "Cryopyrin and pyrin (protein mutated in familial Mediterranean fever) belong to the family of PYRIN domain-containing proteins.", "offsetInBeginSection": 1013, "offsetInEndSection": 1140, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24980720", "text": "BACKGROUND Familial Mediterranean Fever (FMF), characterized by recurrent fever and inflammation of serous membranes, is an autosomal recessive disease caused by mutations in the Mediterranean fever (MEFV) gene.", "offsetInBeginSection": 0, "offsetInEndSection": 211, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810", "text": "Familial Mediterranean fever (FMF) has been traced to mutations in the MEFV gene.", "offsetInBeginSection": 462, "offsetInEndSection": 543, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20437121", "text": "We identified 1 homozygous (E148Q/E148Q), 1 compound heterozygous (M694V/E148Q) and 5 heterozygous MEFV gene mutations; none had their own and/or family history compatible with familial Mediterranean fever.", "offsetInBeginSection": 370, "offsetInEndSection": 576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17431422", "text": "In patients with another autoinflammatory disorder, familial Mediterranean fever (FMF), mutations in the SPRY domain of the Pyrin protein are frequently found.", "offsetInBeginSection": 314, "offsetInEndSection": 473, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20645115", "text": "Mediterranean fever (MEFV) gene mutations might be one of the genetic predisposition factors in the development of ARF/RHD since defect in familial Mediterranean fever (FMF) patients is proposed to be heightened inflammatory response to certain stimuli.", "offsetInBeginSection": 139, "offsetInEndSection": 392, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18219832", "text": "On the other hand, asthma is less frequent in individuals with familial Mediterranean fever, an autoinflammatory disease prevalent in the Iraqi Jewish community and linked to mutations in the familial Mediterranean fever gene, designated MEFV.", "offsetInBeginSection": 230, "offsetInEndSection": 473, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20437121", "text": "We aimed to investigate the rate of MEFV, the gene mutated in familial Mediterranean fever, mutations in patients with myeloid neoplasm and to determine if known mutations of MEFV cause a tendency for myeloid neoplasms.", "offsetInBeginSection": 0, "offsetInEndSection": 219, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810", "text": "The tumour necrosis factor(TNF)-receptor-associated periodic syndromes (TRAPS) have been linked to mutations in theTNFRSF1A gene, encoding a TNF-alpha receptor, and the CIAS1 gene is mutated in familial cold autoinflammatory syndrome.", "offsetInBeginSection": 662, "offsetInEndSection": 896, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7242a22dc08e987e00000e", "body": "Describe swirl sign in intracerebral hemorrhage.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30818076", "http://www.ncbi.nlm.nih.gov/pubmed/25650013", "http://www.ncbi.nlm.nih.gov/pubmed/17705007", "http://www.ncbi.nlm.nih.gov/pubmed/23674525", "http://www.ncbi.nlm.nih.gov/pubmed/1122175", "http://www.ncbi.nlm.nih.gov/pubmed/21792352", "http://www.ncbi.nlm.nih.gov/pubmed/23013418", "http://www.ncbi.nlm.nih.gov/pubmed/33240193", "http://www.ncbi.nlm.nih.gov/pubmed/30844526", "http://www.ncbi.nlm.nih.gov/pubmed/27174523"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24474263", "text": "CONCLUSIONS Detection of hematocrit effect by CT scanning of intracranial hematomas should be cautionary in oral anticoagulant use, while detection of swirl sign should be suggestive of active hemorrhage.", "offsetInBeginSection": 1610, "offsetInEndSection": 1814, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418", "text": "Swirl sign was found in 30% of the study population.", "offsetInBeginSection": 691, "offsetInEndSection": 743, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418", "text": "CONCLUSIONS As swirl sign showed to be an ominous sign, we recommend identification of this sign in cases of ICHs.", "offsetInBeginSection": 1401, "offsetInEndSection": 1515, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418", "text": "Only 19% of patients with swirl sign exhibited favorable outcome at three months compared with 53% of those with no swirl sign (p < 0.001).", "offsetInBeginSection": 858, "offsetInEndSection": 997, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28894943", "text": "Compared with patients without this sign, those exhibiting the swirl sign had a higher mortality rate (24 vs. 6%, respectively; P\u00a0=\u00a00.028) and a worse outcome (Glasgow Outcome Scale score\u00a0\u2264\u00a03: 38 vs. 15%, respectively; P\u00a0=\u00a00.027) at 3\u00a0months.", "offsetInBeginSection": 1089, "offsetInEndSection": 1340, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28894943", "text": "In conclusion, the occurrence of the swirl sign on the head CT scan of patients with AEDH was found to be significantly associated with poor outcome.", "offsetInBeginSection": 1630, "offsetInEndSection": 1779, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418", "text": "61% of patients with swirl sign were dead at one month compared with 21% of those with no swirl sign (p < 0.001).", "offsetInBeginSection": 744, "offsetInEndSection": 857, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28894943", "text": "An adjusted analysis showed that the occurrence of the swirl sign was an independent predictor of poor outcome (death: odds ratio (OR)\u00a0=\u00a04.61; 95% confidence interval (CI): 1.34-15.82; P\u00a0<\u00a00.05; 3-month Glasgow Outcome Scale score\u00a0\u2264\u00a03: OR\u00a0=\u00a03.47; 95% CI: 1.27-9.49; P\u00a0<\u00a00.05).", "offsetInBeginSection": 1341, "offsetInEndSection": 1629, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418", "text": "Patients with swirl sign exhibited larger ICHs with average ICH-volume 52 \u00b1 50 ml (median 42 ml) compared with 15 \u00b1 25 ml (median 6) in patients whose CT did not show swirl sign (p < 0.001).", "offsetInBeginSection": 998, "offsetInEndSection": 1190, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24481974", "text": "BACKGROUND AND PURPOSE Variability in computed tomography angiography (CTA) acquisitions may be one explanation for the modest accuracy of the spot sign for predicting intracerebral hemorrhage expansion detected in the multicenter Predicting Hematoma Growth and Outcome in Intracerebral Hemorrhage Using Contrast Bolus CT (PREDICT) study.", "offsetInBeginSection": 0, "offsetInEndSection": 338, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8718a261bb38fb24000007", "body": "What is the function of yeast TERRA RNAs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9759492", "http://www.ncbi.nlm.nih.gov/pubmed/23935072", "http://www.ncbi.nlm.nih.gov/pubmed/19026778", "http://www.ncbi.nlm.nih.gov/pubmed/20460456", "http://www.ncbi.nlm.nih.gov/pubmed/19716786", "http://www.ncbi.nlm.nih.gov/pubmed/25631008", "http://www.ncbi.nlm.nih.gov/pubmed/24013207", "http://www.ncbi.nlm.nih.gov/pubmed/24074956", "http://www.ncbi.nlm.nih.gov/pubmed/12868058", "http://www.ncbi.nlm.nih.gov/pubmed/8674114"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778", "text": "Thus, telomeric transcription combined with Rat1p-dependent TERRA degradation is important for regulating telomerase in yeast.", "offsetInBeginSection": 681, "offsetInEndSection": 807, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29145644", "text": "The conserved PAF1 complex (Cdc73, Paf1, Ctr9, Leo1 and Rtf1, in yeast), binds RNA pol II, and affects levels of many RNAs.", "offsetInBeginSection": 0, "offsetInEndSection": 123, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19716786", "text": "We show here that TERRA RNA interacts with several telomere-associated proteins, including telomere repeat factors 1 (TRF1) and 2 (TRF2), subunits of the origin recognition complex (ORC), heterochromatin protein 1 (HP1), histone H3 trimethyl K9 (H3 K9me3), and members of the DNA-damage-sensing pathway.", "offsetInBeginSection": 131, "offsetInEndSection": 434, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24074956", "text": "Simultaneous time-lapse imaging of telomerase RNA and TERRA reveals spontaneous events of telomerase nucleation on TERRA foci in early S phase, generating TERRA-telomerase clusters.", "offsetInBeginSection": 573, "offsetInEndSection": 754, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24550456", "text": "Moreover, because TERRA is a long noncoding RNA, these results reveal a function for long noncoding RNA in regulating recombination.", "offsetInBeginSection": 1207, "offsetInEndSection": 1339, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19716786", "text": "siRNA depletion of TERRA caused an increase in telomere dysfunction-induced foci, aberrations in metaphase telomeres, and a loss of histone H3 K9me3 and ORC at telomere repeat DNA.", "offsetInBeginSection": 435, "offsetInEndSection": 615, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778", "text": "Yeast TERRA is polyadenylated and stabilized by Pap1p and regulated by the 5' to 3' exonuclease, Rat1p.", "offsetInBeginSection": 273, "offsetInEndSection": 376, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19716786", "text": "Telomere-repeat-encoding RNA (referred to as TERRA) has been identified as a potential component of yeast and mammalian telomeres.", "offsetInBeginSection": 0, "offsetInEndSection": 130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28666128", "text": "At telomeres, TERRA competes with telomeric DNA for ATRX binding, suppresses ATRX localization, and ensures telomeric stability.", "offsetInBeginSection": 618, "offsetInEndSection": 746, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28666128", "text": "TERRA and ATRX share hundreds of target genes and are functionally antagonistic at these loci: whereas TERRA activates, ATRX represses gene expression.", "offsetInBeginSection": 466, "offsetInEndSection": 617, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e4d22b750ff445500004d", "body": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26346816", "http://www.ncbi.nlm.nih.gov/pubmed/22378147", "http://www.ncbi.nlm.nih.gov/pubmed/34245909", "http://www.ncbi.nlm.nih.gov/pubmed/26499378", "http://www.ncbi.nlm.nih.gov/pubmed/23630135", "http://www.ncbi.nlm.nih.gov/pubmed/15523612", "http://www.ncbi.nlm.nih.gov/pubmed/27813696", "http://www.ncbi.nlm.nih.gov/pubmed/18805831", "http://www.ncbi.nlm.nih.gov/pubmed/15183415", "http://www.ncbi.nlm.nih.gov/pubmed/23359635"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28623093", "text": "Mutations in this gene are the cause of Schimke immune-osseous dysplasia (SIOD), an autosomal recessive disorder characterized by T-cell immunodeficiency and growth dysfunctions.", "offsetInBeginSection": 219, "offsetInEndSection": 397, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27813696", "text": "Mutations in SMARCAL1, which encodes a DNA annealing helicase with roles in DNA replication fork restart, DNA repair, and gene expression modulation, cause Schimke immuno-osseous dysplasia (SIOD), an autosomal recessive disease characterized by skeletal dysplasia, renal disease, T-cell immunodeficiency, and arteriosclerosis.", "offsetInBeginSection": 0, "offsetInEndSection": 326, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18520775", "text": "Schimke immuno-osseous dysplasia (OMIM 242900) is an uncommon autosomal-recessive multisystem disease caused by mutations in SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1), a gene encoding a putative chromatin remodeling protein.", "offsetInBeginSection": 0, "offsetInEndSection": 288, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16648978", "text": "BACKGROUND Schimke immuno-osseous dysplasia (SIOD) is a rare autosomal recessive multisystemic disorder caused by mutations of the SMARCAL 1 gene (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1).", "offsetInBeginSection": 0, "offsetInEndSection": 243, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27411420", "text": "Schimke immuno-osseous dysplasia is an autosomal recessive multisystem disorder caused by defects in SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1 gene (SMARCAL1).", "offsetInBeginSection": 0, "offsetInEndSection": 212, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26354575", "text": "Schimke immune-osseous dysplasia (SIOD) is a rare autosomal recessive disorder characterized by spondylo-epiphyseal dysplasia (SED), progressive renal insufficiency beginning as steroid-resistant nephrotic syndrome (SRNS) and defective cellular immunity.", "offsetInBeginSection": 0, "offsetInEndSection": 254, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23359635", "text": "Schimke immuno-osseous dysplasia is a rare autosomal recessive multisystem disorder characterized by steroid-resistant nephrotic syndrome, immunodeficiency, and spondyloepiphyseal dysplasia.", "offsetInBeginSection": 0, "offsetInEndSection": 190, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24589093", "text": "BACKGROUND Schimke immuno-osseous dysplasia (SIOD, OMIM #242900) is an autosomal-recessive pleiotropic disorder characterized by spondyloepiphyseal dysplasia, renal dysfunction and T-cell immunodeficiency.", "offsetInBeginSection": 0, "offsetInEndSection": 205, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16816006", "text": "Schimke-immuno-osseous dysplasia is very likely if this ratio is < 0.83.", "offsetInBeginSection": 1573, "offsetInEndSection": 1645, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15523612", "text": "Schimke immuno-osseous dysplasia (SIOD) is a rare autosomal recessive disorder characterized by spondyloepiphyseal dysplasia, nephrotic syndrome, and cell-mediated immunodeficiency.", "offsetInBeginSection": 0, "offsetInEndSection": 181, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7727f39e632bc06600000d", "body": "What are the side effects of deflazacort in DMD patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8313930", "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/16980656", "http://www.ncbi.nlm.nih.gov/pubmed/27542440", "http://www.ncbi.nlm.nih.gov/pubmed/31552055", "http://www.ncbi.nlm.nih.gov/pubmed/7511903", "http://www.ncbi.nlm.nih.gov/pubmed/2003854", "http://www.ncbi.nlm.nih.gov/pubmed/31830002", "http://www.ncbi.nlm.nih.gov/pubmed/26599341", "http://www.ncbi.nlm.nih.gov/pubmed/33228255"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1822804", "text": "We conducted a double blind controlled trial in 28 Duchenne muscular dystrophy (DMD) patients with Deflazacort (DF), an oxazoline derivative of prednisolone which reduces its side-effects.", "offsetInBeginSection": 0, "offsetInEndSection": 188, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11038071", "text": "Deflazacort slows the progress of Duchenne muscular dystrophy (DMD) with fewer side effects than prednisone.", "offsetInBeginSection": 0, "offsetInEndSection": 108, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511", "text": "OBJECTIVE We report the long-term effects on muscle strength and side effects with deflazacort in Duchenne muscular dystrophy (DMD).", "offsetInBeginSection": 0, "offsetInEndSection": 132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511", "text": "CONCLUSIONS We conclude that deflazacort can preserve gross motor and pulmonary function in boys with DMD with limited side effects.", "offsetInBeginSection": 1166, "offsetInEndSection": 1298, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28043681", "text": "OBJECTIVE To evaluate clinical outcomes and steroid side effects in a cohort of patients with Duchenne muscular dystrophy (DMD) treated with long-term daily glucocorticoid therapy.", "offsetInBeginSection": 0, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "text": "Deflazacort (DFC) is supposed to have fewer side effects than prednisone (PRED).", "offsetInBeginSection": 144, "offsetInEndSection": 224, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "text": "The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups.", "offsetInBeginSection": 500, "offsetInEndSection": 584, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22655511", "text": "The clinical outcomes showed increased function in the treated boys, and in a single trial with deflazacort, prolongation of ambulation but with different side effects.", "offsetInBeginSection": 143, "offsetInEndSection": 311, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511", "text": "Asymptomatic cataracts developed in 10 of 30 boys who received deflazacort.", "offsetInBeginSection": 959, "offsetInEndSection": 1034, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6e47b1b750ff4455000049", "body": "Is overproduction of transthyretin is associated with amyloidosis associated neuropathy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31135624", "http://www.ncbi.nlm.nih.gov/pubmed/32741838", "http://www.ncbi.nlm.nih.gov/pubmed/25819286", "http://www.ncbi.nlm.nih.gov/pubmed/20132088", "http://www.ncbi.nlm.nih.gov/pubmed/14987380", "http://www.ncbi.nlm.nih.gov/pubmed/31639841", "http://www.ncbi.nlm.nih.gov/pubmed/1966018", "http://www.ncbi.nlm.nih.gov/pubmed/11523162", "http://www.ncbi.nlm.nih.gov/pubmed/26055637", "http://www.ncbi.nlm.nih.gov/pubmed/18584922"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28217248", "text": "DLT for transthyretin amyloidosis is associated with the risk of developing de novo systemic amyloidosis and amyloid neuropathy, and the risk may be greater with some non-Val30Met mutations.", "offsetInBeginSection": 333, "offsetInEndSection": 523, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24082415", "text": "The senile types of cardiac amyloidosis can result from overproduction of atrial natriuretic factor or from accumulation of otherwise normal or wild-type transthyretin.", "offsetInBeginSection": 703, "offsetInEndSection": 871, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25819286", "text": "Hereditary transthyretin amyloidosis (ATTR) is a genetically and clinically heterogeneous disease manifesting with predominant peripheral and autonomic neuropathy; cardiomyopathy, or both.", "offsetInBeginSection": 0, "offsetInEndSection": 188, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139", "text": "Peripheral neuropathy is the most common clinical presentation in TTR amyloidosis although the carpal tunnel syndrome (CTS) may be the first symptom and skin can be involved, as transthyretin amyloidosis is a systemic disease.", "offsetInBeginSection": 109, "offsetInEndSection": 335, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24082415", "text": "Some of the more common diseases associated with amyloidosis include plasma cell dyscrasias, chronic inflammatory disorders, hereditary-familial mutations involving transthyretin, Alzheimer's disease, and so-called \"senile\" or age-related amyloidosis.", "offsetInBeginSection": 306, "offsetInEndSection": 557, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308", "text": "BACKGROUND Hereditary transthyretin amyloidosis is an autosomal dominant inherited disorder, first described in families with sensorimotor and autonomic neuropathy.", "offsetInBeginSection": 0, "offsetInEndSection": 164, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139", "text": "CONCLUSION This TTR mutation (Tyr78Phe) is associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis.", "offsetInBeginSection": 1235, "offsetInEndSection": 1361, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17554795", "text": "It is most frequently seen in patients with hereditary transthyretin (TTR) amyloidosis, but is also present in 20% of patients with systemic immunoglobulin light chain (primary) amyloidosis.", "offsetInBeginSection": 67, "offsetInEndSection": 257, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139", "text": "BACKGROUND More than 80 transthyretin (TTR) mutations have been described, most associated with amyloidosis.", "offsetInBeginSection": 0, "offsetInEndSection": 108, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17554795", "text": "Neuropathy is often a major manifestation of systemic amyloidosis.", "offsetInBeginSection": 0, "offsetInEndSection": 66, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7244aa2dc08e987e00000f", "body": "Which two interleukins are inhibited by Ustekinumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7994626", "http://www.ncbi.nlm.nih.gov/pubmed/24956533", "http://www.ncbi.nlm.nih.gov/pubmed/36320969", "http://www.ncbi.nlm.nih.gov/pubmed/17704992", "http://www.ncbi.nlm.nih.gov/pubmed/8652272", "http://www.ncbi.nlm.nih.gov/pubmed/32782477", "http://www.ncbi.nlm.nih.gov/pubmed/16701191", "http://www.ncbi.nlm.nih.gov/pubmed/19707405", "http://www.ncbi.nlm.nih.gov/pubmed/34656991", "http://www.ncbi.nlm.nih.gov/pubmed/32588044"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062", "text": "A recent example is ustekinumab, a first-in-class therapeutic human immunoglobulin G1 kappa mAb that binds to the interleukins (IL)-12 and IL-23, cytokines that modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets.", "offsetInBeginSection": 499, "offsetInEndSection": 738, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29042094", "text": "Ustekinumab is a monoclonal antibody directed against the p40 subunit, which is part of interleukins IL-12 and IL-23.", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785", "text": "); (2) Ustekinumab is an inhibitor of interleukins 12 and 23, which are believed to be implicated in the onset of psoriasis.", "offsetInBeginSection": 266, "offsetInEndSection": 390, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972", "text": "At present an anti-CD11a antibody (efalizumab), an anti-LFA3/CD2 receptor (alefacept) and 3 antitumor necrosis factor alpha agents (adalimumab, etanercept, infliximab) are now commercially available for the treatment of both psoriasis and psoriatic arthritis.", "offsetInBeginSection": 488, "offsetInEndSection": 747, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972", "text": "Ustekinumab (CNTO 1275, Centocor Inc, Malvern, PA, USA) is a human monoclonal antibody that binds to the shared p40 protein subunit of human interleukins 12 and 23 with high affinity and specificity, thereby preventing interaction with their surface IL-12R\u03b21 receptor.", "offsetInBeginSection": 1027, "offsetInEndSection": 1296, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22758911", "text": "Recent Phase 2 and Phase 3 trials have illustrated the benefits of briakinumab (in Phase 3 clinical development) and ustekinumab (approved in the EU, and also in other territories worldwide) in the treatment of moderate to severe plaque psoriasis.", "offsetInBeginSection": 361, "offsetInEndSection": 608, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19217154", "text": "Ustekinumab is a human monoclonal antibody that inhibits receptor-binding of these cytokines.", "offsetInBeginSection": 255, "offsetInEndSection": 348, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20421912", "text": "Ustekinumab is a monoclonal antibody belonging to a newly developed class of biological, anti-cytokine medications that notably targets the p40 subunit of both IL-12 and -23, both naturally occurring proteins that are important in regulating the immune system and are understood to play a role in immune-mediated inflammatory disorders.", "offsetInBeginSection": 757, "offsetInEndSection": 1093, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062", "text": "Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor \u03b21 subunit of the IL-12 and IL-23 receptor complexes.", "offsetInBeginSection": 855, "offsetInEndSection": 1027, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19886505", "text": "ABT-874 (Abbott Laboratories, Saint-Laurent, QC,) and ustekinumab (CNTO 1275, Ortho Biotech, Toronto, ON) are two monoclonal antibodies against interleukins 12 and 23 (IL-12/23), key mediators of T-cell differentiation in the pathogenesis of psoriasis.", "offsetInBeginSection": 261, "offsetInEndSection": 513, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8863948cb19eca6b000002", "body": "How can network assortativity be applied in the three-dimensional analysis of the genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25894574", "http://www.ncbi.nlm.nih.gov/pubmed/23536826", "http://www.ncbi.nlm.nih.gov/pubmed/22181316", "http://www.ncbi.nlm.nih.gov/pubmed/31640538", "http://www.ncbi.nlm.nih.gov/pubmed/32652546", "http://www.ncbi.nlm.nih.gov/pubmed/32422724", "http://www.ncbi.nlm.nih.gov/pubmed/33643004", "http://www.ncbi.nlm.nih.gov/pubmed/28364742", "http://www.ncbi.nlm.nih.gov/pubmed/30013271", "http://www.ncbi.nlm.nih.gov/pubmed/27967098"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826", "text": "Our analysis demonstrates that Hi-C data can be effectively applied to study tissue-specific genome conformation, chromosome-chromosome interaction, chromosomal translocations, and spatial gene-gene interaction and regulation in a three-dimensional genome of primary tumor cells.", "offsetInBeginSection": 1091, "offsetInEndSection": 1370, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817", "text": "We propose a new approach, using chromatin assortativity, to integrate the epigenomic landscape of a specific cell type with its chromatin interaction network and thus investigate which proteins or chromatin marks mediate genomic contacts.", "offsetInBeginSection": 206, "offsetInEndSection": 445, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25121490", "text": "Here, we use publicly available DNaseI-seq data to measure the assortativity signatures of genome-wide TFNs in 41 distinct human cell and tissue types.", "offsetInBeginSection": 1641, "offsetInEndSection": 1792, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26816262", "text": "In this study we develop a metric, the vector assortativity index (VA-index for short), based on network randomization and (empirical) statistical hypothesis testing that is able to quantify the assortativity patterns of a network with respect to a vector attribute.", "offsetInBeginSection": 793, "offsetInEndSection": 1059, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826", "text": "Particularly, for the first time, we constructed genome-scale spatial gene-gene interaction network, transcription factor binding site (TFBS) - TFBS interaction network, and TFBS-gene interaction network from chromosomal contact information.", "offsetInBeginSection": 1371, "offsetInEndSection": 1612, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826", "text": "We developed and applied a set of bioinformatics methods to reliably generate spatial chromosomal contacts from high-throughput sequencing data and to effectively use them to study the properties of the genome structures in one-dimension (1D) and two-dimension (2D).", "offsetInBeginSection": 824, "offsetInEndSection": 1090, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26816262", "text": "In particular, the assortativity coefficient is used to capture the level of correlation between a single-dimensional attribute (categorical or scalar) of the network nodes and the observed connections, i.e., the edges.", "offsetInBeginSection": 245, "offsetInEndSection": 464, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826", "text": "In this work, we conducted a comprehensive, large-scale computational analysis of this new stream of genome conformation data generated for three different human leukemia cells or cell lines by the Hi-C technique.", "offsetInBeginSection": 610, "offsetInEndSection": 823, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817", "text": "Our approach facilitates the study of multiple genome-wide epigenomic profiles, considering network topology and allowing the comparison of chromatin interaction networks.", "offsetInBeginSection": 1668, "offsetInEndSection": 1839, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26172652", "text": "Using the network Kuramoto model as an example, we find that frequency assortativity can induce chaos in the macroscopic dynamics.", "offsetInBeginSection": 178, "offsetInEndSection": 308, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6fabfeb750ff4455000062", "body": "Are there mammalian promoters with distal enhancer functions?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12821156", "http://www.ncbi.nlm.nih.gov/pubmed/2962899", "http://www.ncbi.nlm.nih.gov/pubmed/23842673", "http://www.ncbi.nlm.nih.gov/pubmed/2516829", "http://www.ncbi.nlm.nih.gov/pubmed/30955885", "http://www.ncbi.nlm.nih.gov/pubmed/2492088", "http://www.ncbi.nlm.nih.gov/pubmed/21321362", "http://www.ncbi.nlm.nih.gov/pubmed/32249388", "http://www.ncbi.nlm.nih.gov/pubmed/23545502", "http://www.ncbi.nlm.nih.gov/pubmed/27311442"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "text": "Inversion of CBS elements within the Pcdh enhancer reconfigures the topology of chromatin loops between the distal enhancer and target promoters and alters gene-expression patterns.", "offsetInBeginSection": 620, "offsetInEndSection": 801, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16128003", "text": "Together, these studies demonstrate that the distal enhancer of the FGF-4 gene determines whether the CCAAT box of the FGF-4 promoter functions as a positive or a negative cis-regulatory element.", "offsetInBeginSection": 988, "offsetInEndSection": 1183, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502", "text": "Several studies have suggested that some promoters might have enhancer functions.", "offsetInBeginSection": 138, "offsetInEndSection": 219, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20937833", "text": "Because this element directly stimulates the transcriptional activity of an Igf2 promoter-reporter gene in differentiating myoblasts, our results indicate that we have identified a bona fide distal transcriptional enhancer that supports Igf2 gene activation in skeletal muscle cells.", "offsetInBeginSection": 1156, "offsetInEndSection": 1439, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26550034", "text": "The coactivator HAT complexes, Tip60- and Mof (KAT8)-containing (NSL and MSL), show a global overlap at promoters, whereas distinct binding profiles at enhancers suggest different regulatory functions of each essential HAT complex.", "offsetInBeginSection": 918, "offsetInEndSection": 1149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20937833", "text": "Here we characterize a distal DNA element within the imprinted mouse Igf2-H19 locus with properties of a muscle transcriptional enhancer.", "offsetInBeginSection": 595, "offsetInEndSection": 732, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20937833", "text": "Because this DNA element is conserved in the human IGF2-H19 locus, our results further suggest that its muscle enhancer function also is conserved among different mammalian species.", "offsetInBeginSection": 1440, "offsetInEndSection": 1621, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14570875", "text": "When mammalian cells are infected with a recombinant baculovirus containing two promoters, the baculovirus polyhedrin and Drosophila hsp70 gene promoter, the hsp70 gene promoter alone is active in these cells, and this activity is further enhanced by the presence of an additional hr1 in the recombinant virus.", "offsetInBeginSection": 1136, "offsetInEndSection": 1446, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16128003", "text": "Here, we demonstrate that the CCAAT box functions as a negative cis-regulatory element when cis-regulatory elements of the FGF-4 enhancer are disrupted, or after EC cells differentiate and the FGF-4 enhancer is inactivated.", "offsetInBeginSection": 444, "offsetInEndSection": 667, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16128003", "text": "Previous studies have shown that the FGF-4 promoter is regulated positively by its CCAAT box and NF-Y in embryonal carcinoma (EC) cells where the distal enhancer of the FGF-4 gene is active.", "offsetInBeginSection": 253, "offsetInEndSection": 443, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a774431faa1ab7d2e000004", "body": "Why is the Fyn kinase considered a promising therapeutic target for Alzheimer's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19456285", "http://www.ncbi.nlm.nih.gov/pubmed/22709448", "http://www.ncbi.nlm.nih.gov/pubmed/22820466", "http://www.ncbi.nlm.nih.gov/pubmed/33213062", "http://www.ncbi.nlm.nih.gov/pubmed/15208330", "http://www.ncbi.nlm.nih.gov/pubmed/23175838", "http://www.ncbi.nlm.nih.gov/pubmed/35963156", "http://www.ncbi.nlm.nih.gov/pubmed/33995031", "http://www.ncbi.nlm.nih.gov/pubmed/24012003", "http://www.ncbi.nlm.nih.gov/pubmed/12791269"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498", "text": "I discuss preclinical studies targeting Fyn as a therapeutic intervention in AD and our recent experience with the safety, tolerability, and cerebrospinal fluid penetration of the Src family kinase inhibitor saracatinib in patients with AD.", "offsetInBeginSection": 884, "offsetInEndSection": 1124, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001", "text": "Targeting Fyn kinase may be a promising therapeutic approach in AD, and a larger Phase IIa clinical trial of AZD0530 for the treatment of patients with AD has recently launched.", "offsetInBeginSection": 2493, "offsetInEndSection": 2670, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001", "text": "Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.", "offsetInBeginSection": 598, "offsetInEndSection": 800, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26881137", "text": "Fyn kinase blockers masitinib and saracatinib have proven to be efficacious in treating AD symptoms in experimental mouse models of the disease.", "offsetInBeginSection": 1230, "offsetInEndSection": 1374, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001", "text": "Fyn kinase has been implicated in AD pathophysiology both in in vitro models and in human subjects, and is a promising new therapeutic target for AD.", "offsetInBeginSection": 448, "offsetInEndSection": 597, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22709448", "text": "Fyn is a potential therapeutic target for the treatment of ischemic stroke and AD.", "offsetInBeginSection": 1322, "offsetInEndSection": 1404, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28840468", "text": "Pre-administration of saracatinib (AZD0530), an inhibitor of Fyn activity, also significantly reduced LID in dyskinetic wild-type mice.", "offsetInBeginSection": 1242, "offsetInEndSection": 1377, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28840468", "text": "These results support that Fyn has a critical role in the molecular pathways affected during the development of LID and identify Fyn as a novel potential therapeutic target for the management of dyskinesia in Parkinson's disease.", "offsetInBeginSection": 1378, "offsetInEndSection": 1607, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26881137", "text": "Fyn causes tyrosine phosphorylation of the NR2B subunit of metabotropic glutamate receptor 5 (mGluR5).", "offsetInBeginSection": 1127, "offsetInEndSection": 1229, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24495408", "text": "We are currently enrolling patients in a phase Ib study of saracatinib (AZD0530), a small molecule inhibitor with high potency for Src and Fyn, for the treatment of AD.", "offsetInBeginSection": 686, "offsetInEndSection": 854, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f7138b750ff445500004f", "body": "How does parathyroid hormone affect circulating levels of periostin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1126058", "http://www.ncbi.nlm.nih.gov/pubmed/3070899", "http://www.ncbi.nlm.nih.gov/pubmed/18411156", "http://www.ncbi.nlm.nih.gov/pubmed/6548873", "http://www.ncbi.nlm.nih.gov/pubmed/5784613", "http://www.ncbi.nlm.nih.gov/pubmed/1115872", "http://www.ncbi.nlm.nih.gov/pubmed/6308327", "http://www.ncbi.nlm.nih.gov/pubmed/35083351", "http://www.ncbi.nlm.nih.gov/pubmed/1218855", "http://www.ncbi.nlm.nih.gov/pubmed/219292"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/1897329", "text": "Our results suggest that treatment with 200 IU of salmon calcitonin daily as a nasal spray does not markedly affect fasting serum levels of parathyroid hormone, human calcitonin, and vitamin D metabolites.", "offsetInBeginSection": 768, "offsetInEndSection": 973, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682", "text": "Serum samples for periostin, 25-hydroxyvitamin D, parathyroid hormone (PTH), C-terminal telopeptide of type I collagen (CTx), and total alkaline phosphatase (tALP) were obtained from 46 postmenopausal women with low bone mass at baseline and 3 months after zoledronic acid infusion and from 30 age-matched, postmenopausal controls with normal bone mass at baseline.", "offsetInBeginSection": 498, "offsetInEndSection": 863, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7354121", "text": "To examine the effect of estrogens on circulating levels of calcium-regulating hormones, total serum calcium, ionized calcium, inorganic phosphate, immunoreactive parathyroid hormone, calcitonin, 1,25-dihydroxyvitamin D, and estradiol (E2) levels were assayed on menstrual cycle days 3 and 13 in 12 healthy young women.", "offsetInBeginSection": 0, "offsetInEndSection": 319, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22927401", "text": "Periostin (Postn) is a matricellular protein preferentially expressed by osteocytes and periosteal osteoblasts in response to mechanical stimulation and parathyroid hormone (PTH).", "offsetInBeginSection": 0, "offsetInEndSection": 179, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26721738", "text": "The development of periostin null mice has allowed to elucidate the crucial role of periostin on dentinogenesis and osteogenesis, as well as on the skeletal response to mechanical loading and parathyroid hormone.", "offsetInBeginSection": 418, "offsetInEndSection": 630, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9838243", "text": "He had suppressed circulating levels of intact parathyroid hormone, whereas parathyroid hormone-related protein (PTHrP) immunoreactivity was elevated in plasma.", "offsetInBeginSection": 97, "offsetInEndSection": 257, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22927401", "text": "Recombinant periostin also suppressed Sost expression, which was mediated through the integrin \u03b1V\u03b23 receptor, whereas periostin-blocking antibody prevented inhibition of MEF2C and Sost by PTH.", "offsetInBeginSection": 890, "offsetInEndSection": 1084, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22927401", "text": "Osteoblastic gene expression levels confirmed a defect of Postn(-/-) osteoblast differentiation with and without PTH, as well as an increased osteoblast apoptosis in the absence of periostin.", "offsetInBeginSection": 1373, "offsetInEndSection": 1564, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682", "text": "Women with higher tALP have independently higher periostin levels.", "offsetInBeginSection": 1654, "offsetInEndSection": 1720, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2125243", "text": "Parathyroid hormone levels and levels of the vitamin D metabolites 1,25(OH)2D3 and 25(OH)D3 did not change during treatment.", "offsetInBeginSection": 471, "offsetInEndSection": 595, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7247182dc08e987e000010", "body": "Describe mechanism of action of Ozanimod.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2176902", "http://www.ncbi.nlm.nih.gov/pubmed/29788338", "http://www.ncbi.nlm.nih.gov/pubmed/18230347", "http://www.ncbi.nlm.nih.gov/pubmed/29500302", "http://www.ncbi.nlm.nih.gov/pubmed/27049060", "http://www.ncbi.nlm.nih.gov/pubmed/34175020", "http://www.ncbi.nlm.nih.gov/pubmed/30930775", "http://www.ncbi.nlm.nih.gov/pubmed/32093531", "http://www.ncbi.nlm.nih.gov/pubmed/35503955", "http://www.ncbi.nlm.nih.gov/pubmed/34011158"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26702336", "text": "Ocrelizumab is a CD20-positive B-cell-targeting monoclonal antibody with a promising new mechanism of action.", "offsetInBeginSection": 508, "offsetInEndSection": 617, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26239599", "text": "Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple sclerosis (MS).", "offsetInBeginSection": 0, "offsetInEndSection": 144, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28812220", "text": "Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis (MS).", "offsetInBeginSection": 0, "offsetInEndSection": 132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27049060", "text": "The sphingosine-1-phosphate receptor-1 (S1P1) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28398597", "text": "Ozanimod safety, PK, and PD properties support the once-daily regimens under clinical investigation.", "offsetInBeginSection": 1601, "offsetInEndSection": 1701, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28398597", "text": "This first-in-human study characterized the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ozanimod in 88 healthy volunteers using a range of single and multiple doses (7 and 28 days) and a dose-escalation regimen.", "offsetInBeginSection": 401, "offsetInEndSection": 628, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26879276", "text": "We assessed the safety and efficacy of the oral selective S1P receptor modulator ozanimod in patients with relapsing multiple sclerosis.", "offsetInBeginSection": 189, "offsetInEndSection": 325, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718", "text": "The effects of high-fat and low-fat meals on the pharmacokinetics (PK) of a single oral dose of ozanimod were evaluated in 24 healthy volunteers in a randomized, open-label crossover trial.", "offsetInBeginSection": 199, "offsetInEndSection": 388, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26967267", "text": "AREAS COVERED This review discusses the current approaches with promising new oral drugs with distinct modes of action, including: the Janus kinase inhibitors (i.e., tofacitinib, filgotinib and peficitinib); the immunomodulatory drug (laquinimod); a small \u03b14 antagonist (AJM300); agonists for sphingosine-phosphate receptors (i.e., ozanimod, APD334, and amiselimod), as well as anti-sense therapy (mongersen) targeting SMAD7, drugs which directly target intracellular pathways of relevance for intestinal inflammation.", "offsetInBeginSection": 561, "offsetInEndSection": 1080, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718", "text": "Given this lack of a food effect on the exposure of ozanimod and its active metabolites, ozanimod can be taken without regard to meals.", "offsetInBeginSection": 1166, "offsetInEndSection": 1301, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a895f51fcd1d6a10c000004", "body": "What is the preferred orientation of CTCF binding sites for chromatin looping?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23607989", "http://www.ncbi.nlm.nih.gov/pubmed/22414750", "http://www.ncbi.nlm.nih.gov/pubmed/25703332", "http://www.ncbi.nlm.nih.gov/pubmed/30955885", "http://www.ncbi.nlm.nih.gov/pubmed/21282187", "http://www.ncbi.nlm.nih.gov/pubmed/21502535", "http://www.ncbi.nlm.nih.gov/pubmed/30359362", "http://www.ncbi.nlm.nih.gov/pubmed/27080371", "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "http://www.ncbi.nlm.nih.gov/pubmed/22415163"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29076501", "text": "CTCF, a conserved 3D genome architecture protein, determines proper genome-wide chromatin looping interactions through directional binding to specific sequence elements of four modules within numerous CTCF-binding sites (CBSs) by its 11 zinc fingers (ZFs).", "offsetInBeginSection": 0, "offsetInEndSection": 256, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21282187", "text": "We further show that in BWS and SRS cells, there is opposing chromatin looping conformation mediated by CTCF--cohesin binding sites surrounding the locus.", "offsetInBeginSection": 1118, "offsetInEndSection": 1272, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25135475", "text": "Chromatin looping was recently identified as a conserved feature of silent HOX clusters, with CCCTC-binding factor (CTCF) binding sites located at the loop bases.", "offsetInBeginSection": 225, "offsetInEndSection": 387, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24990380", "text": "We demonstrate that MeCP2 is required for ATRX recruitment and that deficiency of either ATRX or MeCP2 causes decreased frequency of long-range chromatin interactions associated with altered nucleosome density at CTCF-binding sites and reduced CTCF occupancy.", "offsetInBeginSection": 525, "offsetInEndSection": 784, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "text": "Recent studies identified a correlation between the orientation of CTCF-binding sites (CBSs) and chromatin loops.", "offsetInBeginSection": 144, "offsetInEndSection": 257, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27569350", "text": "Some 55% of these CTCF sites contribute to DNA looping and mark the anchors of 587 putative topologically associating domains (TADs) containing at least one VDR binding site and one 1,25(OH)2D3 target gene.", "offsetInBeginSection": 633, "offsetInEndSection": 839, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27569350", "text": "A self-organizing map approach subdivided the vitamin D-sensitive CTCF sites into seven classes that can be distinguished by participation in DNA loop formation, binding to open chromatin, carrying binding motifs for CTCF or its relative BORIS, overlap with transcription start site (TSS) regions and binding of VDR.", "offsetInBeginSection": 934, "offsetInEndSection": 1250, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24990380", "text": "These findings indicate that MeCP2 and ATRX regulate gene expression at a subset of imprinted domains by maintaining a nucleosome configuration conducive to CTCF binding and to the maintenance of higher order chromatin structure.", "offsetInBeginSection": 785, "offsetInEndSection": 1014, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21282187", "text": "DNA methylation of the ICR controls the reciprocal imprinting of IGF2 and H19 by preventing the binding of the insulator protein, CTCF.", "offsetInBeginSection": 238, "offsetInEndSection": 373, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277", "text": "As recently reported, our data also suggest that chromatin loops preferentially form between CTCF binding sites oriented in a convergent manner.", "offsetInBeginSection": 249, "offsetInEndSection": 393, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a761ac7aacfb9cd4c000003", "body": "What is the ReliableGenome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11654349", "http://www.ncbi.nlm.nih.gov/pubmed/11977505", "http://www.ncbi.nlm.nih.gov/pubmed/11662648", "http://www.ncbi.nlm.nih.gov/pubmed/10297469", "http://www.ncbi.nlm.nih.gov/pubmed/12077793", "http://www.ncbi.nlm.nih.gov/pubmed/12637628", "http://www.ncbi.nlm.nih.gov/pubmed/13228960", "http://www.ncbi.nlm.nih.gov/pubmed/13734009", "http://www.ncbi.nlm.nih.gov/pubmed/11643613", "http://www.ncbi.nlm.nih.gov/pubmed/10262530"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105", "text": "By applying RG to 219 deep human WGS datasets, we demonstrate that VC concordance depends predominantly on genomic context rather than the actual sequencing data which manifests in high recurrence of regions that can/cannot be reliably genotyped by a single method.", "offsetInBeginSection": 805, "offsetInEndSection": 1070, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105", "text": "MOTIVATION The increasing adoption of clinical whole-genome resequencing (WGS) demands for highly accurate and reproducible variant calling (VC) methods.", "offsetInBeginSection": 0, "offsetInEndSection": 153, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105", "text": "RESULTS Here, we describe our method ReliableGenome (RG) for partitioning genomes into high and low concordance regions with respect to a set of surveyed VC pipelines.", "offsetInBeginSection": 470, "offsetInEndSection": 637, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105", "text": "RG outperforms comparable efforts in predicting VC concordance and false positive calls in low-concordance regions which underlines its usefulness for variant filtering, annotation and prioritization.", "offsetInBeginSection": 1198, "offsetInEndSection": 1398, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105", "text": "RG allows focusing resource-intensive algorithms (e.g.", "offsetInBeginSection": 1399, "offsetInEndSection": 1453, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105", "text": "The observed discordance between state-of-the-art VC pipelines, however, indicates that the current practice still suffers from non-negligible numbers of false positive and negative SNV and INDEL calls that were shown to be enriched among discordant calls but also in genomic regions with low sequence complexity.", "offsetInBeginSection": 154, "offsetInEndSection": 467, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105", "text": "AVAILABILITY AND IMPLEMENTATION RG was implemented in Java, source code and binaries are freely available for non-commercial use at https://github.com/popitsch/wtchg-rg/ CONTACT: niko@wtchg.ox.ac.ukSupplementary information: Supplementary data are available at Bioinformatics online.", "offsetInBeginSection": 1821, "offsetInEndSection": 2104, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105", "text": "This enables the application of pre-computed regions to other data created with comparable sequencing technology and software.", "offsetInBeginSection": 1071, "offsetInEndSection": 1197, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105", "text": "Our method combines call sets derived by multiple pipelines from arbitrary numbers of datasets and interpolates expected concordance for genomic regions without data.", "offsetInBeginSection": 638, "offsetInEndSection": 804, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105", "text": "Our method and analysis of discordant calls may further be useful for development, benchmarking and optimization of VC algorithms and for the relative comparison of call sets between different studies/pipelines.", "offsetInBeginSection": 1607, "offsetInEndSection": 1818, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a774585faa1ab7d2e000005", "body": "What is masitinib an inhibitor of?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29127277", "http://www.ncbi.nlm.nih.gov/pubmed/29956478", "http://www.ncbi.nlm.nih.gov/pubmed/35940239", "http://www.ncbi.nlm.nih.gov/pubmed/36048877", "http://www.ncbi.nlm.nih.gov/pubmed/24133586", "http://www.ncbi.nlm.nih.gov/pubmed/22362299", "http://www.ncbi.nlm.nih.gov/pubmed/32011367", "http://www.ncbi.nlm.nih.gov/pubmed/24431074", "http://www.ncbi.nlm.nih.gov/pubmed/23198834", "http://www.ncbi.nlm.nih.gov/pubmed/36406239"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20033487", "text": "Masitinib mesilate is a potent and selective tyrosine kinase inhibitor of the c-KIT receptor.", "offsetInBeginSection": 122, "offsetInEndSection": 215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25122671", "text": "BACKGROUND Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST).", "offsetInBeginSection": 0, "offsetInEndSection": 159, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19614621", "text": "CONCLUSIONS Masitinib, a c-kit and PDGF-receptor tyrosine kinase inhibitor, may represent an innovative avenue of treatment in corticosteroid-dependent asthma.", "offsetInBeginSection": 1472, "offsetInEndSection": 1631, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626", "text": "CONCLUSIONS Masitinib is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity.", "offsetInBeginSection": 1675, "offsetInEndSection": 1829, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21504563", "text": "Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and activity of mast cells.", "offsetInBeginSection": 231, "offsetInEndSection": 358, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25961655", "text": "Masitinib is in Phase III clinical trials for the treatment of malignant melanoma, mastocytosis, multiple myeloma, gastrointestinal cancer and pancreatic cancer.", "offsetInBeginSection": 853, "offsetInEndSection": 1014, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26978025", "text": "This study investigated the therapeutic potential of masitinib, a pharmacologic inhibitor of the SCF receptor cKit, for prevention of diabetes-induced breakdown of blood retinal barrier (BRB).", "offsetInBeginSection": 201, "offsetInEndSection": 393, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18823406", "text": "HYPOTHESIS/OBJECTIVE To evaluate the efficacy of masitinib, a potent and selective inhibitor of KIT, in the treatment of canine MCT.", "offsetInBeginSection": 129, "offsetInEndSection": 261, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21504563", "text": "METHODS A randomised, placebo-controlled, phase 2 study was performed in patients with mild-to-moderate Alzheimer's disease, receiving masitinib as an adjunct to cholinesterase inhibitor and/or memantine.", "offsetInBeginSection": 493, "offsetInEndSection": 697, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19614621", "text": "BACKGROUND Masitinib is a tyrosine kinase inhibitor targeting stem cell factor receptor (c-kit) and platelet-derived growth factor (PDGF) receptor, which are expressed on several cell types including mast cells and bronchial structural cells, respectively.", "offsetInBeginSection": 0, "offsetInEndSection": 256, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f7245b750ff4455000050", "body": "What is the mode of action of teriparatide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27363713", "http://www.ncbi.nlm.nih.gov/pubmed/14758473", "http://www.ncbi.nlm.nih.gov/pubmed/26183106", "http://www.ncbi.nlm.nih.gov/pubmed/2635350", "http://www.ncbi.nlm.nih.gov/pubmed/25947283", "http://www.ncbi.nlm.nih.gov/pubmed/32996362", "http://www.ncbi.nlm.nih.gov/pubmed/35340128", "http://www.ncbi.nlm.nih.gov/pubmed/35220030", "http://www.ncbi.nlm.nih.gov/pubmed/7697699", "http://www.ncbi.nlm.nih.gov/pubmed/29179172"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16234962", "text": "INTRODUCTION The effects of combining two approved treatments for osteoporosis with different modes of action were examined by comparing teriparatide [rhPTH(1-34)] monotherapy with combination teriparatide and raloxifene therapy.", "offsetInBeginSection": 542, "offsetInEndSection": 771, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15940379", "text": "CONCLUSIONS These results confirm the opposite mechanisms of action of teriparatide and alendronate on bone remodeling and confirm the bone formation effect of teriparatide.", "offsetInBeginSection": 2373, "offsetInEndSection": 2546, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26104116", "text": "Teriparatide promotes bone formation, while bisphosphonates suppress bone resorption.", "offsetInBeginSection": 171, "offsetInEndSection": 256, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215", "text": "Most bone-quality data for PTH is from teriparatide.", "offsetInBeginSection": 250, "offsetInEndSection": 302, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15262455", "text": "RESULTS Teriparatide has been studied in postmenopausal women with osteoporosis, drug-induced osteoporosis (specifically, corticosteroid-induced osteoporosis), and men with osteoporosis.", "offsetInBeginSection": 1274, "offsetInEndSection": 1460, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16234962", "text": "Combination treatment with raloxifene may thus enhance the bone forming effects of teriparatide.", "offsetInBeginSection": 2490, "offsetInEndSection": 2586, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215", "text": "Strontium ranelate is thought to have a mixed mode of action, increasing bone formation and decreasing bone resorption.", "offsetInBeginSection": 1075, "offsetInEndSection": 1194, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19281056", "text": "Teriparatide is the only anabolic agent currently approved for treatment of osteoporosis in men.", "offsetInBeginSection": 536, "offsetInEndSection": 632, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841", "text": "Teriparatide is an only available bone anabolic drug in practice.", "offsetInBeginSection": 0, "offsetInEndSection": 65, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215", "text": "Teriparatide results in a rapid increase in bone-formation markers, followed by increases in bone-resorption markers, opening an \"anabolic window,\" a period of time when PTH is maximally anabolic.", "offsetInBeginSection": 303, "offsetInEndSection": 499, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7340962dc08e987e000017", "body": "Is Apremilast effective for Behcet\u2019s syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32876993", "http://www.ncbi.nlm.nih.gov/pubmed/30709830", "http://www.ncbi.nlm.nih.gov/pubmed/28329479", "http://www.ncbi.nlm.nih.gov/pubmed/31218666", "http://www.ncbi.nlm.nih.gov/pubmed/35444448", "http://www.ncbi.nlm.nih.gov/pubmed/23134988", "http://www.ncbi.nlm.nih.gov/pubmed/34218739", "http://www.ncbi.nlm.nih.gov/pubmed/36103985", "http://www.ncbi.nlm.nih.gov/pubmed/30909370", "http://www.ncbi.nlm.nih.gov/pubmed/34607526"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24797159", "text": "Apremilast (Otezla(\u00ae)), an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4), is under development with Celgene Corporation for the treatment of psoriatic arthritis, psoriasis, ankylosing spondylitis, Beh\u00e7et's syndrome, atopic dermatitis, and rheumatoid arthritis.", "offsetInBeginSection": 0, "offsetInEndSection": 300, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24882690", "text": "Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in psoriasis, psoriatic arthropathies, and Beh\u00e7et's syndrome.", "offsetInBeginSection": 0, "offsetInEndSection": 215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27747762", "text": "The most recently introduced treatment option is apremilast, an oral phosphodiesterase 4 inhibitor.", "offsetInBeginSection": 477, "offsetInEndSection": 576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27747762", "text": "RESULTS These trials demonstrate that apremilast is effective for the treatment of active PsA, despite prior conventional DMARDs or biologic treatment.", "offsetInBeginSection": 855, "offsetInEndSection": 1006, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256", "text": "CONCLUSIONS Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.", "offsetInBeginSection": 1732, "offsetInEndSection": 1853, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28213862", "text": "Apremilast (Otezla\u00ae) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4).", "offsetInBeginSection": 0, "offsetInEndSection": 104, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24797159", "text": "Apremilast is indicated for the treatment of active psoriatic arthritis in adults.", "offsetInBeginSection": 301, "offsetInEndSection": 383, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27486641", "text": "Apremilast, an oral immunosuppressant that inhibits phosphodiesterase type 4, has been authorised in the European Union for use in these settings.", "offsetInBeginSection": 317, "offsetInEndSection": 463, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27486641", "text": "This would suggest that apremilast is less effective than a TNF alpha antagonist.", "offsetInBeginSection": 1333, "offsetInEndSection": 1414, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256", "text": "Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inflammatory pathways.", "offsetInBeginSection": 146, "offsetInEndSection": 243, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a857bfffaa1ab7d2e000030", "body": "Can the yeast protein Abf1 act as insulator?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19725934", "http://www.ncbi.nlm.nih.gov/pubmed/7608180", "http://www.ncbi.nlm.nih.gov/pubmed/12466537", "http://www.ncbi.nlm.nih.gov/pubmed/2207166", "http://www.ncbi.nlm.nih.gov/pubmed/12443543", "http://www.ncbi.nlm.nih.gov/pubmed/12841349", "http://www.ncbi.nlm.nih.gov/pubmed/10025948", "http://www.ncbi.nlm.nih.gov/pubmed/11604507", "http://www.ncbi.nlm.nih.gov/pubmed/16862159", "http://www.ncbi.nlm.nih.gov/pubmed/2204808"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15456886", "text": "Autonomously replicating sequence binding factor 1 (ABF1) and repressor/activator protein 1 (RAP1) from budding yeast are multifunctional, site-specific DNA-binding proteins, with roles in gene activation and repression, replication, and telomere structure and function.", "offsetInBeginSection": 0, "offsetInEndSection": 270, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1545789", "text": "Autonomously replicating sequence (ARS) binding factor 1 (ABF1) is an abundant DNA-binding protein that specifically recognizes the motif RTCRYN5ACG at many sites in the yeast genome, including promoter elements, mating-type silencers, and ARSs.", "offsetInBeginSection": 0, "offsetInEndSection": 245, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9430660", "text": "In budding yeast Saccharomyces cerevisiae, an ARS binding factor 1 (Abf1) binds to the sequence-specific DNA element involved in DNA replication and transcription.", "offsetInBeginSection": 0, "offsetInEndSection": 163, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2511628", "text": "The yeast ARS binding factor 1 (ABF1)--where ARS is an autonomously replicating sequence--and repressor/activator protein 1 (RAP1) have been implicated in DNA replication, transcriptional activation, and transcriptional silencing.", "offsetInBeginSection": 0, "offsetInEndSection": 230, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7663308", "text": "Autonomously replicating sequence (ARS)-binding factor 1 (ABF1) is a multifunctional protein involved in transcriptional activation and repression, as well as DNA replication, in yeast.", "offsetInBeginSection": 0, "offsetInEndSection": 185, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18996839", "text": "ABF1 functions in transcription, replication, gene silencing, and NER in yeast.", "offsetInBeginSection": 328, "offsetInEndSection": 407, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10601031", "text": "Yeast ABF1 protein is encoded by an essential gene required for DNA replication, transcriptional regulation, and gene silencing.", "offsetInBeginSection": 345, "offsetInEndSection": 473, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7608180", "text": "ABF1 is a multifunctional phosphoprotein that binds specifically to yeast origins of replication and to transcriptional regulatory sites of a variety of genes.", "offsetInBeginSection": 0, "offsetInEndSection": 159, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7608180", "text": "Although three CKII enzymes, yeast, sea star, and recombinant human, utilize casein as a substrate with similar efficiencies, only the yeast enzyme efficiently phosphorylates the ABF1 protein.", "offsetInBeginSection": 1051, "offsetInEndSection": 1243, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9430660", "text": "We describe in this study how yeast Cdc6 protein stimulates Abf1 protein DNA binding activities.", "offsetInBeginSection": 164, "offsetInEndSection": 260, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8053effaa1ab7d2e00001e", "body": "Describe the Manta algorithm for detection of structural variants", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32192518", "http://www.ncbi.nlm.nih.gov/pubmed/19477992", "http://www.ncbi.nlm.nih.gov/pubmed/35751812", "http://www.ncbi.nlm.nih.gov/pubmed/29197946", "http://www.ncbi.nlm.nih.gov/pubmed/21216738", "http://www.ncbi.nlm.nih.gov/pubmed/24958856", "http://www.ncbi.nlm.nih.gov/pubmed/15460283", "http://www.ncbi.nlm.nih.gov/pubmed/30400818", "http://www.ncbi.nlm.nih.gov/pubmed/20507604", "http://www.ncbi.nlm.nih.gov/pubmed/24526710"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29048532", "text": "We present Genome Rearrangement OmniMapper (GROM), a novel comprehensive variant detection algorithm accepting aligned read files as input and finding SNVs, indels, structural variants (SVs), and copy number variants (CNVs).", "offsetInBeginSection": 300, "offsetInEndSection": 524, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377", "text": "UNLABELLED : We describe Manta, a method to discover structural variants and indels from next generation sequencing data.", "offsetInBeginSection": 0, "offsetInEndSection": 121, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377", "text": "Manta is optimized for rapid germline and somatic analysis, calling structural variants, medium-sized indels and large insertions on standard compute hardware in less than a tenth of the time that comparable methods require to identify only subsets of these variant types: for example NA12878 at 50\u00d7 genomic coverage is analyzed in less than 20\u2009min.", "offsetInBeginSection": 122, "offsetInEndSection": 474, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24575965", "text": "We present the application of an artificial ant colony algorithm to combinatorial molecular design (Molecular Ant Algorithm [MAntA]).", "offsetInBeginSection": 111, "offsetInEndSection": 244, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27770783", "text": "RESULTS We have developed a machine learning algorithm for the detection of large duplications and deletions in the targeted sequencing data generated with PCR-based enrichment step.", "offsetInBeginSection": 802, "offsetInEndSection": 984, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23919138", "text": "We present a novel technique for automated identification of manta rays (Manta alfredi and Manta birostris) by means of a pattern-matching algorithm applied to images of their ventral surface area.", "offsetInBeginSection": 492, "offsetInEndSection": 689, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20529927", "text": "Although various computational methods have been described for the detection of SVs, no such algorithm is yet fully capable of discovering transposon insertions, a very important class of SVs to the study of human evolution and disease.", "offsetInBeginSection": 361, "offsetInEndSection": 597, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27770783", "text": "In the paper, we describe novel algorithm for high-resolution germinal CNV detection in the PCR-enriched targeted sequencing data and present accompanying tool.", "offsetInBeginSection": 639, "offsetInEndSection": 799, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20378554", "text": "RESULTS We introduce an algorithm for identification of structural variants using strobe sequencing data.", "offsetInBeginSection": 737, "offsetInEndSection": 842, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22179552", "text": "The algorithm discovers indels, structural variants, de novo events and copy number-polymorphic processed pseudogenes missed by other methods.", "offsetInBeginSection": 325, "offsetInEndSection": 467, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7d4e9afaa1ab7d2e000013", "body": "How many amino acids does davunetide consist of?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8841616", "http://www.ncbi.nlm.nih.gov/pubmed/21394576", "http://www.ncbi.nlm.nih.gov/pubmed/5325933", "http://www.ncbi.nlm.nih.gov/pubmed/11233175", "http://www.ncbi.nlm.nih.gov/pubmed/12064944", "http://www.ncbi.nlm.nih.gov/pubmed/611430", "http://www.ncbi.nlm.nih.gov/pubmed/7731677", "http://www.ncbi.nlm.nih.gov/pubmed/22339639", "http://www.ncbi.nlm.nih.gov/pubmed/12771367", "http://www.ncbi.nlm.nih.gov/pubmed/611429"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667", "text": "NAP (davunetide), an eight amino acid peptide derived from ADNP partly ameliorated deficits associated with ADNP deficiency.", "offsetInBeginSection": 583, "offsetInEndSection": 707, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22956189", "text": "Davunetide is an eight-amino-acid peptide fragment derived by structure-activity studies from activity-dependent neuroprotective protein, activity-dependent neuroprotective protein (ADNP).", "offsetInBeginSection": 77, "offsetInEndSection": 265, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23971871", "text": "Davunetide is the first neuroprotective peptide in its class, and has preclinical evidence for neuroprotective, neurotrophic and cognitive protective properties.", "offsetInBeginSection": 0, "offsetInEndSection": 161, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22956189", "text": "ADNP haploinsufficiency in mice results in tauopathy and cognitive deficits ameliorated by davunetide treatment.", "offsetInBeginSection": 305, "offsetInEndSection": 417, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24873720", "text": "BACKGROUND In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation.", "offsetInBeginSection": 0, "offsetInEndSection": 109, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667", "text": "Based on these extensive preclinical results, davunetide (NAP) is now being evaluated in a Phase II/III study of the tauopathy, progressive supranuclear palsy (PSP); (Allon Therapeutics Inc.).", "offsetInBeginSection": 1515, "offsetInEndSection": 1707, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667", "text": "In conclusion, NAP (davunetide) provided potent neuroprotection in a broad range of neurodegenerative models, protecting the neuroglial cytoskeleton in vitro and inhibiting tau pathology (tauopathy) in vivo.", "offsetInBeginSection": 1307, "offsetInEndSection": 1514, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667", "text": "NAP (davunetide) interacted with microtubules, protected against microtubule toxicity associated with zinc, nocodazole and oxidative stress in vitro and against tau pathology and MAP6 (stable tubuleonly polypeptide - STOP) pathology in vivo.", "offsetInBeginSection": 708, "offsetInEndSection": 949, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21524250", "text": "NAP (davunetide) is an eight amino acid peptide (NAPVSIPQ) that has been shown to provide potent neuroprotection, in vitro and in vivo.", "offsetInBeginSection": 0, "offsetInEndSection": 135, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24488575", "text": "Davunetide (NAP) is an eight amino acid peptide that has been shown to provide potent neuroprotection.", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a6f77d7b750ff4455000051", "body": "Is autosomal dominant inheritanced form of Osteogenesis imperfecta caused by mutations in the genes associated with collagen production?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17192541", "http://www.ncbi.nlm.nih.gov/pubmed/20089953", "http://www.ncbi.nlm.nih.gov/pubmed/21670757", "http://www.ncbi.nlm.nih.gov/pubmed/29285457", "http://www.ncbi.nlm.nih.gov/pubmed/23301918", "http://www.ncbi.nlm.nih.gov/pubmed/28009707", "http://www.ncbi.nlm.nih.gov/pubmed/30430037", "http://www.ncbi.nlm.nih.gov/pubmed/2886666", "http://www.ncbi.nlm.nih.gov/pubmed/22706122", "http://www.ncbi.nlm.nih.gov/pubmed/11039761"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666", "text": "Autosomal dominant osteogenesis imperfecta is caused by mutations in the COL1A2 and COL1A1 genes of type I collagen.", "offsetInBeginSection": 0, "offsetInEndSection": 116, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541", "text": "Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen.", "offsetInBeginSection": 0, "offsetInEndSection": 169, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18566967", "text": "Autosomal dominant osteogenesis imperfecta (OI) is caused by mutations in the genes (COL1A1 or COL1A2) encoding the chains of type I collagen.", "offsetInBeginSection": 0, "offsetInEndSection": 142, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25656619", "text": "Whereas the vast majority of osteogenesis imperfecta (OI) is caused by autosomal dominant defects in the genes encoding type I procollagen, mutations in a myriad of genes affecting type I procollagen biosynthesis or bone formation and homeostasis have now been associated with rare autosomal recessive OI forms.", "offsetInBeginSection": 0, "offsetInEndSection": 311, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8100856", "text": "Most forms of osteogenesis imperfecta are caused by dominant mutations in either of the two genes, COL1A1 and COL1A2, that encode the pro alpha 1(I) and pro alpha 2(I) chains of type I collagen, respectively.", "offsetInBeginSection": 0, "offsetInEndSection": 208, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20839288", "text": "Autosomal dominant OI is caused by mutations in the genes (COL1A1 or COL1A2) encoding the chains of type I collagen.", "offsetInBeginSection": 187, "offsetInEndSection": 303, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23771926", "text": "Most cases of OI (classical types) have autosomal dominant inheritance and are caused by mutations in the type I collagen genes.", "offsetInBeginSection": 128, "offsetInEndSection": 256, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25007323", "text": "PURPOSE OF REVIEW Osteogenesis imperfecta or 'brittle bone disease' has mainly been considered a bone disorder caused by collagen mutations.", "offsetInBeginSection": 0, "offsetInEndSection": 140, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25007323", "text": "Within the last decade, however, a surge of genetic discoveries has created a new paradigm for osteogenesis imperfecta as a collagen-related disorder, where most cases are due to autosomal dominant type I collagen defects, while rare, mostly recessive, forms are due to defects in genes whose protein products interact with collagen protein.", "offsetInBeginSection": 141, "offsetInEndSection": 482, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19533842", "text": "In approximately 90% of individuals with osteogenesis imperfecta, mutations in either of the genes encoding the pro-alpha1 or pro-alpha2 chains of type I collagen (COL1A1 or COL1A2) can be identified.", "offsetInBeginSection": 126, "offsetInEndSection": 326, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7346662dc08e987e00001a", "body": "What causes \"Puffy hand syndrome\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24220459", "http://www.ncbi.nlm.nih.gov/pubmed/16970240", "http://www.ncbi.nlm.nih.gov/pubmed/25711256", "http://www.ncbi.nlm.nih.gov/pubmed/3429660", "http://www.ncbi.nlm.nih.gov/pubmed/18007214", "http://www.ncbi.nlm.nih.gov/pubmed/19098586", "http://www.ncbi.nlm.nih.gov/pubmed/19216010", "http://www.ncbi.nlm.nih.gov/pubmed/1395345", "http://www.ncbi.nlm.nih.gov/pubmed/29389826", "http://www.ncbi.nlm.nih.gov/pubmed/8953076"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18299911", "text": "Other IVDA complications in the upper extremity affecting blood vessels and lymphatics include hematoma, arterial aneurysm and pseudoaneurysm, thrombosis, thrombophlebitis, \"puffy hand\" syndrome, and lymphadenopathy.", "offsetInBeginSection": 582, "offsetInEndSection": 798, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27269656", "text": "There is a syndrome, rarely observed in rheumatology, resulting in \"puffy hands\": the puffy hand syndrome.", "offsetInBeginSection": 103, "offsetInEndSection": 209, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23856549", "text": "Association of puffy hand syndrome with comorbid psychosis and major depression explained immediate recurrence of ulcerations despite fitted medication and long-term psychotherapy.", "offsetInBeginSection": 348, "offsetInEndSection": 528, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17072191", "text": "Lymphedema treatment currently consists of low-stretch bandaging and wearing elastic garments, which is effective in decreasing the volume of puffy hand syndrome.", "offsetInBeginSection": 1251, "offsetInEndSection": 1413, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15529083", "text": "Puffy hand syndrome appears to be the end result of lymphatic obstruction.", "offsetInBeginSection": 1030, "offsetInEndSection": 1104, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24198977", "text": "Puffy hand syndrome develops after long-term intravenous drug addiction.", "offsetInBeginSection": 0, "offsetInEndSection": 72, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010", "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "offsetInBeginSection": 0, "offsetInEndSection": 78, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010", "text": "Low-stretch bandage and elastic garment, usually used in lymphedema treatment, are proposed to treat the puffy hand syndrome.", "offsetInBeginSection": 509, "offsetInEndSection": 634, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15529083", "text": "The puffy hand sign is a more uncommon complication of hard-core injection addicts.", "offsetInBeginSection": 162, "offsetInEndSection": 245, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24198977", "text": "We retained the diagnosis of puffy hand syndrome revealed by a severe staphylococcal infection with toxic involvement mimicking a four limbs cellulitis.", "offsetInBeginSection": 849, "offsetInEndSection": 1001, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a86e66dfaa1ab7d2e000035", "body": "Does the association of PARP1 and CTCF follow a circadian rhythm?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/14325156", "http://www.ncbi.nlm.nih.gov/pubmed/6722559", "http://www.ncbi.nlm.nih.gov/pubmed/32506625", "http://www.ncbi.nlm.nih.gov/pubmed/26321255", "http://www.ncbi.nlm.nih.gov/pubmed/12622846", "http://www.ncbi.nlm.nih.gov/pubmed/31634367", "http://www.ncbi.nlm.nih.gov/pubmed/15733101", "http://www.ncbi.nlm.nih.gov/pubmed/27551048", "http://www.ncbi.nlm.nih.gov/pubmed/10762034", "http://www.ncbi.nlm.nih.gov/pubmed/6472056"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255", "text": "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation.", "offsetInBeginSection": 487, "offsetInEndSection": 760, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255", "text": "Furthermore, depletion of H3K9me2/3, inhibition of PARP activity by olaparib, or downregulation of PARP1 or CTCF expression counteracts both recruitment to the envelope and circadian transcription.", "offsetInBeginSection": 761, "offsetInEndSection": 958, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255", "text": "PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity.", "offsetInBeginSection": 959, "offsetInEndSection": 1127, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27135601", "text": "We focus on the function of chromatin structure proteins cohesin as well as CTCF (CCCTC-binding factor) in circadian rhythm.", "offsetInBeginSection": 371, "offsetInEndSection": 495, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26305327", "text": "Our studies show that PARP1 associates with epigenetic regulatory elements genome-wide, such as active histone marks, CTCF and DNase hypersensitive sites.", "offsetInBeginSection": 669, "offsetInEndSection": 823, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21985173", "text": "Moreover, we show that Ctcf forms a complex with Dnmt1 and PARylated Parp1 at specific Ctcf target sequences and that PARylation is responsible for the maintenance of the unmethylated status of some Ctcf-bound CpGs.", "offsetInBeginSection": 753, "offsetInEndSection": 968, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28456021", "text": "Here, we demonstrate that binding of PARP1, an important cofactor of CTCF, at the BZLF1 lytic switch promoter restricts EBV reactivation.", "offsetInBeginSection": 369, "offsetInEndSection": 506, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255", "text": "The interactome is regulated by PARP1 and its co-factor CTCF.", "offsetInBeginSection": 307, "offsetInEndSection": 368, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25789928", "text": "These studies have found SIRT1, PARP1, and HSF1 proteins to be the major influencers of the core CLOCKBMAL1:PER-CRY circadian clock.", "offsetInBeginSection": 418, "offsetInEndSection": 550, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27135601", "text": "Global analysis showed that cohesin-CTCF co-binding sites tend to insulate the phases of circadian oscillating genes while cohesin-non-CTCF sites are associated with high circadian rhythmicity of transcription.", "offsetInBeginSection": 802, "offsetInEndSection": 1012, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a805974faa1ab7d2e000020", "body": "What is the Strelka workflow?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33630841", "http://www.ncbi.nlm.nih.gov/pubmed/26528606", "http://www.ncbi.nlm.nih.gov/pubmed/21455901", "http://www.ncbi.nlm.nih.gov/pubmed/30013048", "http://www.ncbi.nlm.nih.gov/pubmed/23444557", "http://www.ncbi.nlm.nih.gov/pubmed/16622169", "http://www.ncbi.nlm.nih.gov/pubmed/33776542", "http://www.ncbi.nlm.nih.gov/pubmed/24845282", "http://www.ncbi.nlm.nih.gov/pubmed/36399058", "http://www.ncbi.nlm.nih.gov/pubmed/31637565"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179", "text": "AVAILABILITY The Strelka workflow source code is available at ftp://strelka@ftp.illumina.com/.", "offsetInBeginSection": 1179, "offsetInEndSection": 1273, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27874022", "text": "Four popular somatic single nucleotide variant (SNV) calling methods (Varscan, SomaticSniper, Strelka and MuTect2) were carefully evaluated on the real whole exome sequencing (WES, depth of ~50X) and ultra-deep targeted sequencing (UDT-Seq, depth of ~370X) data.", "offsetInBeginSection": 0, "offsetInEndSection": 262, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612", "text": "GenomeVIP orchestrates the analysis of whole-genome and exome sequence data using a set of robust and popular task-specific tools, including VarScan, GATK, Pindel, BreakDancer, Strelka, and Genome STRiP, through a web interface.", "offsetInBeginSection": 790, "offsetInEndSection": 1018, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27002637", "text": "For SNV calling, we report EBCall, Mutect, Virmid and Strelka to be the most reliable somatic variant callers for both exome sequencing and targeted deep sequencing.", "offsetInBeginSection": 1295, "offsetInEndSection": 1460, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179", "text": "RESULTS We describe Strelka, a method for somatic SNV and small indel detection from sequencing data of matched tumor-normal samples.", "offsetInBeginSection": 331, "offsetInEndSection": 464, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954988", "text": "We combined two different somatic variant callers with different algorithms, Strelka and VarScan 2, and evaluated performance using whole exome sequencing data obtained from 19 Japanese cases with gastric cancer (GC); then, we characterized these tumors based on identified driver molecular alterations.", "offsetInBeginSection": 465, "offsetInEndSection": 768, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23842810", "text": "Four recently published algorithms for the detection of somatic SNV sites in matched cancer-normal sequencing datasets are VarScan, SomaticSniper, JointSNVMix and Strelka.", "offsetInBeginSection": 483, "offsetInEndSection": 654, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24678773", "text": "RESULTS Using the NIST-GIAB gold standard, we compared the performance of five popular somatic SNV calling algorithms (GATK UnifiedGenotyper followed by simple subtraction, MuTect, Strelka, SomaticSniper and VarScan2) for matched tumor-normal amplicon and exome sequencing data.", "offsetInBeginSection": 686, "offsetInEndSection": 964, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21899774", "text": "These features have a greater affinity with the agile software development method through iterative development phases after trial and error.Here, we show the application of a scientific workflow system Pwrake to bioinformatics workflows.", "offsetInBeginSection": 549, "offsetInEndSection": 787, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24564760", "text": "CONCLUSION We have designed and implemented an approach to improving workflow structure by way of rewriting preserving workflow semantics.", "offsetInBeginSection": 2121, "offsetInEndSection": 2259, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7d535ffaa1ab7d2e000018", "body": "What does the human IVIG treatment for Alzheimer's disease contain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26456831", "http://www.ncbi.nlm.nih.gov/pubmed/21385183", "http://www.ncbi.nlm.nih.gov/pubmed/17337295", "http://www.ncbi.nlm.nih.gov/pubmed/14598048", "http://www.ncbi.nlm.nih.gov/pubmed/8428386", "http://www.ncbi.nlm.nih.gov/pubmed/10855366", "http://www.ncbi.nlm.nih.gov/pubmed/22494053", "http://www.ncbi.nlm.nih.gov/pubmed/2592768", "http://www.ncbi.nlm.nih.gov/pubmed/2312717", "http://www.ncbi.nlm.nih.gov/pubmed/7685668"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506", "text": "OBJECTIVE We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia.", "offsetInBeginSection": 0, "offsetInEndSection": 144, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18294736", "text": "Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer's disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta).", "offsetInBeginSection": 0, "offsetInEndSection": 176, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23735288", "text": "Pilot studies with the IVIG preparations Octagam and Gammagard in individuals with mild-to-moderate Alzheimer's disease (AD) suggested stabilization of cognitive functioning in these patients, and a phase II trial with Gammagard reported similar findings.", "offsetInBeginSection": 131, "offsetInEndSection": 386, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21138577", "text": "IVIG contains naturally occurring auto-antibodies, including antibodies (Abs) against \u03b2-amyloid (A\u03b2) peptides accumulating in the brains of Alzheimer's disease (AD) patients.", "offsetInBeginSection": 211, "offsetInEndSection": 387, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25115546", "text": "Human intravenous immunoglobulin (IVIG) is a mixture of polyclonal IgG antibodies isolated and pooled from thousands of healthy human donors.", "offsetInBeginSection": 188, "offsetInEndSection": 329, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112", "text": "The human polyclonal IgG antibody preparation known as Intravenous Immunoglobulin (IVIG) has been under study as a potential treatment for Alzheimer's disease (AD) since 2002.", "offsetInBeginSection": 0, "offsetInEndSection": 175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109", "text": "Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious.", "offsetInBeginSection": 0, "offsetInEndSection": 271, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18294736", "text": "Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease.", "offsetInBeginSection": 1260, "offsetInEndSection": 1372, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20329802", "text": "Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring autoantibodies (nAbs-Abeta) that specifically recognize and block the toxic effects of Abeta.", "offsetInBeginSection": 460, "offsetInEndSection": 760, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23861639", "text": "A small pilot study of passive immunotherapy using IVIg has suggested cognitive improvement.", "offsetInBeginSection": 577, "offsetInEndSection": 669, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70ce4ab750ff4455000064", "body": "List the 6 genes associated with the autosomal recessive form of Osteogenesis imperfecta", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2894346", "http://www.ncbi.nlm.nih.gov/pubmed/17192541", "http://www.ncbi.nlm.nih.gov/pubmed/20089953", "http://www.ncbi.nlm.nih.gov/pubmed/29285457", "http://www.ncbi.nlm.nih.gov/pubmed/21670757", "http://www.ncbi.nlm.nih.gov/pubmed/23301918", "http://www.ncbi.nlm.nih.gov/pubmed/28009707", "http://www.ncbi.nlm.nih.gov/pubmed/8588573", "http://www.ncbi.nlm.nih.gov/pubmed/9189626", "http://www.ncbi.nlm.nih.gov/pubmed/9481655"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25565926", "text": "Autosomal recessive osteogenesis imperfecta (OI) accounts for 10% of all OI cases, and, currently, mutations in 10 genes (CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, SERPINF1, SP7, BMP1, TMEM38B, and WNT1) are known to be responsible for this form of the disease.", "offsetInBeginSection": 0, "offsetInEndSection": 258, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23301918", "text": "Cultured skin fibroblasts demonstrated compound heterozygosity for mutations in the LEPRE1 gene encoding prolyl 3-hydroxylase 1 confirming the diagnosis of autosomal recessive osteogenesis imperfecta type VIII, perinatal lethal type.", "offsetInBeginSection": 487, "offsetInEndSection": 720, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12110407", "text": "By linkage analysis, we mapped this unique autosomal recessive variant of osteogenesis imperfecta to chromosome 3p22-24.1.", "offsetInBeginSection": 276, "offsetInEndSection": 398, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541", "text": "Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen.", "offsetInBeginSection": 0, "offsetInEndSection": 169, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21670757", "text": "Other causes of recessive osteogenesis imperfecta include deficiency of the collagen chaperones FKBP10 or Serpin H1.", "offsetInBeginSection": 926, "offsetInEndSection": 1042, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21670757", "text": "Murine models are crucial to uncovering the common pathways in dominant and recessive osteogenesis imperfecta bone dysplasia.", "offsetInBeginSection": 1043, "offsetInEndSection": 1168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12110407", "text": "We have identified a novel form of autosomal recessive osteogenesis imperfecta (OI) in a small First Nations community from northern Quebec.", "offsetInBeginSection": 0, "offsetInEndSection": 140, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21670757", "text": "The more prevalent autosomal dominant forms of osteogenesis imperfecta are caused by primary defects in type I collagen, whereas autosomal recessive forms are caused by deficiency of proteins which interact with type I procollagen for post-translational modification and/or folding.", "offsetInBeginSection": 87, "offsetInEndSection": 369, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25656619", "text": "Whereas the vast majority of osteogenesis imperfecta (OI) is caused by autosomal dominant defects in the genes encoding type I procollagen, mutations in a myriad of genes affecting type I procollagen biosynthesis or bone formation and homeostasis have now been associated with rare autosomal recessive OI forms.", "offsetInBeginSection": 0, "offsetInEndSection": 311, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23613367", "text": "Autosomal recessive osteogenesis imperfecta (AR-OI) is an inherited condition which in recent years has been shown with increasing genetic and clinical heterogeneity.", "offsetInBeginSection": 0, "offsetInEndSection": 166, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a737e233b9d13c70800000d", "body": "Does Enzastaurin improve survival of glioblastoma patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26374633", "http://www.ncbi.nlm.nih.gov/pubmed/22023517", "http://www.ncbi.nlm.nih.gov/pubmed/26996897", "http://www.ncbi.nlm.nih.gov/pubmed/26799668", "http://www.ncbi.nlm.nih.gov/pubmed/21438065", "http://www.ncbi.nlm.nih.gov/pubmed/21667043", "http://www.ncbi.nlm.nih.gov/pubmed/20150385", "http://www.ncbi.nlm.nih.gov/pubmed/16103100", "http://www.ncbi.nlm.nih.gov/pubmed/16645590", "http://www.ncbi.nlm.nih.gov/pubmed/23992368"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301", "text": "CONCLUSIONS antiangiogenic drugs did not improve overall survival in glioblastoma patients, either as first or second-line treatment, and either as single agent or in combination with chemotherapy.", "offsetInBeginSection": 1438, "offsetInEndSection": 1635, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22917813", "text": "CONCLUSIONS Enzastaurin was well tolerated but did not improve TTP of BMs, ORR, OS, PFS, or HRQoL after WBRT in LC patients with BMs.", "offsetInBeginSection": 1499, "offsetInEndSection": 1632, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20150385", "text": "Enzastaurin has anti-glioma activity in patients with recurrent high-grade glioma, but does not appear to have enough single-agent activity to be useful as monotherapy.", "offsetInBeginSection": 1516, "offsetInEndSection": 1684, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25398844", "text": "Despite promising phase II clinical trial results and patient benefit in terms of clinical improvement and longer progression-free survival, an overall survival benefit has not been demonstrated in four randomized phase III trials of bevacizumab or cilengitide in newly diagnosed glioblastoma or cediranib or enzastaurin in recurrent glioblastoma.", "offsetInBeginSection": 580, "offsetInEndSection": 927, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19098118", "text": "Enzastaurin is currently in Phase III clinical trials.", "offsetInBeginSection": 1527, "offsetInEndSection": 1581, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22413865", "text": "Inhibition of angiogenic pathways by small molecules, for example, enzastaurin, or anti-integrin-based approaches, for example, cilengitide, represent alternative strategies.", "offsetInBeginSection": 792, "offsetInEndSection": 966, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21896554", "text": "This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma.", "offsetInBeginSection": 0, "offsetInEndSection": 166, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22917813", "text": "This study was designed to determine if maintenance enzastaurin improved the outcome of whole brain radiotherapy (WBRT) in lung cancer (LC) patients with brain metastases (BMs).", "offsetInBeginSection": 83, "offsetInEndSection": 260, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26643807", "text": "Enzastaurin (LY317615) in combination with bevacizumab for recurrent malignant gliomas is well-tolerated, with response and progression-free survival similar to bevacizumab monotherapy.", "offsetInBeginSection": 1766, "offsetInEndSection": 1951, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301", "text": "Bevacizumab did not improve overall survival.", "offsetInBeginSection": 1017, "offsetInEndSection": 1062, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8965f6fcd1d6a10c000005", "body": "Are splicing speckles associated with transcription?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24569078", "http://www.ncbi.nlm.nih.gov/pubmed/7997273", "http://www.ncbi.nlm.nih.gov/pubmed/22871813", "http://www.ncbi.nlm.nih.gov/pubmed/12473687", "http://www.ncbi.nlm.nih.gov/pubmed/16782886", "http://www.ncbi.nlm.nih.gov/pubmed/31953060", "http://www.ncbi.nlm.nih.gov/pubmed/20123736", "http://www.ncbi.nlm.nih.gov/pubmed/11161712", "http://www.ncbi.nlm.nih.gov/pubmed/18053984", "http://www.ncbi.nlm.nih.gov/pubmed/11827980"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12473687", "text": "Removal of the reversible inhibitor DRB resulted in the reactivation of transcription and a rapid, synchronous redistribution of lamins and splicing factors to normal-sized speckles, indicating a close association between lamin speckles and SFCs.", "offsetInBeginSection": 538, "offsetInEndSection": 784, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26441864", "text": "When the nuclear export signal of RSV Gag is mutated (Gag.L219A), the protein accumulates in discrete subnuclear foci reminiscent of nuclear bodies such as splicing speckles, paraspeckles, and PML bodies.", "offsetInBeginSection": 793, "offsetInEndSection": 997, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12473687", "text": "Our results suggest a unique role for lamin speckles in the spatial organization of RNA splicing factors and pol II transcription in the nucleus.", "offsetInBeginSection": 1010, "offsetInEndSection": 1155, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386", "text": "\"Splicing speckles\" are major nuclear domains rich in components of the splicing machinery and polyA(+) RNA.", "offsetInBeginSection": 0, "offsetInEndSection": 108, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12473687", "text": "Treatment of HeLa cells with alpha-amanitin or 5,6-dichlorobenzimidazole riboside (DRB) inhibited RNA polymerase II (pol II) transcription and led to the enlargement of lamin speckles as well as SFCs.", "offsetInBeginSection": 337, "offsetInEndSection": 537, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22871813", "text": "Immunofluorescence microscopy with anti-P-SF3b155 antibodies, coupled with transcription inhibition and a block in splicing after SF3b155 phosphorylation, indicates that post-transcriptional splicing occurs in nuclear speckles and that release of post-transcriptionally spliced mRNA from speckles is coupled to the nuclear mRNA export pathway.", "offsetInBeginSection": 766, "offsetInEndSection": 1109, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21984414", "text": "RBM11 is localized in the nucleoplasm and enriched in SRSF2-containing splicing speckles.", "offsetInBeginSection": 831, "offsetInEndSection": 920, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9135155", "text": "Staining of nuclear factors involved in pre-mRNA splicing or, more recently, transcription, reveals 20-40 speckles per nucleus, resulting in the intriguing suggestion that speckles are nuclear sites of transcription and processing.", "offsetInBeginSection": 236, "offsetInEndSection": 467, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15093744", "text": "It has been found in different nuclear distributions: in discrete sites throughout the nucleoplasm, consistent with a role in transcription, and/or concentrated in \"splicing speckles\", a nuclear compartment mostly devoid of transcriptional activity.", "offsetInBeginSection": 361, "offsetInEndSection": 610, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386", "text": "RNA polymerase II transcribes mRNAs and is required for splicing, with some reports suggesting that the inactive complexes are stored in splicing speckles.", "offsetInBeginSection": 321, "offsetInEndSection": 476, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a80a63ffaa1ab7d2e000023", "body": "What is the HPG pore?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32260804", "http://www.ncbi.nlm.nih.gov/pubmed/28655275", "http://www.ncbi.nlm.nih.gov/pubmed/21030034", "http://www.ncbi.nlm.nih.gov/pubmed/20690592", "http://www.ncbi.nlm.nih.gov/pubmed/18688478", "http://www.ncbi.nlm.nih.gov/pubmed/19067590", "http://www.ncbi.nlm.nih.gov/pubmed/16367806", "http://www.ncbi.nlm.nih.gov/pubmed/20410197", "http://www.ncbi.nlm.nih.gov/pubmed/2362434", "http://www.ncbi.nlm.nih.gov/pubmed/18476729"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234", "text": "HPG Pore is available in GitHub at http://github.com/opencb/hpg-pore.", "offsetInBeginSection": 1162, "offsetInEndSection": 1231, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840", "text": "Increasing the HPG content increased the pore size of the hydrogel scaffold, as well as the porosity, elongation at break, degree of degradation and swelling ratio.", "offsetInBeginSection": 569, "offsetInEndSection": 733, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28655275", "text": "Both HPG-C10-HPG and HPG-C10-PEG are taken up by HT-29 cells through clathrin-mediated endocytosis and macropinocytosis.", "offsetInBeginSection": 767, "offsetInEndSection": 887, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27305828", "text": "To avoid these shortcomings, we synthesized and evaluated a non-PEGylated, hyperbranched polyglycerol nanoparticle (HPG NP) with a hydrophobic core and a hydrophilic HPG shell, HPG-C10-HPG, as a candidate for systemic delivery of anticancer drug.", "offsetInBeginSection": 343, "offsetInEndSection": 589, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25189471", "text": "As a result, hPG with a catecholic functional degree of 10% (hPG-Cat10) and hPG with both catecholic and vinylic functional degree of 5% (hPG-Cat5-V5) were identified as the best catecholic hPGs to prepare bioinert and stable monolayer coatings on TiO2.", "offsetInBeginSection": 1091, "offsetInEndSection": 1344, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28655275", "text": "The polymeric nanoparticle that contains a hydrophobic core and a hydrophilic HPG shell, HPG-C10-HPG, is taken up faster by HT-29 cancer cells than nontransformed cells, while similar uptake rates are observed with both cell types for the nanoparticle HPG-C10-PEG that contains a hydrophobic core and a polyethylene glycol shell.", "offsetInBeginSection": 153, "offsetInEndSection": 482, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234", "text": "RESULTS Here we present HPG Pore, a toolkit for exploring and analysing nanopore sequencing data.", "offsetInBeginSection": 674, "offsetInEndSection": 771, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28655275", "text": "Nontransformed cells, however, take up HPG-C10-HPG and HPG-104 through macropinocytosis, while these cells utilize both clathrin-mediated endocytosis and macropinocytosis to internalize HPG-C10-PEG.", "offsetInBeginSection": 888, "offsetInEndSection": 1086, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24749852", "text": "On the basis of its numerous surface hydroxyl groups, UCNP-g-HPG can be tailored by a representative fluorescent dye rhodamine B to afford a UCNP-g-HPG-RB nanohybrid that simultaneously presents upconversion and downconversion luminescence.", "offsetInBeginSection": 929, "offsetInEndSection": 1169, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25706864", "text": "Hyperbranched polyglycerol (HPG) is a branched compact polymer that has low intrinsic viscosity.", "offsetInBeginSection": 354, "offsetInEndSection": 450, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a70ce82b750ff4455000065", "body": "What is the mode of action of the drug Prolia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22023901", "http://www.ncbi.nlm.nih.gov/pubmed/30444713", "http://www.ncbi.nlm.nih.gov/pubmed/19836866", "http://www.ncbi.nlm.nih.gov/pubmed/36033145", "http://www.ncbi.nlm.nih.gov/pubmed/25509894", "http://www.ncbi.nlm.nih.gov/pubmed/26964445", "http://www.ncbi.nlm.nih.gov/pubmed/22460415", "http://www.ncbi.nlm.nih.gov/pubmed/27025090", "http://www.ncbi.nlm.nih.gov/pubmed/34687651", "http://www.ncbi.nlm.nih.gov/pubmed/21779716"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25509894", "text": "AIM To evaluate the efficacy and safety of Denosumab (Prolia), a first-line osteoporosis (OP) medication that is a fully human monoclonal antibody to the receptor activator of nuclear factor xB ligand (RANKL), within an open-label observational study.", "offsetInBeginSection": 0, "offsetInEndSection": 251, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19836866", "text": "Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases.", "offsetInBeginSection": 231, "offsetInEndSection": 465, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22023901", "text": "Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor-\u03baB ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts.", "offsetInBeginSection": 0, "offsetInEndSection": 207, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26881176", "text": "Although denosumab (Prolia) has been shown to be a safe and efficacious therapy for osteoporotic patients in numerous clinical trials, few studies have determined its effectiveness in real world clinical practice.", "offsetInBeginSection": 0, "offsetInEndSection": 213, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12725566", "text": "Camptothecin, paclitaxel, podophyllin, vinblastine and vincristine were tested, each with a different mode of action.", "offsetInBeginSection": 263, "offsetInEndSection": 380, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26730877", "text": "The antimicrobial peptide showed a different mode of action as all tested antibiotics including polymyxin B and is therefore a good candidate for further drug development.", "offsetInBeginSection": 2036, "offsetInEndSection": 2207, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047", "text": "Requiring claims for a bone or cartilage disorder or osteoporotic fracture after excluding claims for cancer prior to a denosumab-specific administration code gave the highest PPV (95.8%), followed by requiring a Prolia National Drug Code on the same claim as a denosumab-specific or nonspecific administration code (88.2%).", "offsetInBeginSection": 717, "offsetInEndSection": 1041, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25509894", "text": "CONCLUSION The preliminary results of the open-label study of Prolia in postmenopausal OP suggest that the significantly lower BR activity determines the efficacy of this drug and its high safety.", "offsetInBeginSection": 993, "offsetInEndSection": 1189, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047", "text": "CONCLUSIONS Prolia users are most accurately identified with administration code claims in conjunction with claims for Prolia National Drug Code and bone disorder treatment and diagnosis codes.", "offsetInBeginSection": 1181, "offsetInEndSection": 1374, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26730877", "text": "In addition, the mode of action should be different from conventional antibiotics, in consequence peptide candidates can be developed further into drugs against multi-drug resistant bacteria.", "offsetInBeginSection": 849, "offsetInEndSection": 1040, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a75df9483b0d9ea66000001", "body": "What is the mechanism of action of Tisagenlecleucel?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26292636", "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "http://www.ncbi.nlm.nih.gov/pubmed/6572387", "http://www.ncbi.nlm.nih.gov/pubmed/20012482", "http://www.ncbi.nlm.nih.gov/pubmed/12387704", "http://www.ncbi.nlm.nih.gov/pubmed/8957109", "http://www.ncbi.nlm.nih.gov/pubmed/2695408", "http://www.ncbi.nlm.nih.gov/pubmed/18642372", "http://www.ncbi.nlm.nih.gov/pubmed/10029375", "http://www.ncbi.nlm.nih.gov/pubmed/20019471"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "text": "What kind of action understanding, if any, can be ascribed to the mirror mechanism?", "offsetInBeginSection": 298, "offsetInEndSection": 381, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283", "text": "Since its discovery in the monkey and human brain, many have claimed that the mirror mechanism is critically involved in understanding action.", "offsetInBeginSection": 119, "offsetInEndSection": 261, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "WHAT IS NEW AND CONCLUSION Further research is needed to uncover the mechanism of analgesic action of paracetamol.", "offsetInBeginSection": 1072, "offsetInEndSection": 1186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "WHAT IS KNOWN AND BACKGROUND Although paracetamol (acetaminophen), N-(4-Hydroxyphenyl)acetamide, is one of the world's most widely used analgesics, the mechanism by which it produces its analgesic effect is largely unknown.", "offsetInBeginSection": 0, "offsetInEndSection": 223, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "METHODS A literature search was conducted of clinical and preclinical literature and the information obtained was organized and reviewed from the perspective of its contribution to an understanding of the mechanism of analgesic action of paracetamol.", "offsetInBeginSection": 576, "offsetInEndSection": 826, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "RESULTS Paracetamol's broad spectrum of analgesic and other pharmacological actions is presented, along with its multiple postulated mechanism(s) of action.", "offsetInBeginSection": 829, "offsetInEndSection": 985, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20350658", "text": "Such studies need to be accompanied by rigorous correlative analysis if we are to understand the importance of various mechanisms of action of rituximab and use that information to improve on what is already an indispensable component of therapy.", "offsetInBeginSection": 922, "offsetInEndSection": 1168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9721431", "text": "Its unique mechanism of action has created great interest in its use as a biochemical probe of signal transduction pathways that has provided insight into its molecular mechanism of action.", "offsetInBeginSection": 98, "offsetInEndSection": 287, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21054454", "text": "OBJECTIVE To review the clinical profile and preclinical studies of paracetamol as means of gaining insight into its mechanism of analgesic action.", "offsetInBeginSection": 426, "offsetInEndSection": 573, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9721431", "text": "This article reviews the current state of our understanding of the mechanism of action of rapamune.", "offsetInBeginSection": 288, "offsetInEndSection": 387, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a74e6eb0384be9551000009", "body": "What is Morgellons disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16489838", "http://www.ncbi.nlm.nih.gov/pubmed/30446193", "http://www.ncbi.nlm.nih.gov/pubmed/33986606", "http://www.ncbi.nlm.nih.gov/pubmed/23326202", "http://www.ncbi.nlm.nih.gov/pubmed/22253541", "http://www.ncbi.nlm.nih.gov/pubmed/35905899", "http://www.ncbi.nlm.nih.gov/pubmed/21390982", "http://www.ncbi.nlm.nih.gov/pubmed/23245971", "http://www.ncbi.nlm.nih.gov/pubmed/20489569", "http://www.ncbi.nlm.nih.gov/pubmed/24715950"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23326202", "text": "Morgellons disease is an emerging skin disease characterized by formation of dermal filaments associated with multisystemic symptoms and tick-borne illness.", "offsetInBeginSection": 0, "offsetInEndSection": 156, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982", "text": "Morgellons Disease is a condition involving painful skin lesions, fibrous growths protruding from the skin, and subcutaneous stinging and burning sensations, along with symptoms of anxiety, depression, fatigue, and memory and attention deficits.", "offsetInBeginSection": 0, "offsetInEndSection": 245, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19830222", "text": "CONCLUSIONS These data suggest Morgellons disease can be characterized as a physical human illness with an often-related delusional component in adults.", "offsetInBeginSection": 1629, "offsetInEndSection": 1781, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20489569", "text": "Morgellons disease is a new emerging disease that is still controversial and believed to be, by some practitioners, as nothing more than delusional parasitosis.", "offsetInBeginSection": 0, "offsetInEndSection": 160, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982", "text": "Data from this case example suggest that hypnotherapy is a promising intervention for the physical and psychological symptoms associated with Morgellons Disease.", "offsetInBeginSection": 548, "offsetInEndSection": 709, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25192328", "text": "Morgellons disease is well-known in the dermatology and psychiatry literature, where it is typically considered a subtype of delusional parasitosis, but it has not yet been described in the ophthalmology literature.", "offsetInBeginSection": 134, "offsetInEndSection": 349, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20489569", "text": "A first case is reported of an oral lesion and symptoms consistent with Morgellons disease.", "offsetInBeginSection": 305, "offsetInEndSection": 396, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838", "text": "Morgellons disease is a mysterious skin disorder that was first described more than 300 years ago.", "offsetInBeginSection": 0, "offsetInEndSection": 98, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21110523", "text": "Morgellons disease is a controversial and poorly defined symptom cluster of skin lesions and somatic symptoms, most notably 'fibers' in the skin.", "offsetInBeginSection": 0, "offsetInEndSection": 145, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19681520", "text": "Whether Morgellons disease is a delusional disorder or even a disease has been a mystery for more than 300 years.", "offsetInBeginSection": 0, "offsetInEndSection": 113, "beginSection": "abstract", "endSection": "abstract"}]}]}